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Abstract 
This Dissertation is divided into five chapters reporting various aspects of the 
background to my field of study and the results obtained during my research program. 
Chapter 1 gives a very brief introduction to photodynamic therapy including the 
mechanism of the treatment, the localization of photosensitizer in tumor cells, the 
pathways leading to tumor death and characteristics of various photosensitizers such as 
porphyrin-based photosensitizers and non-porphyrin based photosensitizers. 
Chapter 2 reports a total synthesis of zinc(II) isoporphyrins by cyclization of b-bilene salt 
using α-keto esters for the macrocyclization carbon. Functionalization of the resulting 
zinc(II) isoporphyrins was attempted using different strategies such as direct 
functionalization of the isoporphyrin after cyclization of the b-bilene salt and introduction 
of the functional group during the cyclization of b-bilene salt.  
Chapter 3 desrcibes a different total synthesis of zinc(II) isoporphyrins by way of the 
MacDonald 2+2 condensation approach. A serial of zinc(II) isoporphyrins were obtained 
and further functionalization of these compounds was also attempted by use of various 
hydrolytic reactions. Functionalization of dipyrromethanes before cyclization was also 
investigated through hydrolytic and amination reactions.  
Chapter 4 explores novel syntheses of BODIPYs using pyrroketones as starting 
materials. Reactions of pyrroketoned including electropholic alkylation with Meerwein’s 
salt, chlorination using phosgene, and protonation with acids were investigated. The 
reactivity of the derivatives, especially, 5-chloro-dipyrromethenes and 8-chloro-BODIPYs 
were also investigated by using replacement (substitution/elimination) and modern 
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organometallic coupling reactions. Some meso-substituted BODIPYs were obtained and 
their photophysical properties were studied, including absorption, fluorescence and 
quantum yields.  
Chapter 5 presents a synthesis of tri-chloro-BODIPYs. Global and regioselective Stille 
coupling reactions were investigated using tri-chloro-BODIPYs. A novel series of new 
symmetrical and unsymmetrical BODIPYs s were synthesized using this method.  
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Chapter 1: Introduction 
1.1 Photodynamic Therapy (PDT) 
Photodynamic therapy (PDT) was discovered in the 19th century and matured as a 
viable medical technology in the 1980s at several institutions throughout the world, 
in countries such as Canada, USA and Japan. This treatment involves the use of 
photochemical reactions mediated by the interaction of a photosensitizing agent, 
light, and oxygen, to kill malignant tumor cells. Depending on the part of the body 
being treated, the drug is either injected into the bloodstream or applied to the skin; 
over time, the drug is preferentially absorbed by cancer cells and clears from 
normal cells. Then a specific wavelength of light is applied to initiate a 
photochemical reaction and produce singlet oxygen, the active form of oxygen, and 
other active oxygen spevcies which can damage the cancer cell (Figure 1.1).1 
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Figure 1.1: The application of photodynamic therapy.1 
A simplified Jablonski diagram (Figure 1.2) is used to explain what actually happens 
during the treatment. Once photosensitizers are exposed to a specific wavelength of 
light, they are promoted from the ground state S0 to the spin-allowed excited singlet 
states Sn; from this point, the photosensitizers can undergo several electronic changes.
3 
Radiationless deactivation of photosensitizer from upper-lying excited states to the 
lowest excited state is a very fast process on the picosecond time scale. From the lowest 
excited state, the photosensitizers can release energy in the form of fluorescence and 
return to ground state. The pathway which involves intersystem crossing from the lowest 
excited singlet state to triplet state is the key process for PDT and a high population of 
triplet state is required to produce toxic 1O2; if the triplet state population is too low, the 
photosensitizer will return to its ground state with the emission of light as 
phosphorescence. From triplet state, the photosensitizer can transfer the energy to the  
 
Figure1. 2: Jablonski diagram. 
http://www.chemicool.com/img1/chem-ed/quantum/graphics/jablon.gif 
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nearby molecule triplet oxygen through spin exchange and generate the highly reactive 
singlet oxygen, which is believed to be one of the key species toxic to cancer cells. The 
half life of singlet oxygen is less than 0.04 µs and it thus has a migrating radius smaller 
than 0.02 µm2, therefore making PDT a very local treatment.  
1.2 Localization of Photosensitizer in Tumor Cells 
It was discovered that some compounds, especially porphyrins and porphyrin derivatives, 
can selectively localize in tumor cells compared with normal cells.4 Although intensive 
studies have been done to find out the mechanism, there is still no clear result so far. 
However, it has been found that all the different photosensitizers are bound to serum 
protein to some degree after injection into the bloodstream.5 Based on pharmacokinetic 
studies of photosensitizers,6 one of the proposals is that photosensitizers prefer to bind 
to albumin and heavy proteins such as HDL, LDL and VLDL. The assumption in this 
theory is that the tumor cell can overexpress heavy proteins such as LDL-receptors 
compared with normal cells since tumor cells grow faster than normal cells and they 
need more cholesterol to permit the rapid growth of cellular membranes. Therefore, 
when the photosensitizers circulate in a patient’s body, most are absorbed by the tumor 
cells instead of normal cells. There are some other theories, more related to the 
structural difference between cancer cells and normal cells. It was found that tumor cells 
usually have a lower pH environment than do normal cells, and they therefore have 
affinity for anionic photosensitizers. For example, Thomas and Girotti7 found that 
decrease of pH by admistrating glucose into tumor cells can result in a greater 
accumulation of the sensitizer hematoporphyrin derivatives (HpD). The assumption is 
that negatively charged photosensitizers are neutralized once protonated and therefore 
become more lipophilic, which is a very important property during localization since the 
membrane of tumor cells is also lipophilic. Another theory is related to the vascular 
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permeability of photosentizers to tumor cell and lymphatic drainage of tumor cells. It is 
well known that photosensitizers behave as macromolecules because they are either 
bound to large proteins or form intermolecular aggregates.8 Vasculature is 
nonproliferative for adults while the vasculature of tumors has some embryonic vessels 
and neovasculature which are highly proliferative; the photosensitizers usually have an 
affinity for proliferative neovaculature9 over nonproliferative vasculature, therefore 
increasing the permeability of the photosensitizers to the neovasculature of the tumor. 
Additionally, the tumor cells have poorly developed lymphatic drainage; the 
photosensitizers which extravasate from the hyperpermeable tumor neovasculature tend 
to remain in the extravascular space.  
There are some relationships between the structures of photosensitizers and selectivity 
for the tumor, specifically, in different organelles of tumor cells (Figure 1.3). According to 
the structures of the photosensitizers, they could be classified into three categories: 
hydrophilic photosensitizers (such as tetra-sulfonated derivatives of tetraphenylporphine), 
amphiphilic photosensitizers (like benzoporphyrin derivative monoacid) and hydrophobic 
photosensitizers (such as unsubstituted phthalocyanines). According to whether or not 
the photosensitizers carry charges, they could be classified into anionic, cationic or 
neutral photosensitizers. Depending on the properties of photosensitizers, they can 
diffuse across the plasma membrane and selectively relocate in one of the organelles of 
the tumor cell or several of them including mitochondria, lysosomes, Golgi and 
Endoplasmic Reticulum (ER) or plasma. Some correlations between the characteristic of 
photosensitizers and their localizations in tumor cell were found through years of studies. 
The photosensitizers with net negative charges (anionic photosensitizers) tend to 
localize in the lysosomes, while the photosensitizers with positive charges (cationic 
photosensitizers) prefer to localize in mitochondria.10 For example, Woodburn et al. 
reported the intracellular localization of a series of porphyrin 
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Figure 1.3: The configuration of cell. 
Taken from: http://www.enchantedlearning.com/subjects/animals/cell/ 
derivatives with different properties (Table 1.1) such as hydrophobic, anionic or cationic 
characters in V79 Chinese hamster lung fibroblasts and C6 glioma cells.11 The 
localization results are listed in Table 2. One can see that anionic photosensitizers 2, 8, 
and 10 mainly localized in lysosomes and cationic photosensitizer 4, 6, 7 and 9 preferred 
to localize in mitochondria. Lysosomes, and mitochondria are the main subcellular 
compartment PDT targets. Some photosensitizers localized in the Golgi apparatus and 
endoplasmic reticulum (ER) instead of lysosomes and mitochondria. For instance, 
Foscan12 predominantly localized in Golgi and ER with very weak accumulation in 
mitochondria. For the amphipathic photosensitizers, there should be a balance between 
hydrophobic and hydrophilic properties. Hydrophilicities can facilitate the delivery of the 
photosensitizers through the bloodstream and hydrophobic properties can help with the 
permeability of the membrane of tumor cells.  
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Table 1.1. Photosensitizers with Different Properties. 
 
 
 
 
 
Compound R R’ 
1 (HpD)   
2 HC(CH3)OH OH 
3 HC(CH3)OCH3 OCH3 
4 CH=CH2 NH(CH2)2N(CH3)2 
5 HC(CH3)O(CH2)2OCH2CH3 OH 
6 HC(CH3)O(CH2)2OCH2CH3 NH(CH2)2N(CH3)2 
7 HC(CH3)SCH2CONH(CH2)2N(CH3)2 NH(CH2)2N(CH3)2 
8 HC(CH3)S(CH2)2NO OH 
9 HC(CH3)S(CH2)2NO NH(CH2)2N(CH3)2 
10 HC(CH3)O(CH2)2N(CH3)2 OH 
* 
 
Table 1.2. The Localization of Photosensitizers in Different Organelles.  
 
Compound R R’ Localization 
1(HpD)   
Diffuse cytoplasmic plus 
perinuclear 
2 hydrophilic Anionic 
Diffuse cytoplasmic plus 
lysosomes 
3 hydrophobic Hydrophobic 
Diffuse cytoplasmic plus 
lysosomes 
4 hydrophobic cationic mitochondria 
5 hydrophobic Anionic Diffuse cytoplasmic 
6 hydrophobic Cationic 
C6; mitochondira
lysosomes 
V79; mitochondria
lysosomes(vacuolation) 
7 Amphipathic catioic mitochondira 
8 amphipathic Anionic 
cytoplasmic lysosomes
lysosome engorgement 
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Table 1.2 continued 
.  
Compound R R’ Localization 
9 amphipathic Cationic 
C6; mitochondria
lysosomes 
V79; mitochondria 
10 amphipathic Anionic 
cytoplasmic
lysosomes lsysosome 
engorgement 
 
 
1.3 The Pathways Leading to Tumor Cell Death 
 
The outcome of PDT depends on numerrous factors such as the localization of 
photosensitizers, tissue types, and PDT dose, etc. There is no single pathway leading to 
cell death; a combination of factors is necessary to achieve the optimum tumor cures. 
There are three main independent pathways leading to tumor cell death: (1) subcellular 
localization-induced apopotosis and necrosis, which is the direct tumor cell death effect 
of PDT; (2) vasculature destruction is another way to kill tumor cell; and (3) immune 
system response is the impact after the PDT is completed, and is therefore called the 
post-PDT effect. Apoptosis is an energy-consuming process through activation of a 
death receptor or the mitochondrial release of cytochrome;13 both of these pathways 
could activate caspase which can cause damage to subcellular organelles such as 
mitochondira, lysosomes and ER, or initiate DNA fragmentation and cell shrinkage. 
Apoptosis is the dominant, rapid and intermediate form of tumor cell death during 
photodynamic therapy. Another pathway that can lead to direct tumor cell death is 
necrosis. Necrosis14 has been considered an uncontrolled process caused by physical or 
chemical damage. It is an intense and rapid form of degeneration that can cause 
cytoplasmic swelling, damage to organelles and dysfunction of plasma membrane. 
Therefore the necrosis process really depends on the PDT dose such as high 
photosensitizer concentration or a high light fluence, or both; the pathway of cell death 
can switch from apoptotic to necrotic when the PDT dose is excessive. The localization 
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of photosensitizer can also play a role in the cell death pathway. Mitochondria localizing 
photosensitizers usually induce apoptosis while plasma membrane localizing 
photosensitizers are most likely to induce necrosis, which can damage the plasma 
membrane integrity due to acute inflammation. There are another two pathways leading  
 
 
Figure 1.4: The formation of angiogenesis15 (a) photosensitizer in the vessel at the 
beginning; (b) photosensitizer diffused into the surrounding tissue gradually as time 
increases; (c) vascular endothelial growth factor (VEGF); (d) The emergence of new 
blood vessels accompanied by endothelial cell proliferation and migration. 
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to tumor cell death beside apoptosis and necrosis. One of them is vascular damage; as 
was mentioned in discussion of localization in tumor cells, the blood is the medium to 
deliver the nutrient and oxygen to cells through vessels. Damage to the neovasculature 
can lead to thrombosis, hemorrhage and tissue hypoxia. Nutrient deprivation and 
eventual starvation can also cause death of tumor cells15 (Figure 1.4). 
Photodynamic therapy is a local treatment. However, this treatment can also have some 
systemic attributes since it can induce response of the immune system. PDT induced 
anti-tumor immunity is due to the acute inflammatory response, exposure and 
presentation of tumor-specific antigens.16 With the PDT-induced destruction of the tumor 
cells, a strong inflammatory reaction occurs locally at the same time and enables the 
influx of non-affected immune cells into the PDT-site from elsewhere and result in the 
development of a systemic anti-tumor immune response.17 In summary, the effect of 
PDT is the combination of various factors such as subcellular localization of 
photosensitizers, PDT dose and tissue targets, and these factors cannot be localized 
independently.  
1.4 Lights and Penetration of Tissue. 
Light is one of the non-toxic components of photodynamic therapy and is used as an 
energy form to activate the photosensitizers. Therefore, it is very important to develop 
light resources in parallel with photosensitizers. Lasers are the mostly common light 
source used in photodynamic therapy18 due to their capability of generating a coherent 
light beam. The light could be directed to the site need to be treated through optical 
fibers with a 200-400 µm diameter. Figure 1.5 shows the correlation between 
wavelength of light and the depth of penetration into tumor.19 Semiconductor lasers such 
as LED lights will be the preference in the future because they are cheap and easy to 
handle.  
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Figure 1.5: The wavelength dependence of depth of penetration of light into a tumor.19 
1.5 Advantages and Limitations of PDT. 
Photodynamic therapy is a very selective treatment of tumor cells over normal cells. It 
can target the tumor cell very precisely without damage to surrounding tissues due to the 
short-lived 1O2, which only can migrate within the cell about 0.02 µm. Compared with 
traditional cancer treatments such as chemotherapy, radiation, and surgery, 
photodynamic therapy is less invasive, the only invasive operation being the technique 
that is used with the optical fiber, which is very small and is used to penetrate the tissue 
to direct the incoming light. Therefore, there is little or no scar left after treatment of 
superficial tumors. Another advantage of PDT is that this treatment can be used at the 
same site repeatedly until all cancer cells are killed.  
Of course, there are some limitations with this PDT treatment. The main drawback of 
PDT is that it can be only used to treat early stage cancers. Once the tumor cells spread, 
it is hard to target any metastases. It cannot be used to treat larger tumors due to the 
problem of light penetration though tissues. Another inconvenience of this treatment is 
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that the delay time after injection of photosensitizer can be fairly long from 24 hours to 
72 hours. Another complication is that the patients can remain photosensitive after 
treatment for some time depending on the photosensitizer used. Investigators are 
developing more mature photodynamic therapies to solve these issues. 
1.6. Ideal Photosensitizers 
To be an ideal photosensitizer, the compound should meet the following requirements to 
achieve a good outcome in photodynamic therapy:  
1. The compound should have preferential tumor localization over normal cells. The 
better localization can be achieved by conjugation of biomolecule such as amino acids 
or sugars to the molecule.  
2. The photosensitizer candidate should be able to generate singlet oxygen (1O2) 
efficiently which is mostly responsible for the tumor cell death in photodynamic therapy. 
This requires the compound to have a high quantum yield of the triplet state (φT > 0.4) 
with a long lifetime ( t > 100 µs).  
3. The photosensitizers should have an absorption region between 630-800 nm (Figure 
1.6) with high extinction coefficient. The energy gap between 3O2 and 
1O2 can be 
measured by observing its 1270 nm phosphorescence. By detection of the 1270 nm 
phosphorescence emission, theoretically, a photosensitizer with a triplet state energy 
higher than 94kJ/mol (1270 nm) can transfer its energy to ground state 3O2. However, 
the photosensitizer with long wavelength absorption cannot efficiently generate singlet 
oxygen. For example, a reported 34-π conjugated porphyrin with absorption at 940 nm 
did not produce singlet oxygen.20 
4. The photosensitizer should be nontoxic in the absence of light and have minimal 
residual skin photosensitivity.  
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5. The sensitizer should be photostable and biologically stable, and easily to soluble in 
injectable solvents. This requires the photosensitizer should have some amphiphilic and 
hydrophobic groups attached.  
6. The photosensitizers should be chemically pure so that the subsequent studies such 
as pharmacokinetics and dose-response correlation can be performed easily.  
 
 
Figure1.6: The therapeutic window of photodynamic therapy. 
http://www.photobiology.info/Hamblin.html 
 
1.7. Porphyrin-based Photosensitizers 
Porphyrins and their derivatives21 are a class of very important biological products in 
nature. Porphyrins are the building blocks of hemoglobin and myoglobin which are the 
two major oxygen binding proteins in blood. These aromatic macrocyles possess 18-π 
electrons and have very interesting optical spectra with a Soret absorption band around 
400 nm belonging to the π-π* transition and four small Q bands in the visible region. 
When porphyrins are reduced by breaking a cross-conjugated double bonds without 
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interruption of the aromaticity of macrocycle, the Q-band is red shifted with a high 
extinction coefficient19 (Figure 1.7). This is probably due to perturbation introduced to the 
planar and symmetrical porphyrin ring and the energy of the HOMO orbital is raised and 
therefore reduces the energy gap between the HOMO and LUMO orbitals.22 From the 
optical spectrum of porphyrins and their derivatives, one can see that their absorption in 
the visible and IR areas make these molecules very good candidates as potential 
photosensitizers. Porphyrins also possess some other potentially advantageous features 
including their localization in tumor cells, ability to produce singlet oxygen, their 
florescence, low-dark toxicity and high chemical stability. All these properties make 
porphyrin-based compounds extremely useful for PDT. So far, several porphyrin 
derivatives have been developed and some of them have been approved in countries 
such as Canada, the USA, Europe and Japan, for treating various cancers.  
Hematoporphyrin derivatives (HpD) and photofrin23-25 (Figure 1.8) were discovered to 
have the ability to selectively accumulate in neoplastic tissue and function in various 
malignant tissues such as carcinomas of the breast, colon, prostate and malignant 
melanomas. Photofrin is a purified version of hematoporphyrin derivative (HpD) and has 
been approved by the US FDA to treat lung cancer, esophageal cancer, malignant and 
nonmalignant skin diseases, and early-stage cervical cancer.26 Due to the low extinction 
coefficient of the Q bands, significant dosage or a high concentration of Photofrin was 
needed to achieve tumor eradication. This caused serious side effects. Chemical 
modification of hematoporphyrin was performed to overcome the chemical complexity of 
Photofin by functionalization of the benzylic hydroxyl groups or by introducing different 
substituents.27,28 However, the sensitizing efficiency did not change much. Other 
synthetic porphyrin-based photosensitizers available are meso-tetraphenylporphyrin 
(TPP), which was synthesized and modified by  
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Figure 1.7: Optical spectra of porphyrins, chlorins, bateriochlorins and their metal 
complexes.19 
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several groups such as those of Hagan, Czuchajowski and Lozynski29,30 to introduce 
hydrophilic groups and hydrophobic groups including hydrogen, hydroxyl and sulfonate, 
and reduced the porphyrin to the dihydroporphyrin (chlorin) level The investigation of 
biological properties of these porphyrins showed that the o, m, and p-isomers of 
tetra(hydroxyphenyl)chlorins have very potent activity and tissue selectivity in photo-
necrosis. Especially, tetra(m-hydroxy)phenylchlorin was 25-30 times potent than HpD, 
and this is now marketed as Foscan. 
Porphyrins usually can satisfy most of the requirements for effective photosensitizers. 
However porphyrins only have a small Q band with low molar extinction coefficient 
compared with their Soret band. The longest wavelength band of porphyrins can reach 
to around 650 nm. They can not be used to treat deep-seated tumors. Some reduced 
porphyrins were developed, such as chlorins and bacteriochlorins, to solve the problems 
associated with first generation porphyrin-based photosensitizers. These 
photosensitizers are chemically pure and have longer wavelength absorption and less 
side effects after treatment is completed. Since they absorb at long wavelengths, they 
can be used to treat large tumors because long wavelength light travels further through 
tissues. Figure 1.9 lists several chlorin-based photosensitizers.  
Temoporfin31 is bactieriochlorin-based photosensitizer approved in 2001 in Europe to 
treat neck, and head cancers and was the first sensitizer to be used to treat prostate 
cancer in 2002. Compared with Photofrin, this compound has a pronounced Q band at 
652 nm with a higher molar extinction coefficient, therefore a smaller drug dose is 
needed in clinic trials and it has mild to moderate skin photosensitivity. Tumor cell death 
was caused through necrosis and vascular damage. Padoporfin32,33 (palladium- 
bacteriopheophorbide) (figure 1.9) is a lipophilic photosensitizer which has a maximum 
absorption wavelength in the near-infra red region at 763 nm and could be active at a 
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Figure 1.8: Structure of HP, Photofrin, and other porphyrins used in PDT 
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penetration depth of 4 mm using appropriate light, compared with Photofrin (630 nm, 1.6 
mm). Padoporfin is a vascular-acting photosensitizer and was used to treat prostate 
cancer in clinic studies, which showed that Padoporfin-mediated PDT has a very short 
drug exposure–light interval and minimal local damage.34,35 NPe6 (talaporfin, LS II) is a 
second generation photosensitizer approved for the treatment of lung cancer by the in 
Japan. NPe6 is a hydrophilic chlorin derivative due to the aspartyl residue and has  
UV/Visible absorption at 664 nm with a molar extinction coefficient of 4 x 104 M-1cm-1. 
The clinical study36,37 showed that NPe6 is mainly localized in plasma instead of 
organelles and the mechanism of tumor cell death was shown to be vascular stasis 
resulting from direct tumor necrosis. The possibility of using NPe6 to treat other cancers 
is also under investigation too in clinical trials. Only minimal skin photosensitivity was 
caused after the treatment. A synthetic chlorin-based photosensitizer Verteporfin was 
invented by Dolphin and Levy and modified by Callot et al and Pandey et al.38,39 This 
compound has a pronounced Q band at 689 nm and has a very efficient generation of 
singlet oxygen.40 Verteporfin is a lipophilic photosensitizer used for ocular PDT and 
approved for age-related macular degeneration since 2000. In vivo studies showed that 
it prefers to localize in neovascular endotherlium and the localization determined that 
tumor cell death is through vascular damage and it is 10 times more cytotoxic than 
hematoporphyrin in human adherent cell lines.41 Biodistribution studies proved that 
Verteporfin can accumulate in the vasculature rapidly and clear from a patient’s body 
rapidly after treatment. It is metabolized in a less reactive form and in this way reduced 
the photosensitivity period.42  
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Figure 1.9: Chlorin-based photosensitizers. 
Another two porphyrin-type derivatives are phthalocyanine and porphycene (Figure 1.10). 
Phthalocyanine (Pc) was discovered by Braun and Tcherniac in 190743,44 and has been 
recognized as a PDT agent since 1985. From the structure, Pc can be regarded as tetra-
azaporphyrin and it has very strong absorption at 670-770 nm with a molar extinction 
coefficient around 2.5 x 105 M-1cm-1; this makes Pc a very good photosensitizer 
candidate. When chelated with diamagnetic metals such as zinc, aluminum or silicon, Pc 
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gives excellent singlet oxygen yields even close to 100%.45,46 Coordination with metals 
which have valency higher than two, such as silicon, also prevents aggregation by way 
of axial coordination. Silicon phthalocynies in vitro and in vivo studies have shown that 
this hydrophobic photosensitizer exclusively localizes in mitochondria, and tumor cell 
death is mainly caused by the formation of reactive oxygen species. Phthalocyanine is a 
hydrophobic photosensitizer. However, its structural flexibility allows one to introduce 
hydrophilic groups to the molecule to modify its amphiphilicity so that the delivery of the 
drug can be more convenient.  
Porphycene is an isomer of porphyrin. Although the structure of porphycene is strained 
compared with porphyrin, the stability of porphycene is still comparable to that of 
porphyrin due to hydrogen bonding between the NH and N sites. Porphycene was first 
synthesized by Vogel et al.,47,48 and the molecule has absorption around 600 nm with a  
 
Figure1.10: The structures of phthalocyanine (left) and porphycene (right). 
molar extinction coefficient around 5 x 104 M-1 cm-1. Depending on the structure, 
porphycenes localize in different compartments of tumor cells such as mitochondria or 
lysosome,49,50 Tumor cell death is mediated by apoptotic and necrotic responses.  
1.8. Non-porphyrin Based Photosensitizers 
There are some non-porphyrin based photosensitizers that have been developed. Most 
of them are various dyes such as hypericin, methylene blue, and toluidine blue (Figure 
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11). All these dyes have not succeeded in clinical trials due to drug delivery issues or 
their low activity against tumor cells. Hypericin51 has absorption at 590 nm with a molar 
extinction coefficient around 4.5 x 104 M-1 cm-1 and can generate singlet oxygen very 
efficiently. This compound attracted attention because it is an inhibitor of protein kinase, 
which is a key enzyme in the proliferation of tumor cells. Hypericin was found to kill 
tumor cells through direct tumor cytotoxicity and vascular damage.52 Methylene blue53 
has been known as an imaging reagent in the clinic for diagnosis of many diseases. It 
has absorption around 666 nm and a molar extinction coefficient of 8.2 x 104 M-1cm-1. 
Methylene blue is not widely used as a PDT agent due to its high reduction potential in 
tumors cell to give its leuco methylene blue scompound, which is colorless. Therefore 
the activity is lost. In spite of this, in vitro studies showed that methylene blue can reduce 
tumor size significantly against human T-cell and B-cell lymphoma.54 Other dyes used in 
PDT are aza-BODIPYs, which have absorption at 679 nm with a molar extinction 
coefficient of 7.5 x 104M-1cm-1. This molecule is improved as a photosensitizer when a 
halogen is introduced into the structure. The halogen increases the population of triplet 
states while also reducing the fluorescence due to the heavy atom effect. An in vivo 
study of ADMPM06 (Figure 1.11) showed this molecule has no discernable selectivity to 
particular cell compartments. Tumor cell death was induced through direct apoptotic and 
necrotic pathways. A similar strategy was used in BODIPY by introducing halogen to 
molecules. The first BODIPY investigated as a PDT agent is diiodoBODIPY.55 This 
compound has an absorption at 534 nm with a molar coefficient value of 1.1 x 105 M-1cm-
1. The generation of singlet oxygen was observed under IR irradiation when this 
molecule was excited. The localization of BODIPY depends on the structure. Some 
localize in mitochondria, ER and some localize in cell membranes.  
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Figure 1.11: Non-porphyrin based photosensitizers. 
 
To achieve better localization in tumor cells over normal cells, researchers have 
developed various strategies to modify photosensitizers by introducing biomolecules 
such as amino acids, antibodies, and polyethylene glycols (PEGs). This strategy is 
based on the fact that malignant tumor cells have cell surface antigens different from 
normal cells. For example, there is much work focusing on the use of antibodies56 to 
direct the photosensitizers to tumor cell over normal cells. A monoclonal antibody 
(mAB)-PS  conjugate is found to specifically bind to the tumor tissue due to its affinity to 
tumor-associated antigen, which can accumulate up to 108 photosensitizers on a tumor. 
The photosensitizer-biomolecule conjugates are the most promising molecules for 
photodynamic therapy since enhanced biological specificity provides better 
photosensitizer delivery to target tissues.  
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Photodynamic therapy is not only used to treat cancers. This treatment can also be used 
for many other diseases. For example, many skin diseases can be treated using 
photodynamic therapy. The photosensitizer Photofrin is used to treat cancers and also 
was investigated against the HIV virus an in vitro study. Verteporfin is used to treat age-
related macular degeneration. Scientists including chemists, biologists, physicists and 
clinicians are collaborating to explore more possibilities for expanding the applications of 
this treatment.  
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Chapter 2: Total Syntheses and Characterization of Isoporphyrins from b-Bilene 
Salts 
2.1 Introduction 
 Isoporphyrins 11,2 are tautomeric structures of porphyrins 2 with interrupted macrocyclic 
conjugation owing to the presence of a saturated meso-carbon atom (Figure 2.1). This 
interruption of conjugation causes an intense bathochromic shift of the Q-band 
absorption to around 800 nm, thus making isoporphrins promising potential candidates 
as photosensitizers in photodynamic therapy (PDT).  
 
Figure 2.1: Structure of porphyrin and isoporphyrin 
Previous work from our group3 has shown that zinc isoporphyrins have favorable 
properties for a photosensitizer, such as relative low dark toxicity, high phototoxicity, and 
they display multiple localization sites within a cell, especially within mitochiondria. 
Earlier syntheses of others particularly focused on generating transient isoporphyrins 
from tetraphenylporphyrin, including electrochemical oxidation,2 photo-oxidation,4 and 
chemical oxidation.5  However, these isoporphyrins were unstable and easily reverted to 
their corresponding stable porphyrins.  The first thermodynamically stable isoporphyrin 
was achieved in our laboratory in 1992.6 The oxidative re-aromatization of isoporphyrins 
to porphyrins was suppressed by the introduction of suitable geminal substituents at the 
isoporphyrin sp3 meso carbon. Yet another alternative synthesis of isoporphyrins was 
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developed by Smith3 through cyclization of b-bilene salts by using an α-keto ester for the 
interpyrrolic carbon, which makes it possible to approach unsymmetrical isoporphyrins.  
Based on the previous work from our laboratory,3 the objectives of this project are to 
synthesize various zinc(II) isoporphyrins (Figure 2.2) and conjugate them with amino 
acids and study their biological properties as potential photosentizers. Zinc ions were 
inserted into isoporphyrins because metalloisoporphyrins are more stable than metal 
free isoporphyrins and have a significantly more red shifted Q-band (Figure 2.3) 
compared with metal free analogs, usually have a low toxicity, and the potential of 
selective uptake in tumors or necrosis. In addition, we hoped to conjugate 
metalloisoporphyrin with peptides, proteins, PEGs or antibodies to improve the delivery 
of zinc(II) isoporphyrins to cellular targets for photodynamic therapy. 
 
 
Figure 2.2: Target zinc(II) isoporphyrin molecules. 
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Figure 2.3: UV/Visible spectrum of zinc porphyrin and zinc isoporphyrin in CH2Cl2. 
2.2  Previous Syntheses 
Based on the observed stability of phlorins, which are dihydroporphyrins with a structure 
similar to isoporphyrins, Woodward postulated the existence of isoporphyrins in 1961.1 
This prediction was confirmed by Dolphin et al.2 when they reported synthesis of the first 
metalloisoporphyrin in 1970. This discovery encouraged more efforts on synthesis of 
isoporphyrins. Generally, the isoporphyrin was obtained by electrochemical oxidation,2 
chemical oxidation4 or photo-oxidation5 of tetraphenylporphyrin. However, all these 
isoporphyrins are unstable and are easily converted into the corresponding fully 
conjugated porphyrins. The first thermodynamically stable isoporphyrin was obtained by 
Xie and Smith6 by use of a variation of the MacDonald method from dipyrromethanes. 
The introduction of suitable geminal substituents prevented their zinc(II) isoporphyrin 
from isomerization into zinc(II) porphyrin.  
a) Electrochemical oxidation method2 
Dolphin et. al2. reported the first zinc tetraphenylmethoxyisoporphrin 6 as a dark green 
solid  obtained through controlled-potential oxidation of the corresponding zinc meso-
tetraphenylporphyrin 4 followed by nucleophilic attack of methanol (Scheme 2.1). The 
optical absorption spectrum exhibited a maximum absorption at 860 nm. This 
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isoporphyrin could be reduced back to porphyrin 7 with demetalation by addition of KI in 
glacial acetic acid. 
 
Scheme 2.1: Synthesis of tetraphenylisoporphyrin by electrochemical oxidation.2  
.  
b) Chemical oxidation method5 
Gold6a discovered that isoporphyrins could also be generated by peroxide oxidation of 
metalloporphyrins (Scheme 2.2). For example, ferric isoporphyrin 8 was obtained as a 
microcrystalline solid through oxidation of (tetraphenylporphinato) iron(III) complex 9 by 
t-butyl hydroperoxide. Takeda et al.5b also reported synthesis of isoporphyrins by similar 
methods. Zinc tetraphenylbenzoyloxyisoporphyrin benzoate 10 was obtained by 
oxidation of the corresponding porphyrin 4 with benzoyl peroxide. 
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Scheme 2.2: Synthesis of tetraphenylisoporphyrin by chemical oxidation.5b,6a 
c) Variation of MacDonald method6 
Xie and Smith6 successfully achieved the total synthesis of the first thermodynamically 
stable zinc(II) isoporphyrin 13 by using a variation of the MacDonald ‘2+2’ method 
through condensation of dipyrromethane dicarboxylic acid 11 and 
diformydipyrromethane 12 using zinc acetate as a reaction template (Scheme 2.3). The 
5,5-dimethyl groups prevent the isoporphyrin core from going back to the corresponding 
porphyrin.  
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Scheme 2.3: Synthesis of zinc(II) isoporphyrin by the MacDonald approach.6 
d) Cyclization of b-bilene salts3 
Smith and coworkers developed another more efficient synthesis of zinc(II) isoporphyrins 
15 through cyclization of b-bilene salts 14 using an active α-keto ester reagent (Scheme 
2.4). The cyclization mechanism involves a b-bilene to a,c-biladiene transformation. This 
method provided an alternative pathway to synthesize unsymmetrical zinc(II) 
isoporphyrins. 
 
 
Scheme 2.4: Synthesis of tetraphenylisoporphyrin by cyclization of a b-bilene salt.3 
Results and Discussion  
Isoporphyrins possess special physical and chemical properties, such as unique optical 
characteristics and redox behavior. However, in the past twenty years, efforts to 
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synthesize isoporphyrins were hampered in the sense that they are very unstable and 
are easily converted to more thermodynamically stable porphyrins. Oxidation of 
porphyrin to isoporphyrin has been known since the 1980s, but this method was only 
applied to several meso-aryl substituted porphyrins and the resultant isoporphyrins were 
very unstable. Smith’s work6 provided the first stable zinc(II) isoporphyrin and made it 
possible to characterize and investigate the chemistry of isoporphyrins.  
b-Bilene-1,19-dicarboxylate salts are known intermediates in the synthesis of porphyrins7 
and have also been used to synthesize the isoporphyrin by Smith. The route utilizes 
crystalline intermediates at all stages, and the method has no inherent symmetry 
limitations. It could provide an alternative way to synthesize unsymmetrical zinc(II) 
isoporphyrins. We therefore planned to use this method to approach 
metalloisoporphyrins, which we would then conjugate with amino acids and evaluate 
their biological properties as photosensitizers. 
2.3 Retrosynthesis 
The target molecule can be achieved by cyclization of a 1,19-di-tert-
butoxycarbonylctamethy-b-bilene hydrochloride, and the b-bilene could be obtained by 
condensation between a dipyrromethane carboxylic acid and a formyldipyrromethane. 
Dipyrromethane carboxylic acids and diformyldipyrromethanes are both derived from the 
corresponding t-butyl 9-(benzyloxycarbonyl)-3,4,7,8-tetramethyldipyrromethane-1-
carboxylate by hydrogenation and then a Vilsmeier formylation reaction. 
Dipyrromethanes can be synthesized by condensation of a 5-unsubstituted pyrrole with 
a 5-acetoxymethylpyrrole (Scheme 2.5).  
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Scheme 2.5: Retrosynthesis of target isoporphyrin molecule. 
2.4 Synthesis 
The whole synthesis started with only two pyrroles; the 5-acetoxymethylpyrrole 18 was 
synthesized by using the Johnson7a method (Scheme 2.6). Addition of a sodium nitrite 
solution to tert-butyl acetoacetate in acetic acid provided tert-butyl oximinoacetoacetate 
20. Condensation between the oximinoacetate and 3-methyl-2,4-pentanedione in acetic 
acid with portion-wise addition of a mixture of sodium acetate and zinc dust at 70 °C 
furnished t-butyl 3,4,5-trimethylpyrrole-2-carboxylate 21 in about 35% yield. Then, 
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radical oxidation of the α-methyl group by lead tetra-acetate at room temperature led to 
the 5-acetoxymethylpyrrole 18. 
 
Scheme 2.6: Johnson-type synthesis of pyrrole 18. 
The Barton-Zard8 reaction was used to synthesize the 5-unsubsituted pyrrole 19 
(Scheme 2.7). This reaction utilizes a [3+2] cycloaddition of a nitroalkene with an 
alkylisocyanoacetate. Central to this method is the ability of the nitro group to depart as 
nitrite under certain conditions and result in formation of an alkyl 2-unsubstituted pyrrole 
carboxylate. This method is widely used to synthesize the precursors of 
dipyrromethanes and has even been extended to the synthesis of β-nitroporphyrins. 
Henry addition of nitroethane to an aldehyde catalyzed by base, followed by acetylation 
of the hydroxyl group provided 2-acetoxy-3-nitrobutane 23, which was condensed with 
ethyl isocyanoacetate to furnish ethyl ester pyrrole 24 in 80% yield. Here, the acetoxyl 
group in 23 is a very good leaving group, which is easily eliminated under basic 
conditions to generate nitroalkene in situ. Transformation of the ethyl ester pyrrole to the 
benzyl ester pyrrole 25 was realized in greater than 90% yield by a transesterification 
reaction using PhCH2ONa in benzyl alcohol. The benzyl ester group could be easily 
removed to give carboxylic acid under neutral conditions through hydrogenation using 
palladium on activated carbon.  
  
35 
 
 
Scheme 2.7: Barton-Zard synthesis of α-free pyrroles 19 and 24. 
The dipyrromethane 25 was constructed by condensation of the 5-acetoxymethylpyrrole 
18 and the 5-unsubstituted pyrrole 19 using the Lewis acid Montmorillonite K-10 clay as 
a catalyst9 (Scheme 2.8). Almost a 1:1 ratio of these two pyrroles and K-10 clay were 
added to dry CH2Cl2 and the reaction mixture was kept stirring under argon for 24 hours 
at room temperature. tert-Butyl 9-(benzyloxy)carbonyl)-3,4,7,8-tetramethyl-
dipyrromethane-1-carboxylate 25 was obtained in greater than 90% yield. From the 1H 
NMR spectrum the product was shown to be pure enough to go to the next step. Further 
purification could be done through a flash column (3% MeOH/CH2Cl2) or on a regular 
column (CH2Cl2 + a little MeOH) or by recrystallization from CH2Cl2/petroleum ether, and 
then left in the fridge overnight.  
 
 
 
Scheme 2.8: Condensation between 5-acetoxypyrrole 18 and α-free pyrrole 19 in K-10. 
 
Then the precursors of the b-bilene, namely the dipyrromethane carboxylic acid and 
formydipyrromethane were both derived from the mixed ester dipyrromethane 25. 
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Dipyrromethane carboxylic acid 26 was obtained by selectively removing the benzyl 
group through hydrogenolysis over 10% Pd/C catalyst in excellent yield. 
Formyldipyrromethane 27 was synthesized using a Vilsmeier-Haack formylation reaction. 
Decarboxylation was achieved with two equivalents of p-toluenesulfonic acid in CH2Cl2 
for 2 hours. The resultant unsubstituted dipyrromethane was then treated with the 
Vilsmeier reagent prepared in situ, by mixing of DMF and benzoyl chloride, to give the 
desired product formyldipyrromethane 27 upon basic hydrolysis, in good yield (Scheme 
2.9).  
 
 
Scheme 2.9: Synthesis of formyldipyrromethane by the Vilsmeier-Haack reaction 
 
Here, benzoyl chloride was used to replace phosphorus oxychoride because it is more 
moderate compared with the harsh conditions of POCl3/DMF. PhCOCl/DMF generates 
the same intermediate chloromethyleneiminum salt that POCl3/DMF does (Scheme 2.10). 
The latter will generate hydrochloric acid because phosphorus can easily release 
chloride ions in exchange of oxygen and combine with water to produce hydrochloric 
acid. So, the Vilsmeier-Haack10 reagent provided an alternative way for formylation of 
the dipyrromethane, which is sensitive to the action of acetic reagents.  
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Scheme 2.10: Vilsmeier reagent for formylation of dipyrromethane. 
The required b-bilene hydrochloride11 was obtained by condensation of the two 
dipyrromethane halves: dipyrromethane carboxylic acid 26 and 
formyldipyrromethane 27 (Scheme2.11). Condensation of 9-tert-
butyloxycarbonylpyrromethane-1-carboxylic acid 26 with tert-butyl 9-
formylpyrromethane-1-carboxylate 27 catalyzed by two equivalents of p-
tolunesulfonic acid in CH2Cl2 furnished the corresponding b-bilene-1,19-di-tert-butyl 
ester as its toluenesulfonic salt 14. The reaction was monitored by 
spectrophotometry and the b-bilene salt showed a strong absorption around 500 
nm in its UV/Visible spectrum when the reaction was complete. This b-bilene salt 
was converted into the hydrochloride salt by brief treatment by dry HCl gas in 
 
 
Scheme 2.11: Synthesis of b-bilene hydrochloride salt by condensation of 
dipyrromethane carboxylic acid 26 and formyldipyrromethane 27. 
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distilled CH2Cl2 and the solution turned from orange to dark red. Purification of the 
product was done by recrystallization using CH2Cl2/hexane overnight in the fridge to 
give the crystalline hydrochloride in about 70% yield. The UV-visible spectrum of 
the b-bilene hydrochloric salt in CH2Cl2 showed a strong absorption at 502 nm, as 
shown in Figure 2.4. 
 
Figure 2.4: UV-visible spectrum of b-bilene hydrochloride salt 14 in CH2Cl2 
Ring closure of the b-bilene salt is the key step to obtain isoporphyrin. The b-bilene 
has been already used to synthesize porphyrins, employing trimethyl orthoformate 
as a one-carbon linking unit.12 Here, we needed to look for a suitable linking 
reagent13 which is able to prevent the isoporphyrin product from going back to 
corresponding more stable porphyrin. At same time, this reagent must be at least 
as reactive as trimethyl orthoformate toward electrophilic attack by the b-bilene. So 
an α-diketone or α-keto ester was selected. The strategy involved cleavage of  the 
tert-butyl ester group of the b-bilene hydrochloride using trifluoroacetic acid, then 
the reaction mixture was diluted with dry CH2Cl2 followed by addition  
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Scheme 2.12: cyclization of b-bilene salt using methyl pyruvate. 
methyl pyruvate, and the whole reaction was monitored by spectrophotometry. After 
one hour, the UV-visible spectrum showed absorptions at 450 and 520 nm, which 
do not belong to either the starting material b-bilene salt or the product isoporphyrin. 
These two absorptions actually are characteristic of an open chain and non-
conjugated tetrapyrrole. The reaction solution was washed with water containing 
several drops of aqueous sodium bicarbonate to neutralize excess TFA. The color 
of the solution changed from red to green. The spectra of UV-visible spectrum 
indicated two new absorptions at 430 and 790 nm which are very similar to those of 
isoporphyrins. This may be due to the neutral nature of the solution compared with 
acidic conditions. Then zinc acetate was added as a reaction template because of 
its good coordination ability and its partial solubility in organic co-solvents. Zinc 
acetate changed the greenish color of the solution to red and showed absorptions 
at 470 and 540 nm as found under acidic conditions. DDQ was added to oxidize the 
zinc chelated open system to zinc(II) isoporphyrin 28 within ten minutes; 
characteristic absorptions at 430 and 825 nm appeared in the UV-visible spectrum 
in CH2Cl2. Alternatively, the reaction could be left in the air for several days; the 
intermediate was oxidized into zinc(II) isoporphyrin 28 (Scheme 2.12). Purification 
of the product was performed using an alumina column followed by a silica gel 
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column. Recrystallization of the product was performed using CH2Cl2/petroleum 
ether. The identity of the product was confirmed by mass spectrometry (Figure 2.5) 
and the UV-visible spectrum of the product is shown in Figure 2.6. 
 
 
Figure 2.5: The mass spectrum of zinc isoporphyrin 28. 
With the zinc isoporphyrin in hand, it was hoped that saponification of the 5-methyl 
ester group of the isoporphyrin could provide the corresponding carboxylic acid, 
which could then be conjugated with organelle-directing peptides so that we can 
further evaluate its biological properties. The reaction was attempted under basic, 
acidic and neutral condition. When the reaction was performed using 5% NaOH 14 in 
dry methanol, the UV-visible spectrum gave a sharp absorption around 400 nm 
after workup. This is obviously the result of decarboxylation of corresponding 
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carboxylic acid to give porphyrin. The rearrangement of isoporphyrin led to the 
more thermodynamically stable porphyrin. Then, ethylenediamine was used as 1.0, 
 
 
 
 
 
 
 
 
Figure 2.6: UV-visible spectrum of zinc(II) isoporphyrin 28 in CH2Cl2. 
1.5 and 4.0 equivalents vs. isoporphyrin at room temperature in CH2Cl2; the UV-
visible spectra showed peaks around 430 and 670 nm which appear to belong to 
metal-free isoporphyrin. However, these peaks disappeared upon work-up with 
water or dilute HCl. There is a possibility that ethylenediamine removed the zinc 
metal from the isoporphyrin through chelation to form a five membered ring and 
gave metal-free isoporphyrin, which is relatively unstable and decomposed 
immediately (Scheme 2.13). Lithium iodide15 was next used for the cleavage of the 
ester under neutral conditions. The reaction mixture was refluxed in ethyl acetate, 
DMF and pyridine for 24-48 hours, but the UV-visible and 1H NMR spectra of the 
zinc(II) isoporphyrin showed no change. This is perhaps due to the sterically 
hindered isoporphyrin ring system. Therefore, the more active reagent trimethylsilyl 
iodide16 was employed instead of LiI. However, UV-visible spectra did not show any 
peaks above 400 nm. Thus, It appears that the zinc(II) isoporphyrin decomposed 
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during the reaction. A substitute method to produce TMSI in situ by refluxing LiI and 
TMSCl in CH3CN solvent did not work either for the hydrolysis step (Scheme 2.14). 
Lewis acid boron halogens can also be used to cleave relatively simple hindered 
esters. When the reaction was performed at low temperature (around -25 oC), the 
UV-visible absorptions at 430 and 830 nm of the 
 
 
 
Scheme 2.13: Hydrolysis of methyl ester under basic conditions. 
 
isoporphyrin were present, but these absorptions disappeared after work-up with 
water, and a strong new absorption at 400 nm belonging to the corresponding 
porphyrin Soret absorption appeared.  
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Scheme 2.14: Attempted hydrolyses of zinc(II) isoporphyrin methyl ester under neutral 
and acidic conditions.  
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Acidic conditions such as BBr3
17 were also tried on the zinc(II) isoporphyrin but did 
not work. Based on the above work, we surmised that zinc(II) isoporphyr ins are not 
stable under harsh acidic or basic condition and even to strong nucleophiles due to 
the fact that the porphyrin is a good leaving group. Once the ester on isoporphyrin 
is hydrolyzed, the carboxylic acid group tends to decarboxylate immediately and 
form the corresponding porphyrin or ring opened system.  
To avoid this problem, the following strategies were planned. One choice was to 
introduce the benzyl ester group during the cyclization so that the ester group can 
be removed by hydrogenolysis under neutral conditions. Similarly, the b-bilene salt 
might also be cyclized by using 2,3-butanedione and the resultant acetyl group 
could possibly be converted into an amine group by an amination reaction (Scheme 
2.15). The b-bilene salt was successfully cyclized with benzyl pyruvate or 2,3-
butanedione under the same conditions as described above in three steps. The 
obtained zinc(II) isoporphyrins 31 and 32 have UV-visible absorptions at 431 and 
807 nm (Figure 2.7) and 407 and 807 nm (Figure 2.8), respectively.  
The benzyl ester substituted zinc(II) isoporphyrin was subjected to hydrogenolysis 
with Pd/C under hydrogen gas in THF overnight at room temperature; the UV 
spectrum showed typical peaks around 400, 532 and 668 nm which belong to 
porphyrin. This assumption is still consistent with a hydrolysis reaction. The 
carboxylic acid left as a result of decarboxylation and formed the corresponding 
porphyrin. For the acetyl substituted zinc(II) isoporphyrin, attempts to convert the 
ketone group into an amine group through reductive amination18 using BOC-
protected ethylenediamine as nucleophile and sodium triacetoxylborohydride as 
reducing agent failed, probably for similar reasons (Scheme 2.16). The UV/visible 
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spectrum showed a large peak at 406 nm and no peak around 800 nm, which 
indicated the zinc(II) isoporphyrin decomposed or was isomerized to porphyrin.  
 
 
Scheme 2.15: Cyclization of b-bilene salt using benzyl pyruvate or 2,3-butanedione. 
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Figure 2.7: UV/visible spectrum in CH2Cl2 of zinc(II) isoporphyrin 31 from 
cyclization of b-bilene salt with benzyl pyruvate. 
 
 
 
Figure 2.8: UV/visible spectrum in CH2Cl2 of zinc(II) isoporphyrin 32 from cyclization 
of b-bilene salt with 2,3-butanedione. 
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Scheme 2.16: Attempted reductive amination of zinc(II) isoporphyrin 32. 
Another choice was to cyclize the b-bilene salt by using benzyl or ethyl 
acetoacetate; in the product the resultant carboxylic acid group is separated from 
the α-position upon hydrolysis to avoid isomerization of isoporphyrin to porphyrin by 
simple decarboxylation (Scheme 2.17). Both benzyl acetoacetate and ethyl 
acetoacetate were used to cyclize the b-bilene hbydrochloride, and the reactions 
were monitored by UV-visible absorption spectroscopy. All the absorption spectra 
of intermediates are consistent with those intermediates seen during cyclization of 
the b-bilene salt using methyl pyruvate except for the oxidation step (Figure 2.9). 
There was no peak around 800 nm after adding DDQ or leaving it in air for a week, 
which indicated that zinc(II) isoporphyrin was not formed. The possible reason 
could be that the α-H from benzyl acetoacetate is not acidic enough to facilitate 
transformation into the intermediate required for cyclization to take place.  
From the above attempts to functionalize zinc(II) isoporphyrin such as hydrolysis, 
amination and aminolysis, it seems that isoporphyrins are sensitive to strong acid, strong 
base and even nucleophiles such as lithium iodide. Therefore, introducing a functional 
group such as amine during cyclization would be a good choice for modification of zinc(II) 
isoporphyrins. In this way functionalization of the isoporphyrin under harsh conditions 
can be avoided. Pyruvate amide was chosen as a cyclizing reagent with the b-bilene salt, 
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Scheme 2.17: Cyclization of b-bilene hydrochloride using acetoacetate esters. 
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Figure 2.9: UV-Visible spectral changes in CH2Cl2 during cyclization of b-bilene 
hydrochloride 14 with benzyl acetoacetate. 
with the intention that the amine group would be employed later to conjugate with 
biomolecules. Two methods were attempted to make the α-keto amides. One involves a 
peptidic coupling reaction19 between α-keto acids and amines in the presence of 
coupling reagents such as DCC with DMAP，BOP-Cl, PyBOP-PF6 with TEA and EDC 
with HOBt (Figure 2.10). The other method involves chlorination of α-keto acids followed 
by aminolysis with amines. A test reaction between pyruvic acid and hexylamine was 
examined with different coupling agents and the results are presented in Table 2.1. From 
this table it can be seen that coupling agents DCC with DMAP, BOPCl or PyBOP with 
TEA or DIEA only gave trace amount or very low yields of product. In contrast, HOBt 
with EDC led to an improved yield at 47% with DMF as the solvent. However for similar 
synthesis of β,γ-unsaturated α-keto amides reported by Rodriguez,20 both BOPCl/TEA 
and PyBOP/DIEA gave them quantitive yields.  
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Figure 2.10: The coupling reagents used in reactions. 
Table 2.1: The Coupling Reaction Using Different Reagents. 
 
entry Coupling reagents Solvent system yield 
1 DCC/DMAP DCM trace 
2 BOPCl/TEA DCM 10% 
3 PyBOP/TEA DCM 12% 
4 BOPCl or PyBOP/DIEA DCM 15% and 19% 
5 HOBt/EDC DMF 47% 
 
Meantime, a parallel alternative method was tried that involved chlorination of pyruvic 
acid with oxalyl chloride in CH2Cl2 followed by aminolysis
21 with hexylamine using TEA 
as base. A catalytic amount of DMF was added to speed up the reaction (Scheme 2.18). 
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The tedious part of this method is that oxalyl chloride is hard to remove from the reaction 
after chlorination; the remaining oxalyl chloride reacted with hexylamine to give a 
symmetrical diamide 39 which was inseparable from the product on a chromatography 
column. The purification was done by recrystallization using CH2Cl2/diethyl ether as the 
solvent system, to give 52% yield of product 38.  
 
 
Scheme 2.18: Synthesis of pyruvate amide 38 by aminolysis reaction.  
Therefore, the hexyl pyruvatamide was used as a test reagent to see if it was possible to 
cyclize b-bilene salts using an α-ketoamide. Under the same conditions as previously, a 
peak around 821 nm in the UV/visible spectrum appeared with time and indicated the 
formation of zinc(II) isoporphyrin 40 (Scheme 2.19). The hexylpyruvate amide proved 
that α-keto amides can cyclize with a b-bilene salt, so it was decided to synthesize a N-
protected α-keto amine so that it can be deprotected later and used as a group to 
conjugate with amino acids. The similar conjugation reaction between pyruvic acid and 
mono-BOC protected ethylenediamine was performed with HOBt/EDC as coupling 
reagents. The product 41 was generated with a slightly lower yield of 41%. Similarly, the 
BOC-protected lysine was also conjugated with pyruvic acid under the same conditions 
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with a 32% yield of the product 42 (Scheme 2.20). Both of these two pyruvate amides 
were used to cyclize b-bilene salts in three steps. For mono-BOC-protected 
ethylenediamine pyruvate amide, a peak appeared around 826 nm (Figure 2.11) after 
zinc acetate was added and  
 
Scheme 2.19: Cyclization of b-bilene salt with hexyamine pyruvate amide. 
it was left in air for five minutes, which proved that the macrocycle was formed. However, 
the peak disappeared with time unexpectedly since it should be increased in size 
through oxidation by oxygen in air. The assumption is that the cyclization of b-bilene salt 
into zinc(II) isoporphyrin and cyclization to give porphyrin compete with each other; with 
a long chain on the meso-carbon of the isoporphyrin, the ring opening is more favored 
than cyclization, and the open chain compound is cyclized into porphyrin with time. In 
the case of the BOC-protected lysine pyruvate, the cyclization did not succeed, 
UV/visible spectrophotometry gave no proof of formation of zinc(II) isoporphyrin. This is 
probably due to the steric effect from the lysine chain compared with BOC-protected 
enthylenediamine pyruvate (Scheme 2.21).  
 
  
53 
 
 
 
Scheme 2.20: Synthesis of BOC-ethylenediamine and BOC-lysine pyruvate amide 
41 and 42. 
 
 
 
Figure 2.11: The UV/visible spectrum in CH2Cl2 of the cyclization of b-bilene salt 
with BOC-ethylenediame pyruvate amide 42. The peak at 400 nm indicates 
porphyrin formation. 
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Scheme 2.21: Cyclization of b-bilene salt using BOC-lysine and BOC-
ethylenediamine pyruvate amides 41 and 42. 
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2.5. Conclusion 
Zinc isoporphyrins were synthesized by cyclization of b-bilene salts with active α-keto 
esters in good yield. The product was characterized using NMR spectroscopy, mass 
spectroscopy and UV-visible spectroscopy. The resultant zinc(II) 
decamethylisoporphyrin chloride is stable at room temperature in daylight without 
decomposition or transformation into porphyrin. Attempts to hydrolyze the 5-methyl ester 
was so far unsuccessful due to facile decarboxylative conversion into porphyrin during 
the hydrolysis step. Efforts to introduce functional groups or biomolecules onto the zinc(II) 
isoporphyrin during cyclization did not solve the problem of isoporphyrin conjugation with 
biomolecules.  
 
2.6. Experiment Part 
tert-Butyl 3,4,5-trimethylpyrrole-2-carboxylate 21 
Sodium nitrite (11.5 g, 0.16 mol) in water (40 ml) was added drop-wise with stirring and 
cooling to t-butyl acetoacetate（26 g, 0.16 mol）in glacial acetic acid (54 ml) at 0 ºC. 
Stirring was continued for a further 3 h; then the mixture was kept overnight at room 
temperature. The resultant t-butyl oximinoacetate solution was added drop-wise to a 
solution of 3-methyl-2,4-pentanedione (25 g, 0.22 mol) in acetic acid (88 ml) during 
portion-wise addition of an intimate mixture of zinc dust (25 g) and sodium acetate (25 g). 
The addition rate was controlled so that the solution temperature was maintained around 
70 ºC. The addition continued for about 1.5 h and the reaction mixture was refluxed for 2 
h. The reaction was monitored by TLC. After reaction was complete, the reaction 
solution was poured into ice/water and a yellow precipitate was filtered and washed with 
water until neutral. The solid was dissolved in CH2Cl2 and dried over anhydrous Na2SO4 
overnight. The solvent was evaporated and the solid was recrystallized from 
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CH2Cl2/ethanol in the fridge to yield yellow needle crystals. 
1H NMR (CDCl3, 400 MHz) δ 
8.45 (s, br, 1H), 2.22 (s, 3H), 2.17 (s, 3H), 1.90 (s, 3H), 1.55 (s, 9H). 
 
t-Butyl 5-acetoxymethyl-3,4-dimethylpyrrole-2-carboxylate 18 
tert-Butyl 3,4,5-trimethylpyrrole-2-carboxylate (1.74 g, 8.3 mmol) was dissolved in acetic 
acid (39 ml) and acetic anhydride (1.0 ml). Then excess lead tetra-acetate (4.05 g, 9.1 
mmol) was added to the solution portion-wise under argon. After addition was complete, 
the mixture was stirred overnight. The reaction was monitored using TLC. When the 
reaction was complete, the brown solution was treated drop-wise with 40 ml of ice/water 
and a yellow precipitate was formed. The solid was filtered and washed with distilled 
water to remove acetic acid and lead acetate. The solid was dried over anhydrous 
Na2SO4 in CH2Cl2 and recrystallization from CH2Cl2/hexane in the fridge gave a yellow 
solid 1.40g (60%). 1H NMR (CDCl3, 400 MHz) δ 8.88 (s, br, 1H), 5.01 (s, 2H, -CH2-O), 
2.23 (s, 3H, COCH3), 2.07 (s, 3H), 2.00 (s, 3H), 1.56 (s, 9H).  
 
Ethyl 3,4-dimethylpyrrole-2-carboxylate 24 
Acetaldehyde (13.0 ml, 0.465 mol) was stirred into isopropanol (8.5 ml) containing 
potassium fluoride (0.67 g, 0.023 mol, 0.05 mol eq), and the stirring was continued until 
the aldehyde had completely dissolved. To the stirred alcoholic solution was then added, 
drop by drop, nitroethane (16.5 ml, 0.46 mol)in an ice bath during 1 h; after this addition, 
stirring was continued overnight at room temperature under argon. Then the catalyst 
was removed by filtration. The residue, upon the removal of solvent, was poured into 
water and the residual oily matter was extracted with ether. Then the extract was dried 
over anhydrous Na2SO4 and the solvent was removed to give yellow oily product 2-nitro-
butanol-3 (21.35 g, 40%).  
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To a flask was added acetic anhydride (19.2 g, 188 mmol, 1.5 eq), 4-
dimethylaminopyridine (DMAP, 0.2 g) and CH2Cl2 (10 ml). 2-Nitro-3-butanol (15 g, 126 
mmol) was added to the mixture over 20 min. The mixture was allowed to stir for 4 h at 
room temperature under argon. After reaction was complete, methanol (60 ml) was 
added to the solution which was stirred for 30 min to destroy excess acetic anhydride. 
Then, the solution was poured into dilute aqueous NaHCO3 (18 g in 100 ml water) and 
extracted with CH2Cl2 (3 x 40 ml), the organic layer was dried over anhydrous Na2SO4 
and filtered through a short column of silica gel. Removal of solvent gave the product as 
yellowish liquid (20.30 g, 49.5%). 
 
To a solution of ethyl isocyanoacetate (2.51 g, 19 mmol, 1.05 eq), and 
tetramethylguanidine (4.41g, 38 mmol) in 6 ml of THF/Isopropanol (1:1) was added a 
solution of β-acetoxy-3-nitrobutane (3.0 g, 18.6 mmol) in 18 ml THF/isopropanol (1:1) 
drop-wise in an ice bath.  After addition was complete, the solution was stirred at room 
temperature overnight under argon. When TLC showed reaction was complete, the 
resultant solution was concentrated to remove solvent. The oily residue was taken up in 
CH2Cl2 and washed successively with water (6 ml x 3), 5% aqueous HCl (6 ml x 3), 
water (6 ml x 3), aqueous saturated NaHCO3 (6 ml) and brine (6 ml); then the product 
was dried over anhydrous Na2SO4 and the solvent was removed under vacuum to give 
the crude product. Recrystallization from CH2Cl2/hexane gave the product as a yellowish 
solid. 1H NMR (CDCl3, 400 MHz) δ 8.65 (s, br,1H), 6.65 (d, 1H), 4.32 (q, 2H, O-CH2-CH3), 
2.27 (s, 3H), 2.01 (s, 3H), 1.35 (t, 3H, CH2-CH3).  
 
Benzyl 3,4-dimethylpyrrole-2-carboxylate 19 
Sodium metal (0.168 g, 7.3 mmol) was added to benzyl alcohol (60 ml) under argon. 
Once all the sodium had reacted, the ethyl ester pyrrole 24 (2.32 g, 14 mmol) was added 
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and the resultant mixture was heated in an oil bath at 90 ºC for 10 h. The mixture was 
allowed to stand at room temperature overnight and 1 equiv of acetic acid (0.438 g, 7.3 
mmol) was added to neutralize the sodium benzoate. Benzyl alcohol was evaporated to 
dryness under reduced pressure and the residue was dissolved in CH2Cl2, washed with 
water and treated with decolorizing carbon. After filtration through a Celite cake, the 
solution was dried over anhydrous MgSO4 and the solvent was evaporated under 
vacuum to yield a brown solid (1.5 g, 90% yield).1H NMR (CDCl3, 400 MHz) δ 8.70 (s, br, 
1H), 7.26-7.41 (m, 5H), 6.65 (d, 1H), 5.30 (s, 2H), 2.28 (s, 3H), 2.01 (s, 3H).  
 
tert-Butyl 9-(benzyloxycarbonyl)-3,4,7,8-tetramethyldipyrromethane-1-carboxylate 
25 
Montmorillonite clay (K10; 9 g) was added to a solution of 5-acetoxymethylpyrrole 18 
(2.72 g, 10 mmol) and 5-unsubstituted pyrrole 19 (2.52 g, 10.1 mmol) under argon in 
CH2Cl2 (100 ml) in a round-bottomed flask. The resultant mixture was stirred vigorously 
overnight and the reaction was monitored by TLC. After reaction was complete, the clay 
catalyst was filtered off and washed with CH2Cl2 and the solvent was removed on a 
rotary evaporator. From 1H NMR analysis, the crude product was already pure enough to 
be used in the next step. Further purification was done on a silica gel column using 
CH2Cl2 containing a little methanol as elution solvent. Alternatively the product could be 
recrystallized from CH2Cl2/petroleum ether in the fridge. 
1H NMR (CDCl3, 400 MHz) δ 
8.93, 8.68 (s, br,1H each), 7.26-7.35 (m, 5H), 5.27 (s, 2H, CH2-Ph), 3.81 (s, 2H), 2.26 (s, 
3H), 2.22 (s,3H), 1.94 (s, 3H), 1.93 (s, 3H), 1.53 (s, 9H). 
 
1-(tert-Butyloxycarbonyl)-2,3,7,8-tetramethyldipyrromethane-9-carboxylic acid 26 
A solution of mixed ester dipyrromethane 25 (2.0 g, 46 mmol) in approximately 80 ml of 
freshly distilled THF was degassed with argon for approximately 15 min. Then to the 
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solution was added 10% Pd/C (0.13 g) and the suspension was stirred under pressure of 
hydrogen gas at room temperature for 16 h; when the TLC showed the reaction was 
complete, the catalyst was removed by filtering through a bed of Celite and washed with 
THF. The collected filtrate was evaporated and a yellowish foamy solid formed. The 
product was further dried to give 1.50 g of product 26 (95% yield). δ 1H NMR (CDCl3, 400 
MHz) 3.85 (s, 2H), 2.28, 2.18, 2.08, 2.01 (s, 3H each), 1.55 (s, 9H). 
 
tert-Butyl 9-formyl-2,3,7,8-tetramethyldipyrromethane-1-carboxylate 27 
To a 100 ml round bottom flask were added dipyrromethane monocarboxylic acid 26 
(300 mg, 0.86 mmol) and 40 ml of distilled CH2Cl2 under argon. p-Toluenesulfonic acid 
(328 mg, 1.7 mmol) was added portion-wise. Stirring was continued for 1.5 h until TLC 
showed completion of reaction. Saturated NaHCO3 was added to neutralize the solution, 
followed brine, and the organic phase was dried over anhydrous MgSO4. Evaporation of 
the solvent yielded a brown-reddish semi-solid which was dried under high vacuum to 
remove any solvents. Dry DMF (1.0 ml) was added to the crude material and the solution 
was cooled to 0 ºC. Meanwhile, Vilsmeier complex was prepared by adding benzoyl 
chloride (0.6 ml, 5.1 mmol) drop-wise to dry DMF (0.8 ml, 10.3 mmol) at 0 ºC, with 
stirring for 30 min. The Vilsmeier complex was added drop-wise to the decarboxylated 
mixture with stirring and after 15 min, stirring was continued at room temperature for a 
further 50 min. TLC showed formation of the imine salt. Toluene (10 ml) was added and 
small grains of precipitate were formed. The toluene was evaporated and the residue 
was dissolved in ethanol (25 ml), before 1.5 g of NaHCO3 in 25 ml water was added. 
Stirring was continued overnight at room temperature; the yellowish precipitate was 
collected, the solid was dissolved in CH2Cl2 and washed with water and dried over 
anhydrous Na2SO4. Then the solvent was removed by evaporation and the yellowish 
solid was chromatographed on a silica gel column eluting with 3% methanol/ CH2Cl2 to 
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afford 171 mg (60%) of the title product. 1H NMR (CDCl3, 400 MHz) δ 10.05(s, br,1H), 
9.50 (s, 1H), 9.22 (s, br, 1H), 3.88 (s, 2H), 2.26, 2.24, 1.99, 1.96 (s, CH3 each), 1.52 
(s,9H). 
 
Di-tert-butyl 2,3,7,8,12,13,17,18-octamethyl-b-bilene-1,19-dicarboxylate 
hydrochloride 14 
Dipyrromethane monocarboxylic acid 26 (0.14 mmol, 50 mg) and formyldipyrromethane 
27 (0.12 mmol, 40 mg) were dissolved in 10 ml of dry CH2Cl2 and stirred under argon. p-
Toluenesulfonic acid (53.0 mg, 2 equiv) was added portion-wise to the solution and the 
mixture was kept stirring for 2 h; the reaction was monitored using UV/visible 
spectroscopy. When a strong absorption at 502 nm was evident, the dark red solution 
was washed with 5% NaHCO3 solution and water and then dried over anhydrous MgSO4. 
The solvent was evaporated under reduced pressure to provide the b-bilene 
intermediate salt, which was dissolved in 5 ml of dry CH2Cl2 and hydrogen chloride was 
bubbled for 30 sec and whereupon the color changed to dark red as the hydrochloride 
salt formed. The solvent was evaporated and the residue was taken up twice in dry 
toluene and evaporated to remove any traces of water and HCl. The resultant residue 
was recrystallized from CH2Cl2/hexane and kept in the fridge overnight to give red 
product (45 mg, 63%). 1H NMR (CDCl3, 400 MHz) 7.07 (1H), 4.22 (CH2, 4H), 2.22, 2.21, 
2.04, 2.02, (each CH3, 6H), 1.55 (t-butyl, 18H). 
 
Zinc(II) 2,3,5,7,8,12,13,17,18-nonamethyl-5-(methoxycarbonyl)isoporphyrin 
chloride 28 
b-Bilene hydrochloride 14(50 mg, 0.08 ml) was added to a flask and cold TFA (0.3 ml) 
was added under argon and the reaction was kept stirring for 10 min. The solution was 
diluted with 20 ml of CH2Cl2 and this is followed by addition of methyl pyruvate (8.2 mg, 
  
61 
 
0.08 mmol). The mixture was stirred another 2 h. whereupon the UV/visible spectrum 
showed the disappearance of the absorption around 500 nm and new absorptions 
around 450 and 520 nm. The reaction was stopped and the excess TFA was removed 
by washing with water and the reddish solution changed to green after work-up, which 
had absorption maximum around 430 and 790 nm. The green intermediate was 
dissolved in dry CH2Cl2 (30 ml) followed by addition of Zn(OAc)2 (20 mg) in 1 ml of dry 
methanol under argon. The solution immediately changed back to reddish and new 
absorptions around 470 and 540 nm were apparent. After about 10 min, DDQ (50 mg, 
0.22 mmol) was added to oxidize the product for 30 min, the UV-visible spectrum of the 
solution then showed absorptions around 430 and 830 nm, these being characteristic 
absorptions of the zinc(II) isoporphyrin 28. Then the reaction was kept for about 1 h and 
washed with water and brine. The product was dried over anhydrous Na2SO4. The 
purification was performed by chromatography on an alumina column eluting with 
CH2Cl2 and the fraction with the absorption of zinc(II) isoporphyrin was collected. Further 
purification was performed on a silica gel column eluted with CH2Cl2/ethyl acetate (7:3) 
and the product was recrystallized from CH2Cl2/petroleum ether. 
1H NMR (CDCl3, 
400MHz) δ, ppm 7.66 (s, meso-H, 1H), 7.58 (s, meso-H, 2H), 3.63 (s, 5-OCH3, 3H), 2.43, 
2.41, 2.38, 2.18 (s, β-CH3, 24H), 1.97 (s, 5-CH3, 3H). 
 
Zinc(II) 2,3,5,7,8,12,13,17,18-Nonamethyl-5-benzylcarbonylisoporphyrin chloride 31 
This compound was prepared as described above, in 5% yield.1H NMR (CDCl3, 400 
MHz) δ ppm 7.63 (s, 2H), 7.59 (s, 1H), 7.01-6.99 (5H), 5.0 (s, 2H), 2.45, 2.41, 2.37, 1.99 
(s, β-CH3, 24H), 1.94 (s, 3H). 
 
Zinc(II) 2, 3, 5,8,12,13,17,18-nonamethyl-5-acetylisoporphyrin chloride 32 
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This compound was prepared as described above, in 20% yield. 1H NMR (CDCl3, 400 
MHz) δ ppm 8.11-8.04 (m, 3H), 2.60, 2.57, 2.29, 2.27 (s, β-CH3, 24H), 1.92 (s, 3H), 1.89 
(s, 5-CH3, 3H). 
 
Hexylpyruvate amide 38 
Method I: Pyruvic acid (0.20 g, 2.27 mmol) was dissolved in CH2Cl2 (30 ml) and then 
Et3N (0.34 g, 0.47 ml) was added under argon. The mixture was cooled down to 0 
oC, 
and BOPCl (0.70 g, 2.7 mmol) was added in one portion. The mixture was stirred at 0 oC 
for 30 min and then hexylamine (0.34 g, 3.40 mmol) was added. The mixture was 
allowed to warm to room temperature and was then stirred overnight. The solution was 
diluted with CH2Cl2 and washed with aqueous 1N HCl, water and then brine. The organic 
layer was dried over Na2SO4 and the product was purified by silica gel column 
chromatography eluting with 2% MeOH in CH2Cl2 to give the product 38.8 mg (10%).  
Method 2: Pyruvic acid (0.20 g, 2.27 mmol) was dissolved in CH2Cl2 (30ml) and then 
oxalyl chloride (1.5 ml) was added followed by a drop of DMF; when the mixture stopped 
bubbling, it was left stirring for 1 h. Then the solvent was removed in vacuo. The residue 
was dissolved in CH2Cl2 (20 ml) and then hexylamine (0.34 g) was added at 0 
oC, 
followed by TEA (0.34 g, 0.47 ml). The mixture was stirred overnight at room 
temperature. Then the solution was washed with 1 N HCl, water, brine and dried over 
anhydrous Na2SO4. The product was purified by crystallization from CH2Cl2/ether to give 
required product (0.20 g, 52%). 1H NMR (CDCl3, 400 MHz) δ ppm 6.94 (s, 1H), 3.30 (t, 
2H) 2.47 (s, 3H), 1.53 (m, 2H), 1.29 (m, 6H), 0.89 (t, 3H). HRMS (ESI): m/z Calcd for 
C9H17NNaO2: 194.1157; found: 194.1152.  
 
BOC-ethylenediamine pyruvate amide 41: This synthesis followed procedure used for 
compound 38. 
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Yield: 37%, 1H NMR (CDCl3, 400MHz): δ ppm 7.49 (s. 1H), 5.0 (s, 1H), 3.40 (t, 2H), 3.28 
(t, 2H), 2.43 (s, 3H), 1.39 (s, 9H). HRMS (ESI): m/z Calcd for C10H18N2NaO4: 254.1164; 
found: 254.1151. 
 
BOC-lysine pyruvate amide 42: The preparation of lysine pyruvate amide followed the 
procedure used for compound 38. Yield: 40% 1H NMR (CDCl3, 400MHz): δ, ppm 7.38 (s, 
1H), 7.36 (s, 1H) 4.52 (m, 1H), 3.74 (s, 3H), 3.09 (t, 2H) 2.46 (s, 3H), 1.91-1.69 (m, 4H), 
1.41(s, 9H), 1.32(m, 2H). HRMS (ESI): m/z Calcd for C15H25N2O6: 329.1713; found: 
329.1723. 
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2.7 Supporting Information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectra of pyrrole 21 and 18 in CDCl3 at 400 MHz. 
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1H NMR spectra of pyrrole 24 and 19 in CDCl3 at 400 MHz. 
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1H NMR spectra of dipyrromethanes 25 and 27 in CDCl3 at 400 MHz. 
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1H NMR spectra of b-bilene salt 14 and isoporphyrin 28 in CDCl3 at 400 MHz. 
  
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectra of isoporphyrin 32 and pyruvate amide 38 in CDCl3 at 400 MHz. 
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1H NMR spectra of pyruvate amide 41 and 42 in CDCl3 at 400 MHz. 
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Chapter 3: Syntheses of Zinc(II) Isoporphyrins through MacDonald Condensation 
3.1. Background 
Dipyrrolic intermediates including dipyrromethenes1,2 and dipyrromethanes3-6 have been 
used to synthesize porphyrins. Usually the synthesis of the macrocycle involves 
condensation between one half bearing electrophilic groups such as formyl7,8 or 
bromomethyl9 and the other half which acts as a nucleophile, such as an α-free  
 
Scheme 3.1: Synthesis of porphyrin by [2+2] dipyrromethene (Fischer, 3+4 to 1) and 
dipyrromethane (MacDonald, 5+6 to 2) condensation. 
or bromo substituted dipyrromethenes (Scheme 3.1). This method using 
dipyrromethenes was developed by Hans Fischer and is an example of a [2+2]10-12 
approach, usually only applied to synthesize symmetrical porphyrins13,14 since this 
methodology has no selectivity between both ends of the two dipyrrole halves. On the 
other hand, use of dipyrromethanes (MacDonald approach) also yields porphyrins with 
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the same limitations as the Fischer approach, but under milder conditions. For 
asymmetric porphyrins, this method will result a mixture of products due to the selectivity 
limitation unless one or other of the two dipyrromethenes or two dipyrromethanes is 
symmetrically substituted about its central methane carbon atom.. The MacDonald 
dipyrromethane method was expanded successfully to synthesis of symmetrical 
isoporphyrins by Smith’s group,15-17 and became a fairly universal method to synthesize 
symmetrical isoporphyrins. The synthesis of zinc(II) isoporphyrin by the [2+2] approach 
usually involves a condensation reaction between a 1,9-diformyldipyrromethane and 1,9-
unsubstituted dipyrromethane, catalyzed by acid (Scheme 3.2). According to the  
 
Scheme 3.2: Synthesis of zinc(II) isoporphyrin 7 by MacDonald 2 + 2 condensation. 
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structure of the target isoporphyrin, one of the dipyrromethane halves should be meso-
disubstituted by alkyl or other groups. Metal is necessarily needed to serve as a 
template and to stabilize the isoporphyrin compounds once formed. In Chapter 2, 
attempts to introduce functional group such as carboxylate or acetyl group to a meso-
carbon during cyclization of a b-bilene were discussed;18 however, the transformation of 
these groups into carboxylic acid or amine groups failed when attempts were made to 
further functionalize the corresponding zinc(II) isoporphyrins after cyclization. The most 
plausible reason could be due to the fact that porphyrin is a very good and stable leaving 
group, and once the ester or amide bond on the meso-carbon of the zinc(II) isoporphyrin 
is cleaved, the decarboxylation takes place leaving a fully aromatic porphyrin as the 
leaving group. Therefore, to avoid this problem, the isoporphyrin 12 bearing two PMe 
(CH2CH2CO2CH3)
 groups on pyrrole subunits was chosen as the target. From the 
structure we can see the fully conjugated macrocycle is interrupted by one meso-carbon 
which is saturated by geminal methyl groups. 
3.2. Retrosynthesis 
According to the MacDonald 2 + 2 condensation, the target molecule can be cyclized by 
reaction between a 5,5-dimethyldipyrromethane-1,9-dicarboxylate 13 and a 1,9-
diformyldipyrromethane 16 in three steps. These two dipyrromethanes can be obtained 
by debenzylation and and debenzylation and diformylation of the corresponding 
dipyrromethanes, which were obtained through condensation of pyrrole 15 with acetone 
(for 13) and self-condensation of pyrrole 18 (for 16) (Scheme 3.3). The pyrrole starting 
materials were synthesized by conventional methods including synthesis of α-free 
pyrrole 15 by Baton Zard method and Johnson synthesis of pyrrole 18.  
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Scheme 3.3: Retrosynthesis of zinc(II) isoporphyrin 12 by the 2+2 MacDonald 
condensation approach. 
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3.3. Synthesis of Isoporporphyrins 
The synthesis started with pyrroles 18 and 20. Pyrrole 20 was synthesized, as follows, 
by Johnson’s method.19,20 Benzyl acetoacetate was treated with sodium nitrite in acetic 
acid to generate benzyl oximinoacetoacetate 19, which was condensed with 3-methyl-
2,4-pentanedione in glacial acetic acid in the presence of zinc dust and sodium acetate. 
The mixture was refluxed for one hour and the yellow precipitate was separated and 
recrystallized from CH2Cl2/hexane to give the product in around 65% yield. Pyrrole 18 
was synthesized using a similar strategy; the precursor 21 was made by Michael 
addition of methyl acrylate to 2,4-pentanedione under basic conditions, and this was 
then condensed with benzyl oximinoacetoacetate, under the same conditions as 
previously, to afford the pyrrole 18 in around 50% yield. Pyrrole 18 was then treated with 
bromine in dry ether to give the intermediate 2-bromomethylpyrrole, which was 
converted into the corresponding symmetrical dipyrromethane 17 through self-
condensation by refluxing in methanol.21 The product was purified by crystallization from 
cold methanol (Scheme 3.4).  
Dipyrromethane 17 was converted into the dicarboxylic acid 22 by catalytic 
hydrogenation using palladium on activated carbon as catalyst. This dicarboxylic acid 
was further converted into the 1,9-diformyldipyrromthane 16 by a Vilsmeier-Haack 
reaction in two steps. Decarboxylation of the dipyrromethane dicarboxylic acid was 
performed at 160 oC in DMF for one hour and resulted in the 1,9-di-unsubstituted 
dipyrromethane, which was treated with a mixture of DMF and benzoyl chloride 
(Vilsmeier reagent) followed by basic hydrolysis to give the product 16 in 70% yield. The 
other half, 5,5-dimethyldipyrromethane 14,22 was synthesized by condensation between 
the α-free pyrrole 15 (2 equivalents) and acetone with BF3.OEt2 as catalyst. Another  
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Scheme 3.4: Synthesis of pyrroles 18 and 20 and dipyrromethanes 17 and 28. 
major fraction was separated from chromatography column (running faster than the 
designed product), which was identified as compound 23 according to 1H NMR (Scheme 
3.5). Cyclization to give the zinc(II) isoporphyrin was finished in three steps15 (Scheme 
3.6): (1) The dipyrromethane dicarboxylic acid 13 was treated with toluenesulfonic acid 
to decarboxylate the two α-positions of the dipyrromethane; (2) The 
diformydipyrromethane 16 was added, followed by zinc acetate as a template, and the 
reaction mixture was kept in the dark for 12 hours; (3) The reaction mixture was opened 
to air to oxidize the cyclized intermediate. The reaction was monitored by UV/visible 
absorption spectroscopy (Figure 3.1), with the characteristic peak around 800 nm 
becoming more pronounced with time, usually reaching a maximum after seven days. 
The product was purified by chromatography on silica gel, eluted with CH2Cl2/MeOH to 
give a yellowish solid in 20% yield. For zinc(II) isoporphyrin 12, the Soret band and Q-
band showed up at 414 and 799 nm, respectively. The identity of the product was also 
confirmed by mass spectrometry (m/z at 657.2643). 
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Scheme 3.5: Synthesis of dipyrromethane dicarboxylic acid 13  and 
diformydipyrromethane 16. 
 
 
 
Scheme 3.6: Synthesis of zinc isoporphyrin 12 by 2+2 MacDonald cyclization.  
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Figure 3.1: Absorption spectrum of zinc(II) isoporphyrin 12 in CH2Cl2. 
After the success in the synthesis of zinc(II) isoporphyrin 12, we expanded this method 
to the synthesis of other zinc(II) isoporphyrins. Molecules 24 and 29 were therefore 
designed, which have one, two or three ester groups; these isoporphyrins could be 
converted into the corresponding carboxylic acid substituted isoporphyrins so that they 
could be conjugated with biomolecules. In this way one can compare the differences of 
the biological properties of isoporphyrins mono-, di- and tri-conjugated with biomolecules. 
The retrosyntheses of these two molecules are similar to that for zinc(II) isoporphyrin 12; 
these involve two dipyrromethanes with two carboxylic acid groups on both ends of one 
dipyrromethane 25 or 30 and two formyl groups on both ends of the other 
dipyrromethane 26 or 31. Of course, the functional groups can be switched between 
these two dipyrromethanes 27 and 28 or between 32 and 17. Theoretically, there should 
be no differences when these two halves approach each other to form macrocycles 
(Scheme 3.7).  
Dipyrromethane 25 was synthesized by condensation of α-free pyrrole with ethyl 
acetoacetate, catalyzed by BF3.OEt2 in ethanol; the solution was refluxed overnight and 
the product was separated by chromatography to give 7-15% yields. Meanwhile, another 
major fraction was separated and identified to be 5,5-dimethydipyrromethane 14. A 
possible mechanism for formation of 14 supposes that the ethyl acetoacetate was 
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hydrolyzed to carboxylic acid under acidic conditions, which was converted to acetone 
by acid catalyzed decarboxylation through a six membered ring; the α-free pyrrole  then 
reacted with the generated acetone to form 5,5-dimethyldipyrromethane 14 (Scheme 
3.8). The other dipyrromethane half 28 was synthesized with the same strategy as 
previously used, by bromination of the α-methylpyrrole 20 followed by self-condensation 
by refluxing it in methanol. The product 28 was crystallized from methanol to give a white 
solid in 70% yield. Then dipyrromethane 28 was catalytically debenzylated to give the 
dicarboxylic acid, which was treated with TFA/trimethylorthoformate23 and then 
recrystallized from ethanol to give the diformydipyrromethane 26 (Scheme 3.9) in 35% 
yield. The dipyrrolmethane 25 was debenzylated by hydrogenation catalyzed by Pd/C 
and the resultant dicarboxylic acid was used as the precursor of the bis-α-free 
dipyrromethane. The cyclization the corresponding dipyrromethane dicarboxylic acid 
from 25 with the diformyldipyrromethane 26 was performed under the same conditions 
as previously reported in three steps (Scheme 3.10). Unfortunately, the desired product 
was not obtained according to UV/visible absorption spectroscopy, the characteristic 
peak of zinc(II) isoporphyrin around 800 nm being absent. According to Lash’s 
synthesis24 of extended indene-fused porphyrins 39 (Scheme 3.11), when the diformyl 
groups were located on the more strained dipyrromethane 36 instead of 35, the reaction 
gave better yields than the other way around. We therefore took the same strategy with 
the synthesis of our zinc(II) isoporphyrin in this case. Before we switched the carboxylic 
acid and formyl groups between the two dipyrromethanes; we synthesized 
dipyrromethane 30 by reacting the α-free pyrrole 15 with ethyl levulinate, catalyzed by 
BF3.OEt2 in EtOH, to give a 30% yield compared with dipyrromethane 25 (Scheme 3.12), 
which had a lower yield of around 10% because of the competition from production of 
the side product dipyrromethane 23. The cyclization of dipyrromethane 30 with the same 
diformydipyrromethane 26 failed to give the corresponding isoporphyrin, the UV/visible  
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Scheme 3.7: Retrosynthesis of zinc(II) isoporphyrins 24，29 and 33 by MacDonald 2+2 
condensation. 
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Scheme 3.8: Synthesis of dipyrromethanes and the proposed route for formation of side 
product 15. 
 
Scheme 3.9: Sythesis of dipyrromethanes 28 and 26. 
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absorption around 500 nm indicating only one side was joined together to give an open-
chain b-bilene. Therefore, the formyl groups were introduced onto dipyrromethane 30 
instead of dipyrromethane 26, which remained as the dipyrromethane dicarboxylic acid 
prior to cyclization. These two dipyrromethanes 32 and 28 were used for the cyclization 
using the identical previous conditions, and finally gave the desired zinc(II) Isoporphyrin 
product 33. The reaction was mainly monitored by UV/visible absorption spectroscopy, 
and the product possessed a Soret band at 423 nm and a Q-band at 813 nm (Scheme 
3.13).  
 
 
 
Scheme 3.10: Attempt to synthesize Isoporphyrin 24 and 33 by MacDonald 2+2 
condensation.  
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Scheme 3.11: Lash’s synthesis of indene-fused porphyrins.24 
 
 
Scheme 3.12: Synthesis of diformydipyrromethane 30 and diformydipyrromethane 32.  
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Scheme 3.13: Synthesis of zinc(II) isoporphyrin 34 by MacDonald 2+2 condensation 
between diformyldipyrromethane 32 and dipyrromethane carboxylate 28, and UV-visible 
spectrum of 33 in CH2Cl2. 
Based on the route used for synthesis of zinc(II) isoporphyrins 12 and 33, the 
isoporphyrin 40 was produced by cyclization between the dicarboxylic acid of 
dipyrromethane 30 and diformydipyrromethane 16 in around 4% yield. This zinc(II) 
isoporphyrin has a Soret band at 423 nm and a Q-band at 804 nm (Scheme 3.14).  
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Scheme 3.14: Synthesis of zinc(II) isoporphyrin 40 by 2+2 MacDonald condensation, 
and  the UV/visible spectrum of 40 in CH2Cl2. 
 
3.4 Attempts to Hydrolyze Ester Groups on Zinc(II) Isoporphyrins 
After success in the synthesis of the zinc(II) isoporphyrins, various methods to convert 
the meso-methyl ester group into the corresponding carboxylic acid were attempted so 
that they could subsequently be conjugated with biomolecules. As discussed in Chapter 
2, when the ester is directly attached to the 5-position of the zinc(II) isoporphyrin, the 
isoporphyrin will leave as a zinc(II) porphyrin after hydrolysis and spontaneous 
decarboxylation. However, with an ester group on the pyrrole unit of zinc(II) isoporphyrin 
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12, there should be no such problem with the hydrolysis. For the zinc(II) isoporphyrins 
33 and 40, since the ester groups are either distant from the meso-position of the 
isoporphyrin or attached to the -positions of the pyrrole subunits of isoporphyrins, there 
should also be no problem. Therefore, the hydrolysis of zinc(II) isoporphyrins was 
explored mainly using zinc(II) isoporphyrin 12 since it had the best yield during its 
synthesis (Table 3.1). Zinc(II) isoporphyrin 12 was therefore subjected to strong basic 
conditions using NaOH25 in MeOH at room temperature; the reaction was monitored by 
UV/visible spectroscopy. With time the peak around 800 nm disappeared and there was 
a new peak that appeared at 629 nm, which unfortunately belongs to the ring-cleaved 
open chain system. This was unexpected since it seemed unlikely that this can take 
place for zinc(II) isoporphyrin 12. Therefore several neutral hydrolytic conditions were 
tried on zinc(II) isoporphyrin 12 in the hope that the macrocycle of this isoporphyrin 
might be preserved under these mild conditions (Scheme 3.15). With iodide-based 
reagents including LiI,26 TMSI and TMSCl/LiI,27 and CH3CH2CH2SLi,
28 the macro-ring 
opened during hydrolysis although ester hydrolysis did take place, especially when LiI 
was used. A fraction separated by using Sephadex 20, had its major mass peak at m/z 
629.3317, an ion that belongs to the corresponding zinc(II) isoporphyrin carboxylic acid, 
was observed from both the ESI and Maldi mass spectra (Figure 3.2). However, the 
UV/visible absorption of this compound showed no peak around 800 nm; the spectrum 
showed this compound to be an open-ring system, which proved that the LiI hydrolyzed 
methyl ester, but also opened the the isoporphyrin ring. With trimethyltin hydroxide29 and 
bis(trimethyltin) oxide, the zinc(II) isoporphyrin also decomposed; the UV/visible 
absorption was similar to that seen when LiI was used. Enzymatic hydrolysis using 
lipase30 showed no reactivity in phosphate buffer solution even after one week; the mass 
spectrum showed the starting material still remained as the only peak. Some acidic 
conditions such as BCl3
31 and BBr3 were also tried on the zinc(II) isoporphyrin but they 
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did not work either; the spectrophotometry peak around 800 nm became smaller and 
was completely gone after aqueous work up.  
 
 
 
Scheme 3.15: Attempted hydrolysis of zinc(II) isoporphyrin 12 by LiI and the UV/visible 
spectrum in CH2Cl2 of the ring-opened product. 
Table 3.1:The Hydrolysis of Zinc(II) Isoporphyrins Under Different Conditions. 
Tries reagents solvents temperature result 
1 LiI Ethyl acetate reflux ring-opened 
2 TMSI CHCl3 reflux ring-opened 
3 TMSCl/LiI Acetonitrile reflux ring-opened 
4 Li-S-propane CH3CH2CH2SH R. T ring-opened 
5 (CH3)3SnOH 1,2-DCE reflux ring-opened 
6 (CH3)3SnOSn(CH3)3 1,2-DCE reflux ring-opened 
7 Lipase enzyme Phosphate buffer R. T. no reaction 
8 BCl3 or BBr3 CHCl3 R. T ring-opened 
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Figure 3.2: Mass spectrum of product of hydrolysis of zinc(II) isoporphyrin 12 by using LiI. 
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3.5 Functionalization of Dipyrromethanes Before Cyclization to Give Zinc(II) 
Isoporphyrin 
From all the hydrolyses attempted using the above conditions, it seemed that zinc(II) 
isoporphyrins are not very stable to strong acids, bases, or nucleophiles. Under acidic 
conditions, the zinc ion could be removed from the isoporphyrin, but the metal free 
isoporphyrins are not very stable and decomposed rapidly. Trimethyltin hydroxide and 
iodide-based reagents are all strong nucleophiles, which are reactive enough to 
hydrolyze the ester group but they also open the isoporphyrin ring at the same time. 
Enzymatic hydrolysis depends on how the molecule fits into the lipase core, and for this 
case there was no reactivity using zinc(II) isoporphyrins. Since we had no success using 
methyl esters, we changed our synthetic strategy for isoporphyrins conjugation with 
biomolecules.  
Strategy I: A t-butyl ester was introduced into the zinc(II) isoporphyrin since it is easy to 
remove compared with a methyl ester. Therefore, the zinc(II) isoporphyrin 42 was 
designed. The retrosynthetic analysis of this molecule is similar to the previous cases 
(Scheme 3.16). The dipyrromethane dicarboxylate half remained the same, and it was 
necessary to convert the methyl esters of the other half into tert-butyl esters. We tried 
several conditions which could possibly hydrolyze a methyl ester over a benzyl ester on 
the dipyrromethane 17 (Scheme 3.17). But no selectivity under basic conditions between 
these two ester groups was observed, so we moved to acidic conditions with H2SO4 in 
DMSO overnight; the solution turned black and the mass spectrum of the product 
showed only the starting material peak. Then LiI was used in ethyl acetate and THF; 
both solvents gave a low yield of product after purification. Trimethyltin hydroxide29 is a 
very good reagent to hydrolyze methyl esters compared with other esters including ethyl, 
tert-butyl and other more complicated esters, according to the literature. A solution of 
dipyrromethane 17 was refluxed in 1,2-DCE with the presence of trimethyltin hydroxide; 
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with time a white pinkish solid precipitated from the solution and more precipitate came 
out when the solution was cooled down to room temperature. The precipitate was 
collected without further purification. 1H NMR spectroscopy showed it to be pure enough 
to go to next step, and the benzyl esters remained intact. After dipyrromethane 
dicarboxylic acid 44 was obtained, several attempts at tert-butyl esterification of this 
dipyrromethane were made (Scheme 3.18). The dipyrromethane dicarboxylic acid 44 
was treated with oxalyl chloride in THF with a little DMF as a catalyst, followed by 
addition of tert-butyl alcohol and TEA (base) in CH2Cl2. The mixture was heated to 40 
oC 
and kept for ten hours under argon. Unfortunately, the tert-butyl ester was not obtained 
after column chromatography and the mass spectrum did not give any hint of the 
required product. Then, a typical coupling reaction for making an ester group using 
EDCI/DMAP in DMF was tried, but unfortunately the reaction did not take place under 
these conditions. Then ButOAc32 was used as an esterification reagent and solvent 
under acidic conditions, but the product was not detected once again. When neat oxalyl 
chloride was used as chlorinating reagent and solvent, the acyl chloride was formed. 
The dipyrromethane dicarboxylic acid 44 is not very soluble in oxalyl chloride; however, 
when the reaction mixture was heated to 40 oC, the solid disappeared with time, which 
indicated that the carboxylic acid was converted into the acyl chloride. The excess oxalyl 
chloride was removed and the residue was dissolved in CH2Cl2 and treated with tert-
butyl alcohol in presence of TEA, and then the mixture was kept at 40 oC for ten hours. 
As a result, the product was obtained in about 40% yield and its identity was confirmed 
by mass spectrometry, with a peak at m/z 721.3455 (MW+Na). 
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Scheme 3.16: Retrosynthetic analysis of tert-butyl ester substituted zinc(II) isoporphyrin  
42. 
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Scheme 3.17: Attempts to preferentially hydrolyze the methyl esters over the benzyl 
esters of dipyrromethane 17, to synthesize dipyrromethane 44. 
 
 
 
Scheme 3.18: Attempts to transform the carboxylic acid to tert-butyl ester of 
dipyrromethane 45. 
Then the tert-butyl substituted dipyrromethane 44 was subjected to Pd-catalyzed 
hydrogenation in THF to remove the benzyl protecting groups, and the resulting 
dicarboxylic acid was refluxed in DMF at 160 oC for one hour and treated the α-free 
dipyrromethane along with PhCOCl at 0 oC; this was followed by hydrolysis using 
aqueous NaHCO3 in EtOH. A yellow solid was collected and recrystallized from ethanol, 
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giving the diformyldipyrromethane 43 in about 60% yield (Scheme 3.19). Cyclization of 
tert-butyl ester-substituted diformyldipyrromethane 43 with 5,5-dimethyldipyrromethane 
dicarboxylic acid 13 gave the zinc(II) isoporphyrin product 42 smoothly, which has a 
Soret band and Q-band at 409 and 801 nm, respectively (Scheme 3.20). Then the zinc(II) 
isoporphyrin 42 was dissolved in CHCl3 and treated with TFA (several drops) under 
argon; the reaction was again monitored by UV/visible absorption spectroscopy, and the 
peak at 801 nm disappeared with time, possibly indicating that the TFA had removed the 
zinc(II) ion from the isoporphyrin. The TFA was removed using a stream of N2 gas, and 
then zinc acetate in MeOH was added to the solution of the residue in CH2Cl2 [to re-
insert the zinc(II) to stabilize the isoporphyrin]. Unfortunately, the UV/visible spectrum did 
not change at all, (Scheme 3.21). Once the demetalation took place, the isoporphyrin 
must have decomposed very quickly. An attempt was also made to cleave the tert-butyl 
ester by using zinc bromide but this was also unsuccessful.  
 
Scheme 3.19: Synthesis of tert-butyl ester-substituted diformydipyrromethane 43. 
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Scheme 3.20: Synthesis of zinc(II) isoporphyrin 42 by MacDonald 2+2 condensation, 
and UV-visible spectrum of 42  in CH2Cl2.  
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Scheme 3.21: Attempt to hydrolyze tert-butyl ester of zinc(II) isoporphyrin 42 and UV-
visible spectrum in CH2Cl2 of the reaction product. 
Strategy II: Since the transformation of the tert-butyl esters to the corresponding 
carboxylic acids did not succeed, the strategy was again changed. The new plan was to 
introduce an imine group into the molecule before cyclization. The mono BOC-protected 
ethylenediamine was chosen to be introduced into the molecule so that it could be 
deprotected later. Two methods were tried on dipyrromethane 44; the first involved 
chlorination of the dipyrromethane dicarboxylic acid 44 by using oxalyl chloride followed 
by amination with mono-BOC protected ethylenediamine under basic conditions. This 
reaction gave about 25% yield. Another method was to use TBTU/HOBt33 promoted 
conjugation with DIEA as a base, and this gave a better yield (around 40%); purification 
was also easier than in the first method. However, the attempt to convert the 
dipyrromethane 46 in to diformyldipyrromethane 48 failed (Scheme 3.22). The 
assumption is that in the decarboxylation step, N-BOC could be cleaved under high 
temperature conditions, and the free amine will hinder formylation of α-free 
dipyrromethane.  
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Scheme 3.22: Attempted transformation of dipyrromethane 44 into 
diformydipyrromethane 48. 
Then we switched the formyl groups and carboxylic acid groups between these two 
dipyrromethanes in an attempt to avoid the abovementioned problem. Therefore, several 
attempts were made to synthesize the 5,5-dimethyldipyrromethane 49 (Scheme 3.23). 
The first attempt was by Vilsmeier-Haack formylation. Dipyrromethane dicarboxylic acid 
13 was obtained by debenzylation of the diester and then the dicarboxylic acid was 
heated to 160 oC in DMF for one hour before the solution was cooled down to room 
temperature and the PhCOCl/DMF complex was added.  The mixture was stirred for 
another hour followed finally by hydrolysis with NaHCO3 in ethanol. However the 
reaction did not give the desired product. Some yellow solid was obtained by filtration 
after hydrolysis, but it was hard to dissolve it in CHCl3 and it did not move on a TLC plate. 
The problem is probably because of oxidation or decomposition of α-free 
dipyrromethane under the high temperature conditions, or the failure of hydrolysis of the 
Vilsmeier imine intermediate. Then we turned to acidic conditions for decarboxylation, 
using TFA, followed by addition  
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Scheme 3.23: Efforts to synthesize diformydipyrromethane 49 under various conditions. 
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triethyl orthoformate for the formylation step. The reaction still failed to give the required 
product. Yet another another formylation complex, 4-nitro-PhCOCl/DMF, was employed 
since it could generate a better leaving group than PhCOCl/DMF during hydrolysis. 
However, the reaction still failed.  
Since one of the problems was possibly due to incomplete decarboxylation, then we 
tried to look for a method that can give α-free dipyrromethane 52 directly. According to 
the literature,34,35 3,4-dimethylpyrrole can react with acetone, catalyzed by perchloric 
acid, to give 52 directly. Therefore, we tried to synthesize 3,4-dimethylpyrrole by 
hydrolysis of the ethyl pyrrole-2-carboxylate, followed by decarboxylation catalyzed by 
KOH in ethylene glycol. Unfortunately, this reaction only gave a 15% yield of product 51. 
Therefore this route was abandoned. Instead of using the benzyl ester pyrrole, the ethyl 
ester pyrrole was used to synthesize the corresponding dipyrromethane 53,36  which was 
hydrolyzed to give the corresponding carboxylic acid by using KOH/THF/H2O, followed 
TFA/TMOF formylation to give a 20% yield of the product 49. Another route for 
formylation was tried by converting the dipyrromethane 53 into the α-free 
dipyrromethane in one pot by refluxing in ethylene glycol with aqueous KOH. The -free 
dipyrromethane 52 was precipitated by adding water and this was used in the next step 
immediately to make diformydipyrromethane37 using PhCOCl/DMF at 0 oC. To avoid the 
failure of hydrolysis of the imine intermediate, the complex was dissolved in a mixture of 
EtOH/NaHCO3 and refluxed for about ten minutes; the product diformydipyrromethane 
49 was generated in a satisfying 65% yield. 
Then the two halves, diformylpyrromethane 49 and dipyrromethane dicarboxylic acid  47 
(Scheme 3.24) were subjected to the cyclization conditions once again to see if the 
macrocycle could be formed; the reaction failed to give the corresponding zinc(II) 
isoporphyrin , and after one week, there was no peak around 800 nm in the UV/visible 
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spectrum. The assumption is that the N-BOC group was cleaved by p-toluenesulfonic 
acid, especially when the solution of zinc acetate in methanol was added. The N-BOC is 
easily displaced in polar solvents.38 Once the N-BOC was cleaved, the free amine could 
react with the formyl group in competition with the α-free dipyrromethane. Based on this 
assumption, we changed our strategy once again.  
The purpose of adding p-TSA was to cleave the carboxylic acid groups and 
protonate/activate the aldehyde group during cyclization. Therefore, the new plan was to 
remove the carboxylic acid group (to give free α-positions) before cyclization, and then 
an acid weaker than p-TSA can be added to protonate the aldehyde during cyclization to 
avoid the cleavage of the N-BOC group. Therefore, the dipyrromethane was obtained by 
an iodination/de-iodonation procedure. The corresponding dipyrromethane dicarboxylic 
acid of 47 was treated with I2/Na2CO3 to introduce iodine at both α-positions to give 
diiododipyrromethane 55, followed by hydrogenation catalyzed using PtO2,
39 to give the 
α-free dipyrromethane 56 for the next step (Scheme 3.25). Then cyclization of 
dipyrromethanes 49 and 56 was attempted, under the same conditions as earlier, except 
that acetic acid was used instead of p-TSA. The reaction was kept in air for a week but 
no product was formed. The UV/visible spectrum was very similar to the previous one. A 
possible reason could be that acetic acid is not strong enough to promote the reaction 
(Scheme 3.26). Meanwhile we tried other protecting groups, using mono-FMOC 
protected ethylenediamine because it is very stable to acid, which is mandatory during 
cyclization; therefore mono-FMOC protected ethylenediamine was introduced onto 
dipyrromethane dicarboxylic acid 44 by using two methods. The mono-BOC protected 
dipyrromethane 46 was cleaved by TFA, and the resultant dipyrromethane was re-
protected using FMOC-Cl/NaHCO3 in dioxane/H2O. The identity of the product was 
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confirmed by mass spectrometry (m/z at 1137.4724), but only a trace amount was 
separated. Another  
 
 
 
Scheme 3.24: Attempt to synthesize zinc(II) isoporphyrin 54 by MacDonald 2+2 
condensation, and the UV-visible spectrum of the product in CH2Cl2.  
method attempted is the conjugation reaction between dipyrromethane dicarboxylic acid 
44 and mono-FMOC protected ethylenediamine using HATU/DIEA. The product 57 was 
obtained as a redish solid in 30% yield after column chromatography (Scheme 3.27). 
Then the dipyrromethane 57 needed to be converted into its corresponding carboxylic 
acid to achieve cyclization later. Usually, the FMOC group is more easily removed than a 
benzyl ester group under hydrogenolysis conditions. However it has been found that the 
benzyl group can be cleaved in preference to an FMOC group by using TES/Pd 
mediated hydrogenation in MeOH. Therefore the solution of dipyrromethane 57 in MeOH 
was treated with TES/Pd; unfortunately, the benzyl and FMOC were both cleaved. The 
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assumption is the N-FMOC group lessened the difference between benzyl ester 
compared with C-FMOC. 
 
Scheme 3.25: Synthesis of α-free dipyrromethane 56 by iodination to give 55 and de-
iodination reactions.  
 
 
 
Scheme 3.26: Attempt to synthesize zinc(II) isoporphyrin 54 by condensation of 
dipyrromethanes 49 and 56, and UV-visible spectrum in CH2Cl2 of the product. 
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Scheme 3.27: Synthesis of dipyrromethane 59.  
Another way to avoid the deprotection of the benzyl ester in preference to the N-FMOC 
is to introduce a formyl group and then protect the ester groups. Based on this, 
diformydipyrromethane 16 was hydrolyzed first and protected with benzyl ester groups 
so that it could be finally cleaved by hydrogenation (Scheme 3.28). Before protection of 
the carboxylic acids, we used the zinc(II) isoporphyrin 12 as a sample to test the reaction 
to see if the zinc(II) isoporphyrin is stable to Pd-catalyzed hydrogenation. However, the 
test showed that the zinc(II) isoporphyrin was reduced to porphyrin according to the 
UV/visible absorption changes during the reaction. The peak around 800 nm 
disappeared and a new sharp (Soret) peak appeared at 400 nm along with typical zinc(II) 
porphyrin Q bands from 531 to 568 nm (Scheme 3.29). 
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Scheme 3.28: Synthesis of dipyrromethane 60. 
 
 
 
 
 
Scheme 3.29: Instability of zinc(II) isoporphyrin under hydrogenation conditions, and the 
UV-visible spectrum of the zinc(II) porphyrin product in CH2Cl2. 
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3.6 Experiment Part 
Compound 19: Sodium nitrite (15.57 g, 0.225 mol) was dissolved in 30 ml of water, and 
the resulting solution was added to a solution of benzyl acetoacetate (42.05 g, 0.218 
mmol) in 60 ml acetic acid in an ice bath; the mixture was well stirred overnight. The 
solution turned orange and was kept in a refrigerator for use in the next step. 
Benzyl 3,4,5-trimethlpyrrole-2-carboxylate 20: To a solution of 2,4-pentanedione (25 
g, 0.25 mmol) in acetic acid (100 ml) was added a solution of compound 19 dropwise 
over 2 h with vigorous magnetic stirring. Simultaneously, a well-mixed powder of 37 g of 
zinc dust and 37 g of anhydrous sodium acetate was added portion-wise at room 
temperature. Then the solution was heated to 80 oC overnight, and the mixture was 
cooled down to room temperature and poured into ice water with slow stirring. The 
yellow precipitate was collected by filtration, and the pyrrole was redissolved in CH2Cl2 
and filtered again to remove residual zinc. The product was recrystallized from ethanol 
as pale yellow crystals (31.70 g, 60%). Mp 115 oC, (Lit19 mp 119-120 oC). 1H NMR (400 
MHz; CDCl3): δ 8.57 (s, 1H), 7.38-7.30 (m, 5H), 5.28 (s, 2H), 2.28 (s, 3H), 2.17 (s, 3H), 
1.90 (s, 3H). 
 Methyl 4-acetyl-5-oxohexanoate 21: 2,4-Pentanedione (100.4 g, 1 mol) and 
potassium carbonate (3.3 g) were dissolved in 2-butanone (50 ml), and then the 
temperature was brought to refluxing and a solution of methyl acrylate (83 g, 0.93 mol) in 
15 ml of 2-butanone was added slowly to avoid over boiling. After the addition was 
complete, the mixture was refluxed for 5 h. It was then cooled down to room temperature 
and filtered to remove potassium carbonate. The filtrate was evaporated under vacuum 
and further purified by distillation to give a yellow oily liquid (121 g, 70%). 1H NMR (400 
MHz; CDCl3): δ 3.72(t, 1H), 3.66(s, 3H), 2.18(s, 6H), 2.1-2.6(m, 4H). 
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Benzyl 4-(2-methoxycarbonylethyl)-3,5-dimethylpyrrole-2-carboxylate 18: The 
same amount as above of solution of compound 19 (prepared from the same ratio of 
chemicals) was added dropwise to a solution of compound 21 (46.56 g, 0.25 mol) in 70 
ml glacial acetic acid; at the same time, a mixed powder of 43 g of zinc dust and 43 g of 
sodium acetate was added portion-wise. After the addition was over, the solution was 
heated to 80 oC with stirring for 2-3 h. The mixture was then cooled to room temperature 
and poured into ice/water with stirring. The pale yellow precipitate was collected by 
filtration and then the precipitate was dissolved in CH2Cl2 (200 ml) and filtered again to 
remove residual zinc. The residue was crystallized from methanol to give the product as 
a yellowish solid, (34 g, 50%)  M.p 99 oC, (Lit19 mp 99-100 oC). 1H NMR (400 MHz; 
CDCl3): 8.54 (s, 2H), 7.43-7.32 (m, 5H), 5.28 (s, 2H), 3.66 (s, 6H), 2.70 (t, 2H), 2.42 (t, 
2H), 2.29 (s, 3H), 2.20 (s, 3H). 
2,2-Bis(5-benzyloxycarbonyl-3,4-dimethylpyrrol-2-yl)propane 14: Pyrrole 15 (2.29 g, 
0.01 mol) was dissolved in 30 ml of ethanol and 6 ml of acetone, and the solution was 
warmed until all the solid was dissolved.  Then 0.94 ml (8.55 mmol) BF3.OEt2 was added 
and the mixture was refluxed for 1 d, before the solvent was removed and the residue 
was dissolved in CH2Cl2 and washed with Na2CO3, brine and then dried over anhydrous 
Na2SO4. After removing the solvent, the product was purified by chromatography using 
1:5 ethyl acetate/cyclohexane to give the product (1.5 g, 60% yield). Mp 143 oC, (Lit15 
Mp 135-136 oC). 1H NMR (400 MHz; CDCl3): δ 8.79(s, 2H), 746-7.32(m,10H), 5.34(s, 
4H), 2.26(s,6H), 1.66(s, 6H), 1.50(s, 6H). 
Dibenzy 3,7-bis(2-methoxycarbonylethyl)-2,8-dimethyldipyrromethane-1,9-
dicarboxylate 17: Pyrrole 18 (15.7 g, 0.05 mol) was dissolved in 500 ml of anhydrous 
diethyl ether, and bromine (2.56 ml, 0.05 mol) was added dropwise. The solution turned 
brown during addition, and the mixture was kept stirring at room temperature overnight, 
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whereupon a thick precipitate was apparent. Then the diethyl ether was removed to give 
a pink solid which was dissolved in 100 ml methanol and refluxed overnight. When the 
solution was cooled down to room temperature, a precipitate appeared, which was 
filtered and washed with cold methanol to give a white solid (10.70 g, 70%).  Mp 102-104 
oC, (Lit40 mp 96-97 oC). 1H NMR (400 MHz; CDCl3): δ 9.00(s, 2H), 7.38-7.31(m, 10H), 
5.25(s, 4H), 3.97(s, 2H), 3,56 (s, 6H), 2.75(t, 4H), 2.51(t, 4H), 2.28(s, 6H). 
1,9-Diformyl-3,7-bis(2-methoxycarbonylethyl)-2,8-dimethyldipyrromethane 16: 
Dipyrromethane 17 (6.14 g, 0.01 mol) was dissolved in 300 ml THF, and then 5% Pd/C 
(350 mg) catalyst was added. The suspension was stirred under a H2 atmosphere 
overnight. After TLC showed reaction was complete, the reaction was stopped and the 
solution was passed through a Celite cake to remove the catalyst. A sticky solid on the 
top of the Celite cake was redissolved in THF and neutralized in water by ammonia and 
then passed again through the Celite cake. The filtrate was acidified with acetic acid and 
the product precipitated from aqueous solution. The solid was collected by filtration. The 
THF part was evaporated and combined with the solid to give a total of 4.0 g (92%) of 
dpyrromethane dicarboxylic acid. This dipyrromethane dicarboxylic acid (4.00 g, 0.092 
mol) was dissolved in 12 ml of DMF and heated to 160 oC for about 1 h under the 
protection of an argon atmosphere and then the solution was cooled down to room 
temperature and the Vilsmeier complex comprising DMF (4.34 ml) and benzoyl chloride 
(3.25 ml), which had been prepared in advance, was added dropwise at 0 oC. After the 
addition was complete, the reaction continued for another 2 h. Some precipitate 
appeared, so 20 ml of benzene was added and solid was filtered, washed with 
petroleum ether and then dried in the air. Then the solid was dissolved in ethanol and 3 
g of NaHCO3 was added and the mixture was stirred overnight. A yellow precipitate 
appeared, which was collected and air dried to give product (2.6 g, 70%). Mp 174 oC 
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(Lit41 Mp 180-181oC). 1H NMR (400 MHz; CDCl3): δ 10.03(s, 2H), 9.45(s, 2H), 4.05(s, 
2H), 3.71(s, 6H), 2.79(t, 4H), 2.55(t, 4H), 2.29(s, 6H). 
Zinc 13,17-bis(2-methoxylcarbonylethyl)-2,3,4,5,7,8,12,18-octamethylisoporphyrin 
chloride 12: Dipyrromethane 14 (0.249 g, 0.5 mmol) was dissolved in 50 ml THF and 
then 30 mg 10% Pd/C catalyst was added and the mixture was stirred under a H2 
atmosphere for about 2 h, until TLC showed the reaction was complete. Then the 
solution was passed thought a Celite cake to remove catalyst, and the filtrate was 
evaporated to give a yellowish solid. This solid was dissolved in 200 ml of CH2Cl2 and p-
toluenesulfonic acid (0.375 g,1.97 mmol) in 16 ml MeOH was added and the solution 
was heated to 40 oC for about 10 min to remove the carboxylic acid groups. After TLC 
showed the reaction was complete, a solution of diformyldipyrromethane 16 (0.201 mg, 
0.005 mmol) in CH2Cl2 (30 ml) was added, followed by addition of excess zinc acetate 
(0.18 g, 0.82 mmol) in MeOH (5 ml). The mixture was stirred at 38 °C for 3 d and then 
another 4 d at room temperature under air. The solution turned dark with time and finally 
gave a dark brown mixture. Then the solution was washed with water, sodium 
bicarbonate solution, and brine, and dried over anhydrous Na2SO4. The solvent was 
removed and the residue was purified by chromatography eluting with 2-4% MeOH/ 
CH2Cl2 and further recrystallized from hexane/ CH2Cl2 to give a greenish solid. Mp >260 
oC (Lit43 mp > 250oC). 1H NMR (400 MHz; CDCl3): 7.75 (s, 1H), 7.55 (s, 2H), 3.65 (s, 6H), 
3.20 (t, 4H), 2.69 (t, 3H), 2.42 (s, 12H) 2.38 (s, 6H), 1.91 (s, 6H). UV/Vis (CH2Cl2): λmax (ε, 
M-1 cm-1): 414 nm (3.0 x 104), 729 (1.6 x 104), 799 (4.7 x 104). 
Ethyl 4,4-bis(5-benzyloxycarbonyl-3,4-dimethylpyrrol-2-yl)butanoate 25: α-Free 
pyrrole 17 (2.29 g, 0.01 mol) and ethyl acetoacetate (0.651 g, 5.0 mmol) were dissolved 
in 15 ml absolute ethanol and 0.5 ml (4 mmol) of boron trifluoride etherate was added 
and the mixture was refluxed overnight. Another 2.5 mmol (0.22g, 0.25 ml) of ethyl 
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acetoacetate was added and the mixture was refluxed for another 1 d. Then the solvent 
was removed and the residue was taken up in CH2Cl2, washed with water, NaHCO3, 
brine, and dried over anhydrous Na2SO4. The solvent was evaporated and the residue 
was purified by silica gel column chromatography, eluting \with (ethyl acetate/hexane 1:5) 
to give the product (0.40 g, 7%). 1H NMR (400 MHz; CDCl3): δ 9.34 (s, 2H), 7.46-7.31 (m, 
10H), 5.33 (s, 4H), 4.09 (q, 2H), 3.02 (s, 2H), 2.30 (s, 6H), 1.56 (s, 6H), 1.16 (t, 3H). 
Dibenzyl 2,3,7,8-tetramethyldipyrromethane-1,9-dicarboxylate 28: Compound 28 
was synthesized following the procedure for compound 17 to afford the product 
(3.20g,70 %). Mp 180 oC. (Lit42 mp 178-180 oC). 1H NMR (400 MHz; CDCl3): δ 8.79 (s, 
2H), 7.34-7.30 (m, 10H), 5.25 (s, 4H), 3.79 (s, 2H), 2.25 (s, 6H), 1.93 (s, 6H). 
2,2-Bis(5-formyl-3,4-dimethylpyrrol-2-y-l)propane 26: Benzyl 3,4,5-trimethylpyrrole-2-
carboxylate (2.35 g, 0.005 mol) was dissolved in THF (100 ml) and 150 mg of 5% Pd/C 
catalyst was added. The solution was stirred under a H2 atmosphere overnight, 
whereupon the TLC showed the reaction was complete. The solution was passed 
through a Celite cake to remove the catalyst and the sticky part on top of the Celite cake 
was dissolved in water and neutralized by aqueous ammonia and passed through the 
Celite cake again. Then the aqueous solution was acidified with acetic acid to afford a 
white precipitate which was filtered and dried in a vacuum oven. The THF part was 
evaporated and the solids were combined together to give the product dicarboxylic acid 
(1.3 g, 90%). Then the acid was added to cold TFA (20 ml) for 10 min and 4 ml of TEOF 
was added slowly. After addition was complete, the mixture was stirred for about 1 h and 
then poured into 100 ml of ice/water, and ammonium hydroxide was added to 
neutralized the solution to pH=7. Then the solution was extracted with CH2Cl2 (100 ml x 
3). The organic phase was washed with water, brine and then dried over anhydrous 
Na2SO4. The solvent was removed and the brown solid was recrystallized from EtOH to 
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give the pure product (0.23 g, 20% yield).  1H NMR (400 MHz; CDCl3): δ 9.47(s, 2H), 
3.87(s, 2H), 2.24(s, 6H), 1.98(s, 6H). 
Ethyl 4,4-bis(5-benzyloxylcarbonyl-3,4-dimethylpyrrol-2-yl)pentanoate 30: The 
synthesis of compound 30 followed the procedure for compound 25 to afford the product 
as a transparent oil, (1.7 g, 30% yield). 1H NMR (400 MHz; CDCl3): δ 8.71(s, 2H), 7.45-
7.33 (m, 10H), 5.32 (s, 4H), 4.07 (q, 2H), 2.41 (t, 2H), 2.22 (s, 6H), 2.11 (t, 2H), 1.59 (s, 
6H).  
Ethyl 4,4-bis(5-formyl-3,4-dimethyl-1H-pyrrol-2-yl)pentanoate 32: The synthesis of 
compound 32 followed the procedure for compound 16 to afford the product (0.29 g, 
37%) starting with (1.2 g, 2.0 mmol) of 30 1H NMR (400 MHz; CDCl3): 9.54 (s, 2H), 9.20 
(s, 2H), 4.08 (t, 2H), 2.21 (s, 6H), 2.12 (t, 2H), 1,63 (t, 2H), 1.23 (t, 4H). 
3,3'-(2,2'-methylenebis(5-((benzyloxy)carbonyl)-4-methyl-1H-pyrrole-3,2 
diyl))dipropanoic acid 44: Dipyrromethane 17 (0.1 g, 0.159 mmol) was dissolved in 
1,2-DCE (15 ml) and trimethyltin hydroxide(143 mg, 0.796 mmol) was added. The 
mixture was refluxed until a large amount of solid was precipitated and the mixture was 
then refluxed for another 24 h. The mixture was cooled down to room temperature. All of 
the solid was filtered off and dissolved in ethyl acetate and then neutralized using 
aqueous HCl. The organic layer was washed with water, brine, and then dried over 
anhydrous Na2SO4. The solvent was removed and a pink solid was obtained (56 mg, 
60%). 1H NMR (400 MHz; CDCl3): 11.99 (s, 2H), 11.18 (s, 2H), 7.41-7.28 (m, 10H), 5.25 
(s, 4H), 3.85(s, 2H), 2.48 (t, 4H), 2.12 (s, 6H), 2.05 (t, 4H). 
Dibenzyl 5,5'-methylenebis[4-(3-(tert-butoxy)-3-oxopropyl]-3-methyl-1H-pyrrole-2-
carboxylate) 45: Compound 44 (200 mg, 0.34 mmol) was added to oxalyl chloride (20 
ml), and the mixture was warmed to 40 oC under protection of argon for about 30 min to 
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1 h, depending on the reaction scale, but in any case until the solid disappeared. The 
mixture was kept at 40 oC for another 30 min before the oxalyl chloride was removed 
and the residue was dissolved in ButOH/CHCl3 (10 ml/2 ml) at room temperature and 
TEA (1 ml) was added The solution was heated to 45-50 oC and stirred overnight under 
argon. Then the solvent was removed and the solid was taken up in CHCl3, and washed 
with water, 3% aqueous HCl, and then NaHCO3, brine and finally dried over anhydrous 
Na2SO4. The solvent was removed and the residue was purified using silica gel column 
chromatography eluted with 2% MeOH/ CH2Cl2 to give the product as a brown sticky oil 
(95 mg, 40%). 1H NMR (400 MHz; CDCl3): 8.95 (s, 2H), 7.35-7.25) (m, 10H), 5.25 (s, 
4H), 3.92 (s, 2H), 2.68 (t, 4H), 2.34 (t, 4H), 2.28 (s, 6H), 1.38 (s, 18H). ( 
Di-tert-butyl 3,3'-(2,2'-Methylenebis(5-formyl-4-methyl-1H-pyrrole-3,2-
diyl))dipropanoate 43: Compound 45 (410 mg, 0.587 mmol) was dissolved in 80 ml 
THF and 50 mg (10%) Pd/C was added and the solution was stirred under a H2 
atmosphere overnight. After TLC showed the starting material had disappeared, the 
solution was passed through a Celite cake to remove catalyst, and the resulting 
carboxylic acid was dissolved in DMF (5 ml) and the solution was heated to 160 oC with 
stirring for about I h. The solution was then was cooled down to room temperature and 
the Vilsmeier complex of PhCOCl/DMF (0.30/0.40 ml) was added dropwise at 0 oC. The 
mixture was stirred for about 1 h and then the DMF was removed and the residue was 
dissolved in EtOH. Aqueous NaHCO3 was added to hydrolyze the intermediate and a 
yellow precipitate was collected and washed with water, and then air dried. The solid 
was recrystallized from EtOH to give the product (75 mg, 45%).1H NMR (400 MHz; 
CDCl3): 10.62 (s, 2H), 9.36 (s, 2H), 3.96 (s, 2H), 2.64 (t, 4H), 2.30 (t, 4H), 2.22 (s, 6H), 
1.36 (s, 18H). 
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 Dibenzyl 5,5'-methylenebis{4-[3-(2-(tert-butoxycarbonyl)amino)ethyl)amino)-3-
oxopropyl]-3-methyl-1H-pyrrole-2-carboxylate} 46: Method I: Dipyrromethane 44 (0.1 
g, 0.159 mmol) was dissolved in 15 ml oxalyl chloride and heated at 40 oC with stirring 
until all the solid disappeared. The mixture was kept at 40 oC for another 1 h and then 
the oxalyl chloride was removed and the residue was dissolved in CHCl3 and a solution 
of BOC-NHCH2CH2NH2 (50 mg, 0.32 mmol) and TEA (32 mg, 0.32 mmol) in CHCl3 (20 
ml) was added. The solution was stirred at room temperature overnight before being 
washed with water, 3% aqueous HCl, aqueous NaHCO3 and brine, and then dried over 
anhydrous Na2SO4. The residue was purified by silica gel column chromatography 
eluting with 4% MeOH/ CH2Cl2 to give the product (27 mg, 20%).  
Method II: To a solution of 44 (0.1 g, 0.159 mmol) in DMF (1.5 ml) was sequentially 
added HATU (110 mg, 0.29 mmol) and DIEA (0.10 ml) and the solution was stirred at 
room temperature for 1 h before NH2CH2CH2NHBOC (50 mg, 0.32 mmol) was added. 
The solution was stirred for 1 d, and the solution was then diluted with ethyl acetate (50 
ml) and washed with 10% citric acid, saturated NaHCO3 and then brine. The organic 
phase was dried over anhydrous Na2SO4 and the solvent was removed in vacuo and the 
residue was purified by silica gel column chromatography eluting with 4% MeOH/ CH2Cl2 
to give the product (55 mg, 41%). 1H NMR (400 MHz; CDCl3): 9.84 (s, 2H), 7.39-7.28 (m, 
10H), 6.26 (s, 2H), 5.26 (s, 4H), 3.92 (s, 2H), 3.27 (t, 4H), 3.09 (t, 4H), 2.78 (t, 3H), 2.38 
(t, 4H), 2.27 (s, 6H), 1.39 (s, 18H).  
1,9-Diformyl-2,3,5,5,7,8-hexamethyldipyrromethane 49: Method I: Dipyrromethane 14 
(1.245 g, 2.5 mmol) was dissolved in THF (80 ml), and 50 mg (5%) Pd/C catalyst was 
added. The mixture was stirred under an H2 atmosphere overnight before the solution 
was passed through a Celite cake to remove the catalyst. The THF was removed and 
the solid was dissolved and left in TFA (15 ml) for 5 min, before excess TEOF (2 ml) was 
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added to the TFA solution and the mixture was stirred at room temperature for 1 h. The 
solution was poured into ice/water and the aqueous solution was neutralized by aqueous 
ammonia to pH=7. Then the solution was extracted with CHCl3 three times and washed 
with water, brine and finally dried over anhydrous Na2SO4. The solvent was removed 
and the solid was recrystallized from EtOH to give the product (140 mg, 20% yield); 
Method II: Dipyrromethane 53 (1.87 g, 5.0 mmol) and KOH (2.0 g) were dissolved in 
ethylene glycol (15 ml) and a little water was added before the solution was refluxed at 
180-200 oC for 1 h. After the solution was cooled down to room temperature, it was 
diluted with water and the mixture was extracted with hexane three times. The organic 
layer was washed with water, brine and dried over anhydrous Na2SO4. The yellowish oily 
residue was dissolved in DMF (5 ml) and the complex PhCOCl/DMF (2.6/4.2 ml) was 
added at 0 oC dropwise to the solution. After 2 h, 20 ml of toluene was added and the 
mixture was kept in ice/water for a while until most of the precipitate came out. The imine 
salt was filtered and washed with toluene and the solid was taken up in 2 g of NaHCO3 
in 50/50 ml EtOH/H2O. The solution was heated at reflux for 15 min and after the 
solution was cooled down to room temperature, 40 ml of water was added and the 
mixture was allowed to stand overnight. The solid was filtered off, dried and 
recrystallized from chloroform/petroleum ether to give the desired product aldehyde as 
pale yellow crystals (0.92 g, 65% yield). 1H NMR (400 MHz; CDCl3): δ 9.54 (s, 2H), 8.86 
(s, 2H), 2.21 (s, 6H), 1.67 (s, 6H), 1.51 (s, 6H).  
3,4-Dimethylpyrrole 51: Pyrrole 50 (1.67 g, 0.01 mol) and KOH (1.0 g) were added to 
10 ml of ethylene glycol and the solution was refluxed for about 1 h. The solution was 
cooled down to room temperature and diluted with water to 50 ml and the solution was 
then extracted with hexane three times. The organic layer was washed with water, brine, 
and then dried over anhydrous Na2SO4. The solvent was removed and the residue was 
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purified by silica gel column chromatography eluting with hexane/ CH2Cl2 (2:1) to give 
3,4-dimethylpyrrole as a brown liquid (95 mg, 10% yield). 1H NMR (400 MHz; CDCl3): 
7.40 (s, 2H), 6.51 (s, 2H), 2.00 (s, 3H), 1.99 (s, 3H). 
Diethyl 5,5'-(propane-2,2-diyl)bis(3,4-dimethyl-1H-pyrrole-2-carboxylate) 53: The 
synthesis of compound 53 followed the procedure for dipyrromethane 15, starting with 
(3.34 g, 0.02 mol) to obtain product (4.8 g, 70%). Mp 131-133oC, (Lit22 Mp 125-
126oC) .1H NMR (400 MHz; CDCl3): δ 8.69 (s, 2H), 4.30 (q, 4H), 2.22 (s, 6H), 1.66 (s, 
6H), 1.55 (s, 6H), 1.37 (t, 6H). 
Bis(5-iodo-4-(3-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-3-oxopropyl)-3-
methylpyrrole)methane 55: Dipyrromethane 46 (1.08 g, 1.25 mmol) was dissolved in 
THF (80 ml) and 80 mg of (5%) Pd/C catalyst was added before the mixture was stirred 
under a H2 atmosphere overnight. Then the solution was passed through a Celite cake 
and the solvent was removed to give a solid which was added to 90/30 ml (H2O/MeOH) 
and then NaHCO3 (0.6 g) was added and the solution was sonicated until a clear pink 
solution was formed. Then a solution of I2 (0.5 g) in 60 ml of MeOH was added at room 
temperature slowly. The mixture was stirred for 2 h before the reaction was stopped. The 
precipitate was filtered and washed with water, hexane and air dried to give 0.62 g (60%) 
1H NMR (400 MHz; CDCl3): 3.20 (t, 4H), 3.18 (t, 4H), 2.93 (t, 4H), 2.35 (t, 4H), 2.0 (t, 6H), 
1.42 (t, 9H). 
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3.7. Supporting information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectra of pyrrole 18 and 20 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromethane 17 and 28 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromethane 14 and 16 in CDCl3 at 400 MHz 
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1H NMR spectra of isoporphyrin 12 and dipyrromethane 25 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromehane 26 and 30 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromehane 32 and 44 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromehane 43 and 45 in CDCl3 at 400 MHz 
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1H NMR spectra of dipyrromehane 46 and 49 in CDCl3 at 400 MHz 
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Chapter 4: Synthesis of BODIPY Dyes from Dipyrrolyketones and Their 
Transformations 
4.1. Introduction  
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene1,2(Figure 4.1), known well as BODIPY have 
been recognized as one of the most versatile fluorophore dyes in last three decades 
since their potential use as photo labels was discovered.  Because of their sharp 
fluorescence emissions, high quantum yields, large molar absorption coefficients and 
relative chemical and thermal stabilities,3,4 BODIPY dyes have been intensively 
employed as biological labeling reagents5,6 in protein and DNA research. Moreover, the 
electrochemical activity of BODIPYs makes these dyes promising candidates as dopants 
in light emitting devices and polymer-based electroactive films.7  
 
Figure 4.1: The structure of BODIPY. 
Synthetic approaches to BODIPY dyes have not changed much since they were 
discovered. The first synthesis of BODIPY was reported by Treibs and Kreuzer in 1968;1 
however, this molecule was ignored until the potential uses of this this dye in biological 
labeling was discovered at the end of the 1980s. Since then numerous syntheses of 
these molecules were documented. All kinds of functionalization of these molecules 
have also been well-explored. After 30 years, achieving long wavelength absorbing and 
emitting BODIPYs with amphiphilic properties is still the target of chemists.  
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There are several strategies used to synthesize BODIPY dyes. The first synthetic 
method involved condensation of two identical pyrrole  and a carbonyl source  such as 
an aldehyde,8 acyl chloride9 or anhydride10 catalyzed by acid; then oxidation of the 
resulting dipyrromethane into a dipyrromethene followed by complexation with BF3.OEt2 
will lead to BODIPYs (Scheme 4.1A). This method was usually employed to build 
symmetrical BODIPYs. Another method involves acid catalyzed condensation of two 
different pyrrolic units where one of them bears a carbonyl group and the other one is an 
α-free pyrrole11 (Scheme 4.1B). This method can directly give dipyrrins, which can be 
converted into BODIPYs by complexation with BF3.OEt2 in one step. This method is 
generally used to construct unsymmetrical BODIPYs. The third approach is derived from 
method one, which involves condensation of two identical α-formylpyrroles catalyzed by 
POCl3
12
 (Scheme 4.1C). The mechanism is believed to be analogous to the Vilsmeyer-
Haack reaction to form a vinylogous intermediate between one α-formylpyrrole and 
POCl3, followed by attack of another α-formylpyrrole. This method is only suitable to  
(A) 
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(B) 
 
(C) 
 
Scheme 4.1: Various routes to synthesize BODIPYs. 
synthesize meso-unsubstituted BODIPYs. So far, the meso-aryl BODIPYs account for 
most synthesis of these molecules in the literatures and in patents.  
Depending on which substitutuents are required to be introduced on the meso-carbon, 
the methods in Scheme 4.1 can be applied accordingly. For example, for method A, 
para-iodobenzaldehyde or a para-esterified benzaldehyde were used during BODIPY 
synthesis so that BODIPYs could be functionalized later by coupling reactions or by 
conjugation. Carboxylic acids can be introduced into BODIPYs directly when a cyclic 
anhydride was used as the carbonyl source, which can be further conjugated with 
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proteins and used for protein labeling. Method B allows more versatile functionalization 
of BODIPYs since it is easier to modulate the photophysical properties and hydrophobic 
and hydrophilic properties by various functionalizations of different position on BODIPYs. 
Many BODIPY-based labeling dyes are made using this particular method. Method C is 
useful to make highly symmetrical BODIPYs; this reaction gives excellent yields 
compared with method A. 
Scheme 4.2: Some resonance structures of BODIPY. 
According to the resonance structure of BODIPYs (Scheme 4.2), carbons 1, 3, 5, and 7 
are electrophilic positions on BODIPYs, and carbons 2 and 6 are nucleophilic positions. 
So the functionalization of BODIPYs actually follows these fundamental principles. 
Knoevenagel condensation can be performed on the active methyl groups on all 
electrophilic carbons at 1, 3, 5, and 7 with benzaldehyde to extend the π-electron 
conjugation, thereby increasing the wavelength of absorption of BODIPYs since these 
methyl groups are very nucleophilic,13-17(Scheme 4.3A). Another electrophilic point is 
carbon 8, for the meso-free BODIPYs. Nucleophilic attack on carbon 8 usually needs to 
be accomplished with oxidation to remove a hydrogen. So far, there is only one example 
of this case, which is use of NaCN as a nucleophile.1,18,19 Meso-cyanoBODIPYs have a 
significant red shift compared with meso-free BODIPYs.  Introduction of sulfur20 and 
halogens21 at the meso-position allows more versatility for modification of carbon 8.. 
Replacement and coupling reactions can introduce many groups at the meso-carbon. 
Even some natural products have been introduced. Substitution reactions were also well 
explored at the boron to introduce aryl,22 alkynyl23, alkyl,24 alkyloxy,25 etc. From the 
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resonance structure of BODIPYs we can see that the 2, 6 positions are the most 
electron rich sites and therefore most susceptible to nucleophiles. Formylation,26 
nitration,27 sulfonation,28 and halogenation29 were already reported. Palladium catalyzed 
oxidative coupling reactions30 to extend the π-conjugation was also reported (Scheme 
4.3B). 
(A) 
 
 
 
 
 
  
131 
 
(B) 
  
Scheme 4.3: Functionalization of BODIPYs by various methods. 
Dipyrrolyketone (pyrroketones) have not been used much in polypyrrole chemistry. From 
their structure (Scheme 4.4), pyrroketones are actually bis-vinylogous amides and 
therefore do not react as normal ketones. For instance, pyrroketones can not be reduced 
by borohydride31 to dipyrromethane or dipyrromethene.32 Various syntheses of 
dipyrroketones are well documented.  The symmetrical dipyrromethanes can be 
synthesized by treatment of pyrrole Grignard reagents with phosgene in one step 
(Scheme 4.5). 
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Scheme 4.4: Keto-enol tautomers of pyrroketone. 
 
Scheme 4.5: Syntheses of symmetrical pyrroketones. 
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Scheme 4.6: Synthesis of unsymmetrical pyrroketones. 
with phosgene in one step, or treatment α-free pyrroles with thiophosgene followed by 
oxidative hydrolysis of the corresponding symmetrical thioketone products.20 An 
alternative approach for synthesis of symmetrical pyrroketones is to oxidize the 
corresponding symmetrical dipyrromethane with PbO2/Pb(OAc)4 or Br2/SOCl2
33
 (Scheme 
4.5). For the unsymmetrical pyrroketones, the most efficient method involves a modified 
Vilsmeier-Haack reaction between a pyrrole N,N-dimethylcarboxamide complex with 
another different α-free pyrrole using phosphoryl chloride.32  
Some of the methods used to synthesize symmetrical pyrroketone can also be applied to 
unsymmetrical pyrroketone. For example, treatment of a pyrrole acyl chloride with 
another pyrrole Grignard derivative or oxidation of unsymmetrical dipyrromethane with 
PbO2/Pb(OAc)4 or Br2/SOCl2 gives the corresponding unsymmetrical pyrroketones 
(Scheme 4.6). A very important related analogue is a reaction of dipyrromethane N,N-
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dimethylcarboxamide with phosphoryl chloride and another α-free dipyrromethane 
followed by hydrolysis of corresponding tetrapyrrole to give  
 
Scheme 4.7: Synthesis of meso-acetoxyporphyrin from oxophlorin. 
b-oxobilanes, which are stable to acid catalyzed distribution of pyrrole rings because of 
the oxo-function, and therefore can be cyclized into oxophlorin and eventually 
transformed into porphyrin. Acetylation of the oxophlorin with acetic anhydride gives 
meso-acetoxyporphyrin31,34,35 (Scheme 4.7). 
From the above brief introduction to BODIPYs and pyrroketones and to their chemical 
transformation into porphyrins, one can see that BODIPYs and pyrrokeotnes are 
structurally related.  Based on the reactivity of pyrroktones in the synthesis of porphyrins, 
it is possible that pyrroketones can be converted into their fully conjugated 
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dipyrromethene by use of reagents such as acetic anhydride, which can lead to 
BODIPYs directly after complexation with BF3.OEt2. The objective of this project is to 
expore a new synthetic method to BODIPYs from pyrroketones and to further 
functionalization of the new BODIPYs such as nucleophilic addition/elimination and 
coupling reactions. We also wanted to look at various pyrroketones to investigate the 
substituent applicability of any new methods. 
4.2. Synthesis of Pyrroketones and Their Trasformation 
Pyrroketones are actually bis-vinylogous amides; therefore the proposed transformations 
of pyrroketone are shown in Scheme 4.8. Protonation takes place on the oxygen atom, 
and depending on the electrophiles, substituents can be introduced either on nitrogen or 
on oxygen atoms. Pyrroketones can also be converted into their imidoyl halides through 
substitution of the oxygen atom. It was also planned to examine reactions including 
protonation,36 O-alkylation,37 and halogenation38 (highlighted by green arrows) to convert  
 
Scheme 4.8: Transformations of pyrroketones. 
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pyrroketones into their dipyrrins (dipyrromethenes) which can then be used later in 
BODIPY synthesis.  
Firstly, some pyrroketones were synthesized by the methods mentioned above. Two 
major dipyrromethanes bearing ester groups on the α-positions were synthesized 
according to the procedure in Chapter 3. These two dipyrromethane 34 and 35 were 
then oxidized into the corresponding pyrroketones 36 and 3733 with PbO2/Pb(OAc)4 in 
acetic acid in about 50% yield (Scheme 4.9). From the 1H NMR spectrum, protons at 
3.97 and 3.79 ppm, which belong to meso carbon of dipyrromethane 34 and 35 
disappeared, and the identity of these two product 36 and 37 was confirmed by mass 
spectroscopy, with m/z at 651.231(MW + Na) and 484.21, respectively.  
Attempts were made to protonate these two pyrroketones with all kinds of acids such as 
HCl, TFA and BF3.OEt2; all acids partially converted pyrroketones into their dipyrrins 
salts; according to UV-visible absorptions around 430 nm, the most pronounced peak 
still belonged to starting material pyrroketones at 360 nm. Protonated pyrroketones are 
deprotonated during aqueous workup or treatment with bases. Then activation of the 
pyrroketones with acetic anhydride to convert them into their fully conjugated molecules 
was tried. Acetic anhydride and triflic anhydride39 (Scheme 4.10) were therefore tried on 
the pyrroketones 36 and 37. The pyrroketones did not react upon treatment with acetic 
anhydride according their UV-visible absorption. However, the stronger triflic 
anhydride/pyridine mixture formed a red solution and peaks at 432 and 534 nm in the 
UV-visible spectrs indicated the formation of a fully conjugated dipyrrin-type system. 
However, this intermediate can not withstand an aqueous workup and the peak around 
430 nm disappeared. DIEA/BF3.OEt2 was added to if the intermediate could be 
converted into a BODIPY and characterized. However, the intermediate could not 
withstand organic bases either. Another strategy tried was to introduce a bromine atom 
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at the meso carbon by adding LiBr to a solution of activated pyrroketone after 
Tf2O/pyridine treatment;
37,40 this did not work either. 
 
Scheme 4.9: Synthesis of pyrroketone through oxidation.  
 
 
Scheme 4.10: Activation of pyrroketones by acids and anhydrides.  
Eletrophiles such as methyl trifluoromethansulfonate41 and Meerwein’s salts42 (Et3OBF4 
and Me3OBF4) were reacted with pyrroketones 36 and 37 (Scheme 4.11). Methyl 
trifluoromethanesulfonate slightly changed the reaction solution from colorless to red. 
With Meerwein’s reagents, the pyrroketones were converted completely into their 
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dipyrrin analogues based on the orange red color of the reaction solution and their UV-
visible absorption at 446 nm. Unfortunately, upon aqueous workup, this intermediate 
reversed to the starting material according to the UV-visible spectral change (Figure 4.2), 
DIEA/ BF3.OEt2 was added to make corresponding the BODIPY but this did not work. 
However, from 1H NMR spectra (Figure 4.3), extra peaks at 4.20 (q, 2H) and 1.22 (t, 3H)  
 
 
Scheme 4.11: Alkylation of pyrroketone using Et3OBF4 in CHCl3.  
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Figure 4.2: UV/Vis absorption spectrum of Alkylation of pyrroketone using Et3OBF4 in 
CH2Cl2 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: 1H NMR spectra of pyrroketone 36 and product 39 in CDCl3 
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attributed to ethyl group on the heteroatom nitrogen proved the ethyl group actually went 
to the nitrogen of the pyrrole instead of the oxygen on the meso carbon, and this result 
was further confirmed by the mass spectrum with m/z at 656.27 
From all the protonation and nucleophilic substitution reactions tried on the pyrroketones, 
one can see that even strong acids do not react with pyrroketones, and strong 
nucleophiles can convert pyrroketones partially or completely into their fully conjugated 
dipyrrin intermediates. The problem is that these intermediates are not stable enough to 
withstand water or nucleophiles during work-up. Halogenation reactions were also 
attempted on the two pyrroketones. Typical chlorinating reagents such as POCl3,
43 
PCl5,
37 oxalyl chloridel44 and phosgene45 were tried under different conditions at room 
temperature or at reflux. All these reagents gave a red solution which indicated the 
formation of the fully conjugated dipyrrin system, and UV-visible absorption 
spectroscopy showed a sharp peak around 500-530 nm. However, the stability of these 
compounds or intermediates was was a serious problem which made them hard to 
separate and they easily decomposed upon aqueous work-up or interaction with 
nucleophiles. Specifically, when POCl3/DMF was used to chlorinate the pyrroketone, the 
fully conjugated system was formed according to UV-visible absorptions at 528 
(pyrroketone 36) and 534 nm (pyrroketone 37), which are most  likely the intermediates 
or products (Scheme 4.12). Especially for pyrroketone 36, a peak at m/z 645.17 in the 
mass spectrum showed that the product 40 was actually formed (Figure 4.4), along with 
some other side products, such as a dimer or trimer. However, it was not possible to 
separate the product by chromatography or by crystallization. When POCl3/PCl5
46
 was 
used as the chlorinating reagent， the UV-visible absorptions at 505 and 529 nm 
(pyrroketone 37) indicated the fully conjugated dipyrrin system had been formed and 
aqueous workup did not destroy it since the UV-visible absorptions almost had no 
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change. Mass spectrometry showed m/z peaks at 1279.4662 (MW+K) for pyrroketone 
36, which indicated the formation of dimer of dipyrromethene (Scheme 4.13). 
 
 
 
 
Scheme 4.12: Chlorination of pyrroketone 36 using POCl3 and the UV-Visible absorption 
spectrum in CH2Cl2.  
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Scheme 4.13: Chlorination of pyrroketone 36 using POCl/PCl5 and the UV-visible 
absorption spectrum in CH2Cl2. 
 
Figure 4.4: Mass spectrum of the product from chlorination of pyrroketone 36 with 
POCl3/PCl5. 
The reactivity of various activiting reagents such acids, anhydrides and halogenating 
reagents on pyrroketones were investigated. Specifically, triflic anhydride can only 
partially convert pyrroketones into their dipyrryl system; soft halogenating reagents such 
as SOCl2 have no reactivity. For strong chloronating reagents such as POCl3 or PCl5, the 
pyrroketones are completely converted into the fully conjugated dipyrrin intermediates or 
Profile of chlorodipyrromethene 
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products. However, these intermediates or products are not stable enough to survive 
aqueous workup, base treatment, or other nucleophiles. The combination of POCl3 and 
PCl5 transformed the pyrroketones into their dipyrrin, but this deduction is based only on 
its mass spectrum. From the chemistry of pyrroketones used in porphyrin synthesis, it is 
assumed that the electron-withdrawing benzyl ester groups on the pyrroketone 
destablize the conjugated intermediates which revert to starting material very easily 
upon attack of water or other nucleophiles (Scheme 4.14). Therefore, It was planned to 
eliminate the electron withdrawing group from pyrroles on the pyrroketones and use alkyl 
substituted pyrroketone to explore all these reactions. Extremely successful reactions 
with the dipyrroketone dibenzyl esters 36 and 37 are reported in Chapter 5 of this 
Dissertation. 
 
 
Scheme 4.14: The reversible process of pyrroketone and its dipyrromethene. 
Before synthesis of the new alkylpyrroketones, several α-free pyrroles were made by the 
following methods depending on the structure of pyrroles (Scheme 4.15). (1) The 2-
ethoxyl carbonyl pyrroles were converted into corresponding α-free pyrroles 44, 45 and 
46 by de-esterification under basic conditions.47 (2) The 5-tert-butoxylcarbonylpyrrole 47 
was transformed into α-free pyrrole 48 by de-esterification under acetic conditions.48 (3) 
5-Benzyl ester pyrroles 50 and 51 were debenzylated, followed by decarboxylation of all 
resultant carboxylic acids to make α-free pyrroles 48 and 52. (4) 2-Ethoxylpyrrole 49 was 
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reduced to give the α-free pyrrole 48 using LiAlH4 directly.
49 Specifically, α-free pyrroles 
44, 45 and 46 were made by refluxing pyrroles 41, 42 and 43 using NaOH as base in 
ethylene glycol solvent at 180 oC, all with a yield around 30%. Pyrrole 48 was made by 
treatment of pyrrole 47 with TFA in 10% yield. Pyrroles 48 and 52 were made by 
debenzylation of pyrroles 50 and 51, respectively, followed by decarboxylation with TFA. 
These reacxtions gave a yield around 30%. α-Free pyrrole 48 can also be obtained 
directly by reducing the ester group of α-free pyrrole to alkyl using LiAlH4 in THF. Some 
α-free pyrroles were made in 2 or 3 steps by a combination of these methods. For 
example, pyrrole 44 was also made by de-esterification of pyrrole 53 followed by 
reduction of the acetyl group at the 3-position of pyrrole 54. This two-step reaction 
actually gave a higher yield than the one step reaction using Method (1). Overall, de-
esterification under basic conditions gave better yields than under acidic conditions, and 
reduction gave the best yield among all these condtions. All these compounds were 
characterized by 1H NMR, 13C NMR and HRMS (ESI). Usually the de-esterification 
causes the peaks of the ester to disappear from the 1HNMR spectrum and the resultant 
α-free pyrrole shows a new 2-H peak around 6.30-6.50 ppm. These α-free pyrroles are 
not very stable in light or air; therefore, once synthesized, they were stored in the freezer 
or immediately used in the next step for syntheses of thioketones.  
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Scheme 4.15: Syntheses of α-free pyrroles from their precursors under various 
conditions. 
Some of the α-free pyrroles 44-46 and 48 were used to synthesize dipyrrothiones 
(Scheme 4.16). Pyrroles 44, 45, 46 and 48 were treated with thiophosgene20,50,51 in THF 
or ether at 0 oC; the reaction was monitored by TLC until starting material had 
disappeared. Then methanol was added to destroy excess thiophosgene. The residue 
was purified by silica gel column chromatography, eluting with toluene/chloroform (4/1) 
or hexane/ethyl acetate (4/1) to give an organge solid in about 40% yield. From 1H NMR, 
the pyrrole α-H around 6.40 ppm disappeared, and the NH group of the product 
pyrrothiones exibited a huge downshift from 7.4 to 9.0 ppm compared with the α-free 
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pyrroles. The structures of the pyrrothiones 55 and 58 were comfired by their mass 
spectra, with peaks at m/z 289.1739 (MW+H) and 233.1106 (MW+H), respectively.  
 
Scheme 4.16: Synthesis of pyrrothiones and pyrroketones.  
During chlorination of thioketones with various chlorinating reagent such as POCl3, 
oxalyl chloridfe or phosgene at room temperature, the solutions of these intermediates 
turned red upon addition of the chlorinating reagent but turned brown with time. Then the 
reaction was tried at 0 oC this also happened; low temperature can not prevent the color 
change. The reaction was monitored by UV-visible spectroscopy; the thiokeone 55 has 
an absorption at 421 nm, and the fully conjugated intermediate shifted to 500 nm after 
chlorination with phosgene in CH2Cl2. Similarly, thioketone 58 has an absorption at 437 
nm and the intermediate shifted to 518 nm after chlorination with oxalyl chloride in 
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CH2Cl2. All these peaks disappeared with time, probably because the strong chlorinating 
reagents decomposed the thioketones. Since chlorination of thioketones failed to give 
chlorodipyrromethene, the thioketones were transformed into pyrroketones by using 
hydrogen peroxide under basic conditions. Analytically pure samples were purified by 
sublimition using a strong vaccum pump. The product sublimed around 220 oC. 
Compared with thioketones, the NH group is slightly shifted from about 9.00 to 8.50 ppm; 
the alkyl groups on thioketones have nearly same shift as do those of pyrroketones. 
These structures of the two pyrroketones were confirmed by mass spectra, with peaks at 
m/z 233.1334 and 273.2013, respectively.  
From the previous experiments and discussion, pyrroketone with electron withdrawing 
group do not have significant reactivity toward acid and eletrophiles; therefore, It was 
dedided to try the same reactions on electron rich alky substituted pyrroketones. 
Therefore pyrroketone 59 was protonated by HCl gas in CH2Cl2. The solution turned 
yellow from colorless, and UV-visible spectroscopy showed a sharp peak at 428 nm 
compared with pyrroketone 59 which has an absorption around 341 nm (Figure 4.5). An 
attempt was made to convert the meso-hydroxydipyrromethene system into a BODIPY 
using DIEA/BF3.OEt2 (Scheme 4.17). Unfortunately, the intermediates were not stable 
upon treatment with the organic base, DIEA, and they reverted to the starting material 
pyrroketone by deprotanation. Then pyrroketones 59 and 60 were subjected to 
treatrment with DIEA/BF3.OEt2 directly, and sharp peaks at 466 and 476 nm (Figure 4.6), 
respectively,were observed in the UV-visible spectra (Figure 4.5). Purification was still 
problematic using a chromatography column. But isolation of product 62 was confirmed 
by its mass spectrum with m/z at 338.3426. Since pyrroketones can be protonated into 
their meso-hydroxydipyrromethene salt, it is very likely they can also be converted into 
similar intermediates by electrophiles. 
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Scheme 4.17: Attempts to synthesize meso-hydroxy BODIPY. 
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Figure 4.5: Optical spectra in CH2Cl2 of dipyrrylketone (A) and salt (B) after treatment 
with HCl(g). 
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Figure 4.6: The Abosorption spectra of pyrroketone 59 and its corresponding BODIPY 
61 in CH2Cl2. 
 
 
Therefore reactions with Meerwein’s reagent Et3OBF4 were attempted (Scheme 4.18). 
Pyrroketones 59 and 60 were treated with Et3OBF4
52
 in CHCl3. and a red solution 
resulted, indicating the presence of fully conjugated dipyrrin system; this was confirmed 
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by UV-visible spectroscopy, showing peaks at 438 and 451 nm, repectively. The solution 
was washed with water and saturated NaHCO3 and the intermediates were not 
destroyed or decolorized according to their UV-visible spectra.  
 
 
Scheme 4.18: Reaction of pyrroketones with Meerwein’s salt in CHCl3.
  
Figure 4.7: Crystal structures of BODIPY 63 and 64. 
These new intermediates were treated with DIEA/BF3OEt2 in CHCl3 to give the 
corresponding BODIPYs. BODIPY 63 has an absorption maximum at 487 nm and 
BODIPY 64 has its absorption at 508 nm. Characteristic resonances for the ethoxy 
group in their 1H NMR spectra appeared at 4.12 (q) and and 1.52 (t) ppm The X-ray 
structures for both BODIPYs 63 and 64 were also obtained (Figure 4.7). The molecule 
63 has very nearly Cs symmetry, with the BF2 plane and dipyrryl plane forming a dihedral 
angle of 89.37(4)o, with the atoms of the OEt group lying a mean of 0.012 Ả from the BF2 
63 64 
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Figure 4.8: Normalized aborption and fluorescence spectra of BODIPYs 63 and 64 in 
CH2Cl2. 
 
plane; BODIPY 64 has a similar structure, with dihedral angle 88.68(1)o, but the dipyrryl 
ethyl groups are anti related to each other. Their nomalized absorption and fluorescence 
were also studied and showed in Figure 4.8. The spectra of these two BODIPYs are of 
comparable shape to those already described in the literature with a narrow absorption 
band around 500 nm (which belongs to S0-S1 transition) plus a weak broad absorption 
around 460 nm. The two BODIPYs also have a slightly shifted sharp emission bands at 
493 and 518 nm, respectively, with a mirror image shape compared to the absorption 
spectra. 
Next, chlorination of pyrroketones 59 and 60 was attempted using phosgene in CH2Cl2 
(Scheme 4.19). Pyrroketone 59 and 60 were dissolved in CHCl3 and treated with 
phosgene solution in toluene. The solution turned red with time and the UV-visible 
spectra showed peaks at 485 and 505 nm (Figure 4.9). Then nitrogen gas was passed  
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Scheme 4.19: Chlorination of pyrroketone using phosgene. 
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Figure 4.9: Absorption spectra of pyrroketones and their meso-chlorodipyrrins in CH2Cl2. 
 
through solution to purge excess phosgene into a NaHCO3 solution. The products 65 
and 66 were crystallized from CH2Cl2/petroleum ether system as red solids in about 90% 
yield. The most noticeable change in the 1H NMR spectrs is the downfield shift of the NH 
group, which is shifted from around 8.60 ppm to 12.50 and 12.93 ppm for 
dipyrromethenes 65 and 66. The identity of the products was also comfirmed by mass 
spectroscopy, with m/z at 235.0992 and 291.1623, respectively. Figure 4.8 shows the 
UV-visible changes during chlorination.  
  
153 
 
The chlorination of pyrroketone was explored first by Fisher53 in 1933. However, very 
little work has been done with chlorodipyrromethene. Therefore, we explored several  
electrophilic substitution reactions and some coupling reactions using chloro-
dipyrromethene to investigate their reactivities. 
Chlorodipyrromethene 65 was used as the substrate and several replacement (addition-
elimination) reactions were explored (Scheme 4.20). The first one attempted was with 
the Grignard reagent EtMgBr. From the resulting mass spectra, both meso-ethyl 
dipyromethene 67 and meso-free dipyrromethene 68 were obtained when 65 was 
treated with EtMgBr. However, It was difficult to separate these two products using silica 
gel column chromatography. Therefore, they were converted into the corresponding 
BODIPYs by complexation with BF3.OEt2  using DIEA as base. The two resulting 
BODIPYs 69 and 70 were easily separated with CH2Cl2/hexane as eluting system on a 
silica gel column. Meso-free BODIPY was found to be the major product in 47% yield, 
and the expected ethyl-substituted product was obtained as the minor product in only 17% 
yield. From the 1H NMR spectra, the meso-ethyl group of BODIPY 69 appeared at 3.02 
ppm (q) and the meso-H of BODIPY 70 appeared at 7.02 ppm. The structures of these 
two BODIPYs were also comfirmed by mass spectroscopy with m/z at 276.1713 and 
248.1404, respectively. 
Addition/elimination reactions using sodium methoxide were also tried on 
chlorodipyrromethene 65; instead of giving the meso-methoxy dipyrromethene 71, the 
product was found to be α-methyl ester pyrrole 72. Sodium ethoxide was also used to 
test if the reaction was reproducible, and once again α-ethyl ester pyrrole 73 was the 
product; the structures of these two unexpected pyrroles were also confirmed by their 
crystal structures. A possible mechanism for their formation is proposed in Scheme 4.21. 
This involves the addition of the the meso-chloro of the meso-dipyrromethene to give a 
methoxy intermediate, which re-aromatized into meso-alkoxy dipyrromethene through 
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elimination of chloride (the better leaving group), followed by attack of alkoxide to form 
5,5-dimethoxydipyrromehtane intermediate. This then undergoes a base-catalyzed 
version of the already known pyrrole and very facile deacylation reaction to give the 
unexpected pyrroles 72 or 73; the overall mechanism involves a dipyrrole cleavage 
reaction.  
Replacement reactions by weak nucleophiles such TBAF and KCN were attempted but 
did not work. For coupling reactions, Suzuki and stille coupling reactions were attempted 
on chlorodipyrromethene but they failed to give the expected products.  
Since chlorodipyrromethenes seemed unstable and products from them were difficult to 
separate, they were converted into their BODIPYs which are more stable and more easy 
to isolate. Chlorodipyrromethene 74 and 75 were treated with DIEA/BF3.OEt2 and their 
BODIPYs (Scheme 4.22) showed about a 20 nm red-shifted UV-visible absorption at 
503 and 527 nm (Figure 4.10) compared with the starting materials at 485 and 505 nm, 
respectively. Both showed a small shoulder at 460 nm in their UV/visible absorption 
spectra. The structures of the products were confirmed by mass spectroscopy, with 
peaks at m/z 282.1010 and 319.1550 (MW – F) for BODIPYs 74 and 75, respectively. 
Single crystals suitable for X-ray structure analysis were obtained for both 8-chloro-
BODIPYs 74 and 75 (Figure 4.11). The non-hydrogen atoms. except for fluorine in 74, 
are fairly coplanar, with mean deviation 0.052 Ả, and the BF2 plane is nearly orthogonal 
to it, with dihedral angle 89.88(2)o. Compound 75 has three molecules in the asymmetric 
unit, two of which have the ethyl groups related syn, and one with anti ethyls, Analogous 
dihedral angles in the three molecules are in the range 88.45(2)-89.37(2)°.  
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Scheme 4.20: Investigation of reactivity of meso-chloro dipyrromethene and X-ray 
Crystal structure of unexpected pyrroles 72 and 73.  
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Scheme 4.21: Proposed mechanism for cleavage of meso-chlorodipyrromethene by 
alkoxide. 
 
 
Scheme 4.22: Synthesis of meso-chloro BODIPYs.  
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Figure 4.10: Normalized absorption and relative fluorescence spectra, in CH2Cl2 of 
chloro-BODIPYs. 
 
 
Figure 4.11: Chrystal structures of meso-chloro BODIPYs 74 and 75.  
 
The same addition/elimination reactions were tried on BODIPY 74 (Scheme 4.23). A 
solution of EtMgBr24 in THF was added at -78 oC and also at room temperature and the 
two reactions gave different products. The replacement reaction only took place at the 
meso-position without effecting the fluorides on the boron to give product 69 in a 75% 
yield at low temperature. However, at room temperature,7,22 all the halogens, including 
the two B-F groups were replaced by EtMgBr to give the fully substituted product 76 in 
74 
75 
  
158 
 
83% yield. Both BODIPYs 69 and 76 have characteristic UV-visible absorptions at 499 
nm and m/z at 276.1713 and 296.2507, respectively. The 1H NMR spectra of BODIPYs 
69 and 76 showed the characteristic 8-ethyl protons at 3.02 (q) and 1.32 (t) ppm, 
respectively; the B-ethyl protons of BODIPY 76 appeared at 0.79 and 0.30 ppm.  
The replacement reaction with the oxygen-centered nucleophile25 sodium methoxide 
was performed both at room temperature and under reflux at 80 oC (Scheme 4.23); both 
conditions gave mixtures of meso-substituted and boron-substituted products but in 
different percentages. At room temperature, displacement of meso-chlorine ocurred 
rapidly to give the major product 77, and one of the boron florines was also displaced 
with extended reaction times to give the minor product 78. If the same reaction was 
performed at reflux with exess sodium methoxide, the fully substituted product 79 was 
obtained as the major product. The B-monomethoxy product 78 was found to be the 
minor product. The 1H NMR spectra of BODIPYs 77, 78 and 79 showed the 8-OMe 
protons as a singlet around 3.97 ppm, while the B-OMe protons of 78 and 79 appeared 
at around 2.89 ppm. All three methoxy substituted products were structurally confirmed 
by mass spectroscopy with m/z at 278.1504 for 77, 259.1392(MW-F) for 78, and 
324.1719 (MW-OMe) for BODIPY 79. 
The same reaction was carried out with sodium ethoxide to compare with the yield of  
alkylation of pyrroketones with Meerweit’s reagents. The replacement reaction gave a 
slightly lower yield (46-52%) compared with when Meerwein’s reagent was used. 
Another oxygen-centered nucleophile, sodium phenoxide, was also tried using BODIPY 
74, and the reaction gave the expected product 80 in 81% yield. The aromatic phenoxy 
group has resonances around 6.99-7.33 ppm in the 1HNMR spectrum, and mass 
spectroscopy showed a m/z at 340.1662. The normalized absorption and fluorescence 
spectra are shown in Figure 12. All these BODIPYs absorption/emission spectra have a 
similar shape to the BODIPYs described in the literature with a sharp absorption peak 
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Scheme 4.23: Replacement reactions of meso-chloroBODIPY by various nucleophiles. 
around 500 nm and a small shoulder around 460 nm, (Figure 4.12). Compared with the 
starting material, meso-chloroBODIPY, substitution by an alkoxy group caused a blue 
shift of 12-16 nm, and alkyl substitution gave the BODIPY a mirror blue shift of 4 nm. 
Their emission bands are slightly shifted to long wavelength as a mirror image with 
around a 10 nm Stokes shift. 
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Figure 4.12: Normalized absorption and relative fluorescence spectra of BODIPYs 63, 
69, 76, 77, 79 and 80 in CH2Cl2. 
 
Three sulfur nucleophiles54 (Scheme 4.24) were also reacted with BODIPY 74. Typically 
a solution of chloroBODIPY 74 and sulfur nucleophile in THF was stirred in the presence 
of K2CO3 as base at room temperature and gave a very good yield of products. With 2-
mercaptobenzothiozole, the reaction gave BODIPY 81 in 56% yield, while 1-
mercaptomethyl-p-carborane gave 82 in 92% yield and SH-1,2-carborane gave BODIPY 
83 in 90% yield. One nitrogen-centered nucleophile, propargyl amine, was investigated 
using chloroBODIPY 74. The reaction gave BODIPY 83 in 92% yield with excess 
propargyl amine as base.  
BODIPYs 81, 82 and 83 showed red-shifted UV-visible absorptions at 539 and 529  and 
554 nm, respectively, (Figure 4.13). Amine-substituted BODIPY 83 showed a blue shift 
from 503 to 458 nm compared with the starting material 74. In the 1H NMR spectrum of 
BODIPY 81, the aromatic protons appear at 7.28-7.98 ppm and BODIPY 82 has the 
SCH2 protons at 2.95 ppm; BODIPY 84 has chemical shift at 5.25 for the amine group 
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and 2.47 for the ethynyl group. Mass spectroscopy confirmed the structure of BODIPYs 
81, 82 and 83 with m/z at 394.1019 (MW-F), 437.3033 and 423.2571, respectively. 
BODIPYs 81, 82 and 83 were characterized by X-ray crystallography (Figure 4.14). In 
BODIPY 81, the dipyrryl and BF2 planes form a dihedral angle of 88.03(7)
o, while the 
mercaptobenzothiazole plane forms a dihedral angle of 77.03(2)o with the dipyrryl unit. In 
BODIPY 82, the dipyrryl and BF2 planes form a dihedral angle of 88.8 (1)°, the linkage 
between dipyrryl and p-carborane is extended, with a C-S-CH2-C torsion angle of  
 
Scheme 4.24: The replacement reactons of meso-chloroBODIPY by sulfur and nitrogen 
centered nucleophiles. 
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Figure 4.13: Normalized absorption and relative fluorescence intensity of BODIPYs 81 
and 82 in CH2Cl2. 
 
    
Figure 4.14: The crystal structures of BODIPYs 81-83. 
175.3(6)o. The best plane of the CSCC linkage forms a dihedral angle of 83.8(2)o with 
the dipyrryl plane. 
Replacement reactions with Grignard reagents7,55 such as phenyl magnesium bromide, 
vinyl magnesium bromide and phenyethynyl magnesium bromide were attempted in 
order to introduce meso-phenyl, vinyl or phenylenthynyl substitutents into the BODIPYs. 
However, all these reagents were unreactive toward meso-chloroBODIPY with used with 
only one equivalent. Excess of these reagents quenched the fluorescence of 
chloroBODIPY. Once heated, the BODIPY would precipitate immediately and there were 
some TLC spots appearing under short wavelength UV light. Some weak nucleophiles 
such as TBAF and KCN were also investigated using chloroBODIPY, but they did not 
react either.  
81 82 83 
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Pd(0)-catalyzed cross-coupling procedures with BODIPYs have been well explored, 
including use of the Suzuki,56 Stille,57 Heck58 and Sonogoshira59 reactions. These 
transformations have been performed either directly on the BODIPY core30,60,61 or on a 
substituent,26 and have largely facilitated the functionalization of BODIPYs. In particular 
coupling reactions of 3,5-dichloro-BODIPYs afforded many sophisticated products.60 
Compared with the 3,5-positions, the meso-carbon is more electrophilic based on their 
vibration structures and Mulliken-charge analysis on the core carbon atoms of 
tetramethyl-BODIPY.13 Recently, various Pd(0)-catalyzed cross-coupling reactions were 
performed on 8-halo-BODIPYs.21 We also attempted numerous coupling reactions of 
BODIPYs with intention to provide more a versatile functionalization access to new 
BODIPYs.  
The Suzuki coupling reaction56,62-65 was attempted first. ChloroBODIPY 74 was coupled 
with phenylboronic acid using Pd(PPh3)4 as catalyst and K2CO3 as base (Scheme 4.25). 
The mixture was heated under refux in DME or THF for 24 hours and monitored using 
UV-visible spectroscopy and TLC. The starting material disappeared with time and 
several new peaks appeared in the UV-visible spectra around 500 nm in CH2Cl2, 
indicating a mixture of products. The expected product, meso-phenyl BODIPY 85 was 
separated as the major fraction in 46% yield. 1H NMR spectroscopy showed the 
expected aromatic area at 7.27-7.49 nm, which is consistent with literature reports and 
the structure of the product was also confirmed by its mass spectrum with m/z at 
324.1717. Another two fractions were also separated upon chromatography, which were 
found to be meso-phenoxy-BODIPY 80 and the meso-free BODIPY 70. The mechanism 
of formation of the meso-phenoxy BODIPY is still under investigation, and all data are 
identical with those from the replacement reaction with sodium phenoxide. The 1H NMR 
spectrum of meso-free BODIPY is also identical with that from the replacement reaction 
when a Grignard reagent is used. Some alkyl boronic acids such as methyl, ethyl, 
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isopropyl, and vinyl boronic acid were also used. However, only meso-free BODIPY was 
separated and the starting material was still the major fraction. The reaction was also 
tried under microwave conditions but again did not work. This is probably due to the fact 
that these boronic acids have a small organic part compared with phenyl boronic acid.  
 
 
 
Scheme 4.25: Suzuki coupling reactions of BODIPY 74 with boronic acids. 
The Sonogashira coupling reacton66-68 of ethylnyltrimethylsilane with chloroBODIPY 74 
catalyzed by PdCl2(PPh3)2 was performed under standard conditions with TEA as base 
(Scheme 4.26). The mixture was refluxed in THF for about 24 hours and the reaction 
was monitored by TLC and UV-visible spectroscopy. The reaction resulted a very 
obvious color change caused by the product which has about a 40 nm red shift 
compared with the starting material. The separation of product was problematic using 
silica gel column chromatography. Separation was achieved later using a peptic TLC 
plate to give about a 35% yield of product 86 with UV/visible absorption at 544 nm in 
CH2Cl2. A similar compound was also recently synthesized by conventional methods 
using an alkynyl aldehyde as electrophile.69 In the replacement reaction, Grignard 
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reagents did not work on chloroBODIPYs, so a coupling reaction of Grignard reagent 
with BODIPYs was attempted. The chloroBODIPY was treated with phenylethynyl 
magnesium bromide in the presence of the catalyst Pd(PPh3)4 in THF and the mixture 
was refluxed for five minutes. The reaction resulted in a red solution and the UV/visible 
absorption spectrum showed a sharp peak at 554 nm. The structure of the product was 
confirmed by 1H NMR spectroscopy to be the fully substituted BODIPY 87. The 
assumption is that the strong Grignard reagents diminished the difference between 
chloride and fluoride under palladium catalysis.  
Finally, Stille coupling reactions57,70,71 were performed on chloroBODIPY with 
tributylphenylstannane catalyzed by Pd(PPh3)4 without any base. The mixture was 
refluxed in toluene and TLC showed the reaction was not only completed within five 
hours, but also the product was the only spot on a TLC plate. The product 85 was 
separated with a flash column on silica gel to remove very minor reaction impurities to 
give the product in 93% yield. This yield is far better than those from the Suzuki reaction. 
Heck coupling reactions were attempted with styrene using Pd(II)(PPh3)2Cl2  as catalyst 
and TEA as base, but the reaction did not yield any useful product. There was no 
UV/visible absorption change during this reaction.  
From the above coupling reactions performed on cloroBODIPY 74, one can see that 
Suzuki, Stille and Sonogashira coupling reactions all worked, but the Heck coupling 
reaction did not. The products from these reactions were obtained in 36-93% yields, with 
the lowest yield obtained for the 8-chloro-BODIPY under Suzuki conditions and highest 
yield with organotin reagent.  
Since we observed the Stille coupling reaction to be the most efficient and economic 
reaction among all these coupling reactions, we therefore further investigated the Stille 
coupling reaction with other reagents to see if we could expand this method to more 
substrates and make it a more versatile approach for functionalization of BODIPYs. 
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Various organotin reagents bearing alkyl, alkenyl, alkynyl and heterocyclic aromatic 
groups were used in coupling reactions to investigate the sp2-sp3, sp2-sp2 and sp2-sp 
coupling reactions with BODIPYs (Table 4.1). All the coupling reactions produced the 
corresponding 8-functionalized BODIPYs in nearly quantitative yields, except for the 
reaction with tributylethynyltin, which gave BODIPY 91 in only 31% yield. When TMS-
protected ethynyl organotin was used, the yield improved to 71% yield for product 86, 
presumably because the TMS-protected ethynyl product is more stable. Aromatic Stille 
reagents such as 2-(tributylstannyl)pyrrole, 2-(tributylstannyl)thiophene and 2-
(tributylstannyl)pyridine were also employed since these compounds can also be 
synthesized by traditional methods. For the first two electron-rich stannane reagents, the 
products 92 and 93 were obtained in excellent yields around 95-99%, However, for the 
electron deficient pyridyl tin reagent, only meso-free BODIPY was generated. The 
structures of the BODIPY products were confirmed by 1H and 13C NMR, HRMS (ESI-
TOF) mass spectrometry and UV-visible spectroscopy. The 1H NMR spectrum of 8-
phenyl-BODIPY 85 showed aromatic protons between 7.49-7.27 ppm, consistent with 
literature reports,40,41 and the structure of the product was confirmed by mass 
spectroscopy (m/z 324.1717). The meso-methyl group of BODIPY 88 appeared at 2.40 
ppm in its 1H NMR spectrum and the product showed m/z at 262.1556. For BODIPYs 89 
and 90, the 1H NMR spectra showed the alkene group as two doublets at 6.74 (dd),5.69 
(dd) and 5.56 (dd) ppm for BODIPY 89 and 4.46 (dd), 4.37 (dd) ppm for BODIPY 90. 
The ethoxy group of 90 absorbed at 3.90 (q) and 1.38 (t) ppm. The mass spectra 
confirmed the identity of the two product with m/z at 274.1557 and 318.1817, 
respectively. BODIPY 91 has a typical peak at 3.92 ppm for the alkynyl group in its 1H 
NMR spectrum, and m/z at 272.1380. BODIPY 86 showed the TMS protecting group at 
0.29 ppm in its 1H NMR spectrum and m/z 325.1708 (MW-F) in its mass spectrum; the 
aromatic ring of BODIPYs 92 and 93 showed peaks between 6.77-6.06 ppm and 7.51-
  
168 
 
6.98 ppm, and the N-CH3 of BODIPY 92 showed a peak at 3.40 ppm in its 
1H NMR 
spectrum. These two BODIPYs were also characterized by m/z at 327.1799 and 
352.1094, respectively. The X-ray crystal structures of BODIPYs 85, 88, 89, 92 and 93 
were also obtained by slow diffusion of hexane into a CH2Cl2 solution of each, and they 
are shown in Figure 4.15. 
In the X-ray structures, BODIPY 85 deviates from its potential Cs symmetry by the BF2 
and phenyl planes being twisted in opposite directions from orthogonality with the 
dipyrryl plane, the BF2 forming a dihedral angle of 88.13(5)° and the phenyl a dihedral 
angle of 82.40(3)° with it. BODIPY 88 is unusual in that its dipyrryl group lies in a 
crystallographic mirror and its BF2 across it; thus they are exactly orthogonal.The X-ray 
structure for BODIPY 89 was also obtained. Its dipyrryl and BF2 planes form a dihedral 
angle of 88.82(2)o. The ethene substitutent is not quite orthogonal to the dipyrryl nor 
coplanar with the BF2, a C-C-C=C tortion angle about the bond to it being 65(10)°. 
BODIPY 92 deviates only slightly form Cs symmetry, with the BF2 plane forming a 
dihedral angle of 89.51(9)o with the dipyrryl plane and the methylpyrrole plane forming 
an angle of 85.77(4)o with it, only one of the major orientations of the disordered 
thiophene is shown for BODIPY 93; it forms a dihedral angle of 84.31(8)° with dipyrryl, 
and the BF2 plane forms a dihedral angle of 88.56(4)° with the dipyrryl plane. 
The spectroscopic properties of these compounds were studied and their UV/visible 
absorption and steady-state fluorescence emission spectra in CH2Cl2 were recorded.  As 
an example, Figures 4.10, 4.12, 4.13 and 4.16 show the normalized absorption and 
fluorescence spectra of some BODIPYs. Specifically, literature compounds 85 and 88 
have absorption and emission values similar to those previously reported.42 The newly 
synthesized BODIPYs 74, 63 75 and 64 show spectra of comparable shape to those 
BODIPYs described in the literature, with a narrow absorption band (λmax ca. 500 nm), 
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Scheme 4.26: Coupling reactions of BODIPY 74 with different reagents. 
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Table 4.1: Stille coupling reactions of 8-chloro-BODIPY 74 
 
BODIPYS Organotin R Yield (% ) 
85 Bu3SnPh 
 
93 
86   71 
88 Me4Sn  97 
89 Bu3Sn(CH=CH2)  97 
90 Bu3Sn(EtOC=CH2) 
 
93 
91 Bu3Sn(C CH)  31 
92 
  
95 
93 
  
99 
Note: The reaction was performed using 0.2 mmol for all the organotin reagents except 
for 86 which started with (25 mg, 0.088 mmol).  
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Figure 4.15: X-Ray structures of BODIPYs synthesized from Stille coupling reactions. 
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Figure 4.16: Normalized absorption and relative fluorescence intensity spectra, in CH2Cl2, 
of BODIPYs 85, 86, 90, 91, 92 and 93. 
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which belongs to the s0-s1 transition, plus a weak broad absorption around 460 nm 
assigned to s0-s2 transition. All the BODIPYs have a slightly shifted sharp emission band 
with a mirror image shape. Table 4.1 presents the photophysical data of these BODIPYs, 
including the maximum absorption and fluorescence wavelengths, molar extinction 
coefficients and fluorescence quantum yields in CH2Cl2. Meso-chloro-BODIPY 74 has an 
absorption at 503 nm and a 9 nm Stokes-shifted fluorescence. The replacement of the 
chloro- by methoxy- (BODIPY 77), ethoxy- (BODIPYs 63 and 64), or phenoxy- (BODIPY 
80) causes a 12-16 nm blue-shift of the BODIPYs. On the other hand, substitution with 
alkenyl- (BODIPYs 89 and 90), ethynyl- (BODIPYs 86 and 91), thio- (BODIPYs 81, 82 
and 83) or an aromatic heterocyclic ring (BODIPYs 92 and 93) causes a red-shift (within 
40 nm) in the corresponding BODIPYs. Carbon nucleophiles induce a very small blue 
shift The fluorescence quantum yields of 74 and 75  are around 0.51 and 0.33; 
replacement of the meso-chloro by an oxygen-centered nucleophile causes the quantum 
yields to increase significantly. In particular, for 63 and 64, they increased about 0.30 
compared with their meso-chloro-BODIPY counterparts 74 and 75; in particular, the 
quantum yield of BODIPY 63 is close to 1.00. Substitution of the chloro- by alkyl- (e.g. 
methyl and ethyl as in BODIPY 69 and 88) or aromatic (phenyl) groups (BODIPY 85) 
also causes the quantum yields to increase significantly compared with the precursor 
chloro-BODIPY. However, sulfur-centered nucleophiles (BODIPY 81-83) caused the 
quantum yield to decrease; for example, the corresponding compounds 81 and 82 have 
very low quantum yields (0.04 and 0.09, respectively). Meso-alkenyl-, ethynyl- and 
heteroaromatic ring-substituted BODIPYs 89-93 have relatively low quantum yields, 
especially so for BODIPY 89 which is almost non-fluorescent. Substitution on the boron 
has no significant impact on absorption, but does have a large effect on the quantum 
yield. For example, the substitution by a methoxy group on boron causes the quantum 
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yield to increase by 0.42 (BODIPY 79). However, alkyl substitution on the boron reduces 
the quantum yield of BODIPY 69 from 0.83 to the 0.32 value of BODIPY 76 . 
Steady-state Absorption and Fluorescence Spectroscopy  
The absorption measurements were carried out on an Agilent 8453 spectrophotometer 
and the steady-state fluorescence spectroscopic studies were performed in CH2Cl2 on a 
PTI QuantaMaster4 / 2006SE spectrofluorometer. The slit width was 3 nm for both the 
excitation and emission measurements. The fluorescence quantum yields of BODIPYs 
was obtained by comparing the area under the corrected emission spectrum of the test 
sample with that of Rhodamine 6G in ethanol.  
The fluorescent quantum yields (Фexp) were calculated using the following equation 
         
          
 
            
  
 
Фref is the standard fluorescent quantum yield, Fx is the area under the sample 
emission peak, Fstd is the area under the standard’s emission peak, Astd is the optical 
density at which the standard was excited, Ax is the optical density at which the sample 
was excited, n represents the refractive index of the solvent of sample solution, and nstd 
is the refractive index of the standard’s solvent. 
 
Table 4.2. Spectral properties of BODIPYS in CH2Cl2 at room temperature. The 
fluorescence quantum yields (λexc = 490 nm) were calculated using, rhodamine 6G (0.80 
in ethanol) as the reference32 and a PTI Quantum Master4/2006SE spectrofluorimeter 
was used 
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BODIPY 
Abs 
λmax (nm) 
Emission 
λmax (nm) 
φf 
Log ε 
(M-1.cm-1) 
63 487 493 0.99 4.77 
64 508 518 0.67 4.44 
69 499 505 0.83 4.75 
74 503 512 0.51 4.79 
75 527 542 0.33 4.50 
76 499 507 0.32 4.20 
77 487 493 0.57 4.95 
79 487 496 1.00 4.67 
80 491 499 0.99 4.71 
81 539 553 0.04 4.69 
82 529 542 0.09 4.23 
85 501 511 0.62 4.76 
86 545 556 0.13 4.63 
88 497 508 0.77 4.82 
89 505 511 0.00 4.67 
90 513 522 0.14 4.61 
91 544 556 0.29 4.57 
92 513 521 0.10 4.73 
93 514 521 0.05 4.87 
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4.3 Conclusion 
Symmetrical pyrroketones were made via thioketones by treatment with PbO2/Pb(OAc)2 
The chemistry of pyrroketones was investigated by electrophilic alkylation with 
Meerwein’s salt, chlorination by phosgene and protonation by acids. Reactivity of their 
derivatives, 8-chloro-dipyrromethenes and 8-chloroBODIPYs, were compared using 
nucleophilic substitution (addition/elimination) with, for example, oxygen-centered 
nucleophiles, sulfur-centered nucleophiles and carbon-centered nucleophiles and 
coupling reactions including Sonogashira, Heck, Suzuki and Stille coupling were also 
investigated. The resuls show that BODIPYs are more stable than dipyrromethenes 
(dipyrrins) in most of the reactions, and they are easy to handle during purification. The 
advantage of dipyrrins over BODIPYs is that there are no competitive reactions involving 
the B-F bonds during substutition reactions. Some BODIPYs were obtained by 
substitution (addition/elimination) or coupling reactions of 8-chloroBODIPYs, which are 
hard to synthesize by conventional methods. The photophysical properties of these new 
BODIPYs were studied including absorption, fluorescence and determination of their 
quantum yields. 
 
4.4 Experimental Part 
General information: 
All the solvents and chemicals were purchased from Aldrich, Fisher and TCI. Silica gel 
60 (230 x 400 mesh) and TLC plates (0.2 mm thickness) were purchased from Sorbent 
Technologies. All conmertial reagents were used without further purification. Water and 
air sensitive reactions were performed under argon protection and in dry solvents. 
Melting points were measured on an electrothermal Mel-Temp instrument, UV/visible 
absorption spectra was measured on an Agilent 8453 spectrophotometer and the steady 
state fluorescence spectroscopic studies were performed on a PTI 
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QuantaMaster4/2006SE spectrofluorometer with the slit width set at 3 nm. High and low 
resolution mass spectra were performed on Bruker ProFlex III MALDI-TOF and Hitachi 
M8000 ESI mass spectrometers. FT-IR data were obtained on a Bruker Tensor 27 
system (2004), 1H NMR and 13C NMR spectra were obtained with a Bruker AV-400 MHZ 
spectrometer, and chemical shifts are expressed in ppm.  
Dibenzyl 5,5’-carbonylbis(4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-
carboxylate) 36: A solution of dipyrromethane 34 (2.0 g, 3.25 mmol) in acetic acid (80 
ml) was treated with Pb(OAc)4 (3.12 g, 7.0 mmol) and stirred at room temperature for 4 d 
under argon. Then PbO2 (2.4 g, 9.3 mmol) was added and the solution was stirred for 
another two d. The solution was centrifuged and the supernatant was poured into ice 
water. The precipitate was collected and dissolved in diethyl ether, before being washed 
with water, 5% NaHCO3 and brine and then dried over anhydrous Na2SO4. Then the 
solution was concentrated to a minimum volume and crystallized in a refrigerator to give 
product as a yellowish white solid (1.2 g, 60%). 1H NMR (400 MHz; CDCl3): 7.38-7.31 (m, 
10H), 5.00 (s, 4H), 3,67 (s, 6H), 3.01 (t, 3H), 2.71 (t, 3H), 2.27 (s, 6H).  1H-NMR (400 
MHz; CDCl3): 176.73, 173.56, 161.74, 135.02, 132.23, 130.16, 128.66, 128.36, 127.73, 
126.97, 121.68, 66.77, 51.58, 35.19, 20.28, 10.37.   
Dibenzyl 5,5'-carbonylbis(3,4-dimethyl-1H-pyrrole-2-carboxylate) 37 was 
synthesized using the same procedure as used for 36: (0.79g, 50%)1H NMR (400 MHz; 
CDCl3): 7.37 (m, 10H), 5.14 (s, 4H), 2,25 (s,3H), 2.23 (s, 3H). 
Benzyl 5-(5-((benzyloxy)carbonyl)-3-(3-methoxy-3-oxopropyl)-4-methyl-1H-pyrrole-
2-carbonyl)-1-ethyl-4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-carboxylate 
39: 1H NMR (400 MHz, CDCl3): 9.22 (s, 2H), 7.46-7.27 (m, 10H), 5.34 (s, 2H), 5.35 (s, 
2H), 4.30 (q, J = 4.29 Hz, 2H), 3.56 (s, 3H), 3.62 (s, 3H) 2.89 (t, 2H) 2.59 (t, 2H), 2.47 (t, 
2H)2.35 (t, 2H) 2.31 (s, 3H), 2.25 (s, 3H), 1.22 (t, J = 4.29 Hz, 3H); 
13C NMR 
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(CDCl3):179.40, 173.06, 172.82, 161,28, 160.71, 135.99, 135.53, 133.26, 131.03, 
130.87, 128.67, 128.62, 128.47, 128.42, 128.33, 128.29, 128.26, 127.82,124.37, 
122.94, 122.05, 66.67, 51.56, ,42.16, 34.89, 34.26, 29..69, 19.96, 19.87, 17.35, 
14.15, 14.11, 11.50, 10.07. 
 
Preparation of α-Free Pyrroles 
General procedure for hydrolysis under basic conditions: α-Ester pyrrole (5.0 mmol) 
was dissolved in 10-15 ml of ethylene glycol. Then potassium hydroxide (10.0 mmol) 
was added under an argon atmosphere and the mixture was refluxed for 2 h. After the 
reaction had cooled down to room temperature, the mixture was diluted with water and 
extracted with hexane and then washed with water, brine and finally dried over 
anhydrous Na2SO4. After removal of the solvent, the residue was purified by 
chromatography on a silica gel column eluted with hexane/ CH2Cl2 (2/1) to give the pure 
product.  
General procedure for hydrolysis under acidic conditions: tert-Butyl ester pyrrole or 
pyrrole carboxylic acid (2.0 mmol) was dissolved in TFA at 0 oC, the mixture was stirred 
for 1 h and then poured into ice water and neutralized with ammonia to pH = 7. The 
solution was extracted with hexane or CH2Cl2 and washed with water, brine, and dried 
over anhydrous Na2SO4. After removal of the solvent, the residue was purified by 
chromatography on a silica gel column eluted with hexane/ CH2Cl2 (2/1) to give the pure 
product 
General procedure for reduction of ester pyrrole to alkyl pyrrole: 2-Unsubstituted 5-
ester pyrrole (2.0 mmol) was dissolved in dry THF (50 ml) and the solution was added to 
a suspension of LiAlH4 (2.4 mmol). The mixture was refluxed for 5 h and then it was 
cooled to room temperature and the excess LiAlH4 was destroyed by addition of 
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aqueous saturated Na2SO4. The solution was extracted with hexane or CHCl3 and then 
washed with water, brine and dried over anhydrous Na2SO4 and the residue was purified 
by chromatography on a silica gel column eluted with hexane/ CH2Cl2 or hexane/ethyl 
acetate.  
 
2,4-Dimethyl-3-ethylpyrrole 44: 1H NMR (400 MHz; CDCl3): 7.48 (s, 1H), 6.40 (s, 1H), 
2.42 (q, 2H), 2.10 (s, 3H), 2.00 (s, 3H), 1.09 (t, 3H). 
2,4-Dimethylpyrrole 45: 1H-NMR (400 MHz; CDCl3): 7.64 (s, 1H), 6.50 (s, 1H), 5.89 
(s,1H), 2.34 (s, 3H), 2.22 (s, 3H). 
2,4-Dimethyl-3-butylpyrrole 46: 1H NMR (400 MHz; CDCl3): 7.51 (s, 1H), 6.45 (s, 1H), 
2.45 (t, 2H), 2.24 (s, 3H), 2.12 (s, 3H), 1.48 (m, 4H), 1.04 (t, 3H). 
2,3,4-Trimethylpyrrole 48: 1H NMR (400 MHz; CDCl3): 7.45 (s, 1H), 6.40 (s, 1H), 2.16 
(s, 3H), 2.12 (s, 3H), 1.94 (s, 3H) 
2,4-Dimethyl-3-acetylpyrrole 54: 1H NMR (400 MHz; CDCl3): 8.45 (s, 1H), 6.35 (s, 1H), 
2.50 (s, 3H)， 2.42 (s, 3H), 2.27 (s, 3H) 
2,4,7,9-Tetramethyldipyrryl-5-thioketone 55 : A solution of thiophosgene (1.15 g, 10.0 
mmol) in toluene (10 ml) was added dropwise to a solution of 2,4-dimethylpyrrole 45 (2.0 
g, 21.0 mmol) in dry ether (30 ml) at 0 °C. The mixture was stirred for about 1 h (until 
TLC showed the starting material had disappeared). Then methanol (30 ml) was added 
and the mixture was stirred for another 30 min. The solvents were removed in vacuo and 
the residue was purified on a silica gel column eluted with toluene/chloroform (4:1). The 
thioketone product was obtained as an orange solid (980 mg, 40%), with Mp 180-
181°C.1H NMR (400 MHz; CDCl3): 
 8.96 (s, 2H), 5.91 (s, 2H), 2.27 (s, 6H), 2.07 (s, 6H); 
13C NMR (CDCl3): δ 175.30, 133.30, 127.98, 127.56, 111.74, 13.09, 12.65; HRMS (ESI): 
Calcd m/z for C13H16N2S:
 233.1107; found: 233.1106. 
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The synthesis of 3,5-dibutyl-2,4,7,9-tetramethyldipyrryl-5-thioketone 56 followed the 
procedure reported above for 55: (Yield: 1.23g, 34%). 1H NMR (400 MHz; CDCl3): 8.95 
(s, 2H), 2.36 (t, 4H), 2.23 (s, 6H), 1.99 (s, 6H), 1,40-1.31(m, 8H), 0.92(t, 6H). HRMS 
(ESI): Calcd m/z for C17H25N2S:
 344.5572; found: 344.5576. 
The synthesis of 3,8-diethyl-2,4,7,9-tetramethyl-5-dipyrryl-5-thioketone 58 followed 
the procedure reported above for 55. Yield 1.30 g, (43%). Mp 205-207 oC 1H NMR (400 
MHz; CDCl3): 8.95 (s, 2H), 2.40-2.35 (q, J = 7.5 Hz, 4H), 2.23 (s, 6H), 2.00 (s, 6H), 1.07-
1.03 (t, J = 7.5 Hz, 6H); 13C-NMR (CDCl3): 189.39, 136.19, 134.67, 126.67, 125.56, 
17.47, 14.99, 11.73, 10.88. HRMS (ESI): Calcd m/z for C17H25N2S:
 289.1733; found: 
289.1739.  
2,4,7,9-Tetramethyldipyrryl-5-dipyrroketone 59: To the thioketone 55 (232 mg, 1.0 
mmol) in EtOH (95%, 100 ml) was added KOH (1.0 g) and to the mixture was added 
aqueous H2O2 (5%, 10 ml) dropwise in an ice bath. Then the solution was heated on a 
steam bath for about 5 min. The solution was cooled to room temperature and water 
(300 ml) was added and it was then extracted with chloroform three times. The organic 
layers were collected and washed with water, brine and then dried over anhydrous 
Na2SO4. The solvent was evaporated and the residue was purified by sublimation to give 
the product dipyrrylketone as a pale yellow solid. (170 mg, 78%). Mp 232-233 °C. 1H 
NMR (400 MHz; CDCl3): 
 8.63 (s, 2H), 5.85(s, 2H), 2.28 (s, 6H), 2.19 (s, 6H); 13C-NMR 
(CDCl3): 175.30, 133.30, 127.98, 127.56, 111.74, 13.09, 12.65; HRMS (ESI): Calcd m/z 
for C13H16N2O:
 217.1335; found: 217.1334. UV/vis (CH2Cl2) λmax (ε) 295 nm (8600), 341 
nm (14600). IR νmax (C=O) (Nujol) 1573 cm
-1. 
3,5-Diethyl-2,4,7,9-tetramethyl-5-dipyrroketone 60: Yield, 224 mg, (82%). Mp 205-
207 °C . 1H NMR (400 MHz; CDCl3): 8.61 (s, 2H), 2.43-2.37 (q, J = 7.5 Hz, 4H), 2.23 (s, 
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6H), 2.14 (s, 6H), 1.07 (t, J = 7.5 Hz, 3H) 13C-NMR (CDCl3): 175.23, 129.65, 127.24, 
125.27, 124.25, 17.37, 15.20, 11.41, 10.70. HRMS (ESI): Calcd m/z for C17H25N2O: 
273.1967; found: 273.2013. UV/vis λmax (CHCl3) 288 nm (11700), 357 (25000). IR νmax 
(C=O) (CHCl3 or Nujol) 1575 cm
-1. 
BODIPY 63: Method A: Dipyrrylketone 59 (60 mg, 0.27 mmol) was dissolved in dry 
CHCl3 (20 mL) and triethyloxonium tetrafluoroborate (105.1 mg, 0.54 mmol) was added. 
The solution turned red with time and UV-visible spectroscopy showed a sharp peak at 
438 nm. The mixture was stirred overnight and then washed with water, brine and finally 
dried over anhydrous Na2SO4. After evaporation, the residue was dissolved in CHCl3 
(30.0 ml) and DIEA (1.62 mmol, 6 equiv) was added and the solution was stirred for 
about 30 min before addition of BF3.OEt2 (2.7 mmol, 10 equiv); the reaction solution was 
then stirred overnight. UV-visible spectroscopy showed a sharp peak at 487 nm. Then 
the mixture was washed with aqueous NaHCO3, brine and then dried over anhydrous 
Na2SO4. The residue was purified by chromatography (eluted with CH2Cl2/hexane) to 
give BODIPY 63 as an orange red solid. (64 mg, 82%). 
Method B: BODIPY 74 (56.4 mg, 0.20 mmol) was dissolved in MeOH (20 ml) in an ice 
bath and NaOEt (20.4 mg, 0.3 mmol) was added. The mixture was stirred for 45 min 
while being monitored by TLC and UV-visible spectroscopy. The solvent was removed in 
vacuo and the residue was taken up in CHCl3 and washed with water, brine and then 
dried over anhydrous Na2SO4. The product was purified by chromatography (eluted with 
CH2Cl2/hexane) to give an orange solid (26.8 mg, 46%). Mp. 126-128 °C; 
1H NMR (400 
MHz; CDCl3): 6.02 (s, 2H), 4.12 (q, J = 7.1 Hz, 2H), 2.51 (s, 6H), 2.38 (s, 6H), 1.53 (t, J = 
7.1 Hz, 3H); 13C NMR (100 MHz; CDCl3): 159.12, 154.13, 139.13, 127.94, 119.57, 74.14, 
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15.31, 14.45, 13.75; HRMS (ESI): m/z Calcd for C15H19BF2N2O: 292.1668; found: 
292.1654; UV/vis (CH2Cl2) λmax (ε) 487 nm (58900). 
BODIPY 64:  Method A: Yield: (66 mg, 71%); Method B: Yield: (36.2 mg, 52%); Mp. 135-
137 °C; 1H NMR (400 MHz; CDCl3): 4.09 (q, J = 7.1 Hz, 2H), 2.48 (s, 6H), 2.48 (q, J = 
7.5 Hz, 4H), 2.32 (s, 6H), 1.55 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.5 Hz, 6H); 13C NMR (100 
MHz; CDCl3): 158.04, 152.19, 134.73, 131.53, 73.88, 17.04, 15.29, 14.68, 12.41, 11.22; 
HRMS (ESI): m/z Calcd for C19H27BFN2O (M
+-F): 329.2200; found: 329.2167.; UV/vis 
(CH2Cl2) λmax (ε) 508 nm (27500). 
5-Chloro-2,4,7,9-tetramethyldipyrromethene hydrochloride 65: Dipyrrylketone 59 
(314 mg, 1.45 mmol) was dissolved in CHCl3 (100 ml) and excess phosgene in toluene 
solution was added and stirred at room temperature for 1 h. When the reaction was 
complete according to UV-visible spectra and TLC, nitrogen gas was passed through 
solution to purge it of excess phosgene that was directed into an aqueous NaHCO3 
solution trap. Solvent was then removed in vacco and the red solid was recrystallized 
from CHCl3/petroleum ether to give 65 as a red solid (306 mg, 90%). Mp > 260 °C. 
1H 
NMR (400 MHz; CDCl3): 12.93 (s, 2H), 6.23 (s, 2H), 2.59 (s, 6H), 2.34 (s, 6H); 
13C NMR 
(CDCl3): 153.70, 144.35, 139.63, 128.18, 120.71, 16.27, 14.38; HRMS (ESI): Calcd m/z 
for C13H16ClN2:
 235.0997, found: 235.0992. UV/vis (CH2Cl2) λmax(ε) 485 nm (23500). 
5-Chloro-3,8-diethyl-2,4,7,9-tetramethyldipyrromethene hydrochloride 66. Yield: 
392 mg, (93%). Mp >300 °C. 1H NMR (400 MHz; CDCl3): 12.50 (s, 2H), 2.35 (s, 6H), 
2.15 (s, 6H), 2.40 (q, 4H), 1.05 (t, 6H). 13C NMR (CDCl3): 152.41, 138.81, 137.68, 
133.13, 128.08, 17.44, 14.28, 12.72, 12.63 HRMS (ESI): Calcd m/z for C17H24ClN2
 
291.1623, found: 291.1635. Anal. Calcd for C17H24Cl2N2: C, 62.4; H, 7.3; N, 8.6; found: C, 
62.7; H, 7.5; N, 8.8%. UV/vis (CHCl3) λ max(ε) 509 nm (57500). 
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BODIPY 69: Method A: 5-Chloro-dipyrrin 65 (100 mg, 0.37 mmol) was dissolved in 
CHCl3 (40 mL) and 1.0 M EtMgBr in THF (1.30 mL, 1.30 mmol) was added dropwise at 
0 °C; the mixture was left stirring for 1 h at 0 °C and then for another 2 h at room 
temperature. Then the solution was poured into ice/water to destroy excess EtMgBr and 
it was extracted with CHCl3. The organic layers were combined and washed with water, 
brine and then dried over anhydrous Na2SO4. After evaporation, the residue in CHCl3 (30 
mL) and DIEA (0.45 ml, 7 equiv, 2.58 mmol) in an ice bath was treated with BF3.OEt2 
(0.53 ml, 12.0 equiv, 4.3 mmol) and the mixture was stirred overnight. The solvent was 
removed and the residue was purified on a silica gel column (eluted with CH2Cl2/hexane) 
to give BODIPY 69. Yield: 20.1 mg, 19.6%.  
Method B: ChloroBODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in anhydrous THF (30 
ml) and 1.0 M EtMgBr in THF (0.5 mL, 0.5 mmol) was added dropwise to the solution at 
- 70 °C with vigorous stirring. When the reaction was complete according to TLC and 
spectrophotometry, the solution was poured into ice/water to destroy the exess Grignard 
reagent. Then the mixture was extracted 3 times with CHCl3 and the organic phases 
were combined and washed with water, brine and then dried over anhydrous Na2SO4. 
The solvent was evaporated and the residue was purified by silica gel column 
chromatography (eluted with CH2Cl2/hexane) to give the product 69 as an orange-red 
solid (40 mg, 75%); Mp. 214-216 °C; 1H NMR (400 MHz; CDCl3): 6.05 (s, 2H), 3.01 (q, J 
= 7.5 Hz, 2H), 2.52 (s, 6H), 2.44 (s, 6H), 1.32 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz; 
CDCl3): 153.87, 147.87, 140.30, 131.20, 121.55, 21.29, 16.30, 15.45, 14.45; HRMS 
(ESI): m/z calcd for C15H19BF2N2: 276.1718; found: 276.1713; UV/vis (CH2Cl2) λmax (ε) 
499 nm (56200). The meso-unsubstituted BODIPY was also eluted from the column (6.0 
mg, 10%); Mp. 185-187 °C; 1H NMR (400 MHz; CDCl3): 7.04 (s, 1H), 6.05 (s, 2H), 2.53 
(s, 6H), 2.25 (s, 6H); 13C NMR (100 MHz; CDCl3): 156.75, 141.20, 133.41, 120.07, 
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119.02, 14.67, 11.28; HRMS (ESI): m/z Calcd for C13H15BF2N2: 248.1405; found: 
248.1404; UV/vis (CH2Cl2) λmax (ε) 507 nm (19600). 
Methyl 3,5-dimethylpyrrole-2-carboxylate 72: Chlorodipyrrin hydrochloride 65 (47.0 
mg, 0.17 mmol) was dissolved in CHCl3 and 0.5 M NaOMe in MeOH (1.0 mL, 0.5 mmol) 
was added at room temperature; the mixture was stirred overnight and the reaction was 
monitored by TLC and spectrophotometry. The solution was washed with water, brine 
and then dried over anhydrous Na2SO4. The solvent was removed and the product was 
purified by silica gel column chromatography (eluted with MeOH/CH2Cl2); Yield: 21 mg, 
80.8%; Mp 93-95 °C (lit.44 98-99 °C); 1H NMR (400 MHz; CDCl3): 9.27 (s, 1H), 5.79 (s, 
1H), 3.83 (s, 3H), 2.30 (s, 3H), 2.25 (s, 3H); 13C NMR (100 MHz; CDCl3): 163.43, 132.97, 
129.14, 117.53, 111.34, 50.92, 12.96, 12.82. HRMS (ESI): m/z Calcd for C8H12NO2 
(M+H+): 154.0868; found: 154.0870.  
Ethyl 3,5-dimethylpyrrole-2-carboxylate 73: This compound was prepared as 
described for pyrrole 72 (above) except that sodium ethoxide was used as the base in 
ethanol. Yield: 19.0 mg, 66.2%. Mp. 118-119 °C (lit.45 125 °C); 1H NMR (400 MHz, 
CDCl3): 8.68 (s, 1H), 5.79 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 2.30 (s, 3H), 2.24 (s, 3H), 
1.34 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz; CDCl3): 161.69, 132.28, 129.02, 117.78, 
111.35, 59.68, 14.57, 13.07, 12.77; HRMS (ESI): m/z Calcd for C9H14NO2 (M+H
+): 
168.1019; found: 168.1016  
BODIPY 74: Chloro-dipyrrin hydrochloride 65 (235 mg, 0.87 mmol) was dissolved in 
CHCl3 and DIEA (8 mmol, 9.0 equiv) was added before the mixture was stirred for 30 
min. Then BF3.OEt2 (14 mmol, 16 equiv) was added. The resulting mixture was stirred 
overnight at room temperature. The solution was washed with saturated aq NaHCO3, 
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brine and then dried over anhydrous Na2SO4. The solvent was evaporated and the 
residue was purified by chromatography on a silica gel column (eluted with 
CH2Cl2/hexane) to give the BODIPY 74 (230 mg, 94%); Mp. 235-237 °C; 
1H NMR (400 
MHz; CDCl3): 6.09 (s, 2H), 2.52 (s, 6H), 2.45 (s, 6H); 
13C NMR (100 MHz; CDCl3): 
155.26, 142.84, 136.54, 129.72, 121.36, 16.68, 14.54; HRMS (ESI): m/z Calcd for 
C13H15BClF2N2: 282.1016; found: 282.1010; UV/vis (CH2Cl2) λmax (ε) 503 nm (61700). 
BODIPY 75: This BODIPY was prepared using the same procedure, from 5-chloro-
dipyrrin hydrochloride 66 (yield: 325 mg, 96%). Mp. 173-175 °C; 1H NMR (400 MHz; 
CDCl3): 2.50 (s, 6H), 2.41 (m, 10H), 1.05 (t, J = 7.6 Hz, 6H); 
13C NMR (100 MHz; CDCl3): 
153.36, 138.10, 135.16, 133.20, 129.16, 17.11, 14.75, 13.82, 12.49; HRMS (ESI):  m/z 
Calcd for C17H22BClFN2 (M
+-F): 319.1549; found: 319.1550; UV/vis (CH2Cl2) λmax (ε) 527 
nm (31600). 
BODIPY 76: 1.0 M Ethyl magnesium bromide (1.0 ml, 1.0 mmol) in THF was added to 
chloro-BODIPY 65 (56.4 mg, 0.2 mmol) in THF (20 ml) at room temperature and stirred 
for 1 h; the reaction was quenched by addition of aqueous NH4Cl and then extracted 
with CHCl3. The organic extract was washed with water, brine and then dried over 
anhydrous Na2SO4. The BODIPY 76 was isolated as the sole product using silica gel 
column chromatography (eluted with CH2Cl2/hexane). Yield: 49 mg, 83%; Mp. 135-137 
°C; 1H NMR (400 MHz; CDCl3): 6.08 (s, 2H), 3.07 (q, J = 7.5 Hz, 2H), 2.46 (s, 6H), 2.44 
(s, 6H), 1.31 (t, J = 7.5 Hz, 3H), 0.79 (m, 4H), 0.30 (m, 6H); 13C NMR (100 MHz; CDCl3): 
150.08, 135.52, 131.77, 122.06, 21.34 16.97, 16.39, 15.93, 9.00, 1.02; 11B-NMR (128 
MHz; CDCl3): δ = 1.37; HRMS (ESI): m/z Calcd for C19H30BN2: 296.2533; found: 
296.2507; UV/vis (CH2Cl2) λmax (ε) 499 nm (15800). 
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BODIPYs 77 and 78: 8-Chloro-BODIPY 65 (56.4 mg, 0.2 mmol) was dissolved in MeOH 
(30 ml) in an ice bath and NaOMe (16.5 mg, 0.3 mmol) was added; the mixture was 
stirred for 45 min and the reaction was monitored by TLC and spectrophotometry. The 
solvent was removed in vacuo and the residue was taken up in CHCl3 and washed with 
water, brine and then dried over anhydrous Na2SO4. The product was purified by silica 
gel column chromatography (eluted with CH2Cl2/hexane). The major fraction was the 
desired BODIPY product 77. Yield: 37.1 mg, 67%; Mp. 160-161 °C; 1H NMR (400 HMz; 
CDCl3): 6.03 (s, 2H), 3.98 (s, 3H), 2.51 (s, 6H), 2.40 (s, 6H); 
13C NMR (100 MHz; CDCl3): 
159.95, 154.76, 138.33, 128.30, 119.56, 64.32, 49.12, 14.47, 13.76; HRMS (ESI): m/z 
Calcd for C14H18BF2N2O: 278.1511; found: 278.1504; UV/vis (CH2Cl2) λmax (ε) 487 nm 
(89100). The monomethoxy-boron substituted BODIPY 78 was also separated as a 
minor fraction from the column (Yield: 12.0 mg, 21%); 1H NMR (400 MHz; CDCl3): 6.02 
(s, 2H), 3.97 (s, 3H), 2.89 (s, 3H), 2.51 (s, 6H), 2.37 (s, 6H); 13C NMR (100 MHz; CDCl3): 
159.95, 154.76, 138.33, 128.30, 119.56, 64.24, 49.12, 14.47, 13.76; 11B NMR (128 MHz; 
CDCl3): δ = 1.58; HRMS (ESI): m/z Calcd for C14H17BFN2O (M
+-OMe): 259.1418; found: 
259.1392. A small amount of the dimethoxyboron-BODIPY 79 was also isolated from the 
column, but in insufficient quantity to characterizeit  from this reaction.  
BODIPY 79: 8-Chloro-BODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in MeOH (30 ml) 
and NaOMe (54.0 mg, 0.75 mmol) was added before the solution was refluxed under 
argon for 12 h. The solvent was removed and the residue was taken up in CHCl3 and 
washed with water, brine and then dried over anhydrous Na2SO4. The product was 
separated by silica gel column chromatography (eluted with MeOH/CH2Cl2). Yield: 38 
mg, 65%; Mp. 93-95 °C; 1H NMR (400 HMz; CDCl3): 6.01 (s, 2H), 3.97 (s, 3H), 2.86 (s, 
6H), 2.48 (s, 6H), 2.41 (s, 6H); 13C NMR (100 MHz; CDCl3): 159.92, 154.87, 137.38, 
129.02, 119.33, 64.13, 49.04, 14.41, 13.81; 11B NMR (128 MHz; CDCl3): 2.39; HRMS 
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(ESI): m/z Calcd for C16H23BN2NaO3 (M
++Na): 324.173; found: 324.1719; UV/vis 
(CH2Cl2) λmax (ε) 487 nm (46800).  The monomethoxy-boron substituted BODIPY (see 
earlier) was also separated as a minor fraction from the column (Yield: 9.3 mg, 16%). 
BODIPY 80: 8-ChloroBODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in THF (30 ml) in 
an ice bath and sodium phenoxide (34.8 mg, 0.3 mmol) was added; the mixture was 
stirred for 2 h at room temperature and monitored by TLC and spectrophotometry. The 
solvent was removed in vacuo and the residue was taken up in CHCl3 and washed with 
water, brine and then dried over anhydrous Na2SO4. The product was purified by column 
chromatography (eluted with CH2Cl2/hexane). Yield: 55 mg, (81%). Mp. 188-190 °C 
1H 
NMR (400 HMz; CDCl3): 
 7.33-7.29 (m, 2H), 7.08-7.06 (m, 1H), 7.01-6.99 (m, 2H), 5.99 
(s, 2H), 2.55 (s, 6H), 2.04 (s, 6H); 13C NMR (CDCl3): 157.52, 155.78, 151.59, 140.42, 
130.08, 127.62, 122.84, 119.99, 114.70, 14.60, 14.14; HRMS (ESI): Calcd m/z for 
C19H20BF2N2O:
 340.1668, found: 340.1662. λmax (CH2Cl2) 491 nm (ε 51286). 
BODIPY 81: A solution of 8-chloro-BODIPY 74 (56.4 mg, 0.2 mmol), 2-
mercaptobenzothiozole (40.0 mg, 0.24 mmol) and K2CO3 (41.5 mg, 0.3 mmol) in THF 
(30 ml) was stirred at room temperature for 12 h or until the starting material was 
completely consumed. The solvent was removed in vacuo and the residue was taken up 
in CHCl3 and washed with water, brine and then dried over anhydrous Na2SO4. The 
product was purified by silica gel column chromatography (eluted with CH2Cl2/hexane). 
Yield: 46.1 mg, 56%; Mp. 208-210 °C. 1H NMR (400 HMz; CDCl3): 7.90 (dt, J = 8.4, 0.9 
Hz, 1H), 7.68 (m, 1H), 7.44 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.31 (ddd, J = 8.3, 7.3, 1.2 Hz, 
1H), 6.10 (s, 2H), 2.58 (s, 6H), 2.46 (s, 6H); 13C NMR (100 MHz; CDCl3): 166.56, 158.25, 
153.59, 144.75, 135.37, 134.42, 128.70, 126.46, 124.76, 123.07, 122.00, 121.08, 17.26, 
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14.97; HRMS (ESI): m/z Calcd for C20H18BFN3S(MW -F): 394.1019;  found: 394.1010; 
UV/vis (CH2Cl2) λmax (ε) 539 nm (49000). 
BODIPY 82: A solution of chloroBODIPY 4a (56.4 mg, 0.2 mmol), p-carborane thiol 
(45.6 mg, 0.24 mmol) and K2CO3 (41.5mg, 3.0 mmol) in THF (30 ml) was stirred at  
room temperature for 12 h or until the starting material was consumed, The solvent was 
removed in vacuo and the residue was taken up in CHCl3 and washed with water, brine 
and then dried over anhydrous Na2SO4. The product was purified by silica gel column 
chromatography (eluted with CH2Cl2/hexane) and was obtained as a red solid. Yield: 80 
mg, (92%). Mp 150-152 °C. 1H NMR (400 MHz; CDCl3): 6.06 (s, 2H), 2.95 (s, 2H), 2.51 
(s, 3H), 2.49 (s, 3H), 2.17-1.68 (m, 11H); 13C NMR (CDCl3): 156.14, 143.51, 136.84, 
134.23, 122.50, 59.04, 46.04, 31.91, 16.91, 14.68. HRMS (ESI): Calcd m/z for 
C16H26B11F2N2S: 437.2808, found: 437.3033. . λmax (ε)(CH2Cl2) 529 nm (17000). 
BODIPY 83: yield :94%1H NMR (400 MHz; CDCl3): 6.15 (s, 2H), 2.57 (s, 6H),2.49 (s,6H), 
2.20-1.70 (m, 11H); 13C NMR (CDCl3): 158.91, 143.66, 129.61, 123.83, 135.66, 60.07, 
17.15, 15.10; HRMS (ESI): m/z Calcd for C19H20BF2N2: 423.2882; found: 423.2871. 
BODIPY 84: yield 92% 1H NMR (400 MHz; CDCl3): δ 6.05 (s, 2H), 5.25 (s, 1H), 4.19 (q, 
2H), 2.51 (s, 3H), 2.47 (t, 1H), 2.42 (s, 3H). 
BODIPY 85: Method A: In a Suzuki coupling reaction, 8-chloro-BODIPY 74 (56.4 mg, 
0.2 mmol), Pd(PPh3)4 (10.0 mg, 5% mmol ), phenylboronic acid (24.4 mg, 0.2 mmol) and 
K2CO3 (41.5mg, 0.3 mmol) were added to THF or DME (30 ml). The reaction flask was 
evacuated and filled with argon several times. Then the solution was refluxed overnight 
under argon. The solvent was removed and the residue was taken up in CHCl3 and 
washed with water, brine, and dried over anhydrous Na2SO4. The solvent was removed 
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and the product was purified by chromatography on a silica gel column (eluting with 
CH2Cl2/hexane), The product is the major fraction from the column. (yield: 30.3 mg, 
46%).  
Method B: In a Stille coupling reaction, 8-chloro-BODIPY 74 (56.4 mg, 0.2 mmol), 
Pd(PPh3)4 (10.0 mg, 5% mmol) and tributylphenyl tin (80.0 mg, 0.24 mmol) were added 
to a round-bottomed flask. The flask was flushed with argon and then anhydrous toluene 
(20 ml) was added. The mixture was refluxed for 5 h after which the reaction was 
completed; the toluene was then removed and the residue was taken up in CH2Cl2 and 
washed with water, brine and then dried over anhydrous Na2SO4. The crude product 
was purified by silica gel column chromatography (eluting with CH2Cl2/hexane). Yield: 
60.1 mg, 93%; Mp. 165-166 °C. 1H NMR (400 MHz; CDCl3): 7.49-7.47 (m, 3H), 7.29-
7.27(m, 2H), 5.98 (s, 2H), 2.56 (s, 6H), 1.37 (s, 6H); 13C NMR (100 MHz; CDCl3): 154.90, 
142.19, 140.52, 131.14, 123.79, 121.11, 17.24, 14.55; HRMS (ESI): m/z Calcd for 
C19H20BF2N2: 324.1718; found: 324.1717. UV/vis (CH2Cl2) λmax (ε) 501 nm (57500). 
BODIPY 86: Method A: In a Sonogashira coupling reaction, 8-chloro-BODIPY 74 (56.4 
mg, 0.2 mmol), Pd(PPh3)2Cl2 (7.0 mg, 5% mmol ), ethynyltrimethylsilane (21.6 mg, 0.22 
mmol), TEA (10.0 ml) and THF (10.0 ml) were mixed together and the reaction flask was 
flushed  with argon several times. Then the solution was refluxed overnight under argon. 
Before the solvent was removed, the residue was taken up in CHCl3 and washed with 
water, aqueous 1 M HCl, water and brine, and then the organic layer was dried over 
anhydrous Na2SO4. The solvent was removed and the product was purified by silica gel 
column chromatography (eluting with CH2Cl2/hexane), and the product was isolated as a 
deep red solid (22.6 mg, 35%).  
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Method B: In a Stille coupling reaction,8-chloro-BODIPY 74 (25.0, 0.088 mmol), 
Pd(PPh3)4 (4.6 mg, 5% mmol) and TMS-ethynyltin (41.0 mg, 0.11 mmol) were added to 
a round-bottomed flask. The flask was flushed with argon and then anhydrous toluene 
(20 ml) was added and the mixture was refluxed for 5 h, after which the reaction was 
completed; the toluene was then removed and the residue was taken up in CH2Cl2 and 
washed with water, brine and then dried over anhydrous Na2SO4. The crude product 
was purified by silica gel column chromatography (eluting with CH2Cl2/hexane).Yield: 
(21.7 mg, 71%); Mp. dec. ~250 °C; 1H NMR (400 MHz; CDCl3): 6.06 (s, 2H), 2.52 (s, 6H), 
2.46 (s, 6H), 0.29 (s, 9H); 13C NMR (100 MHz; CDCl3): 154.40, 142.23, 133.05, 120.78, 
120.05, 115.01, 110.44, 15.54, 14.61, 0.68; HRMS (ESI): m/z Calcd for C18H23BFN2Si: 
325.1708 (M+-F); found: 325.1699; UV/vis (CH2Cl2) λmax (ε) 545 nm (42500). 
BODIPY 87: 8-Chloro-BODIPY 74 (25 mg, 0.088 mmol) and Pd(PPh3)4 (5.0 mg, 5% 
mmol) was dissolved in anhydrous THF (20 ml). Then the mixture was cooled to 0 oC 
and 1 M phenylethynyl magnesium bromide (0.264 mmol, 0.26 ml) was added and the 
reaction was refluxed for 5 min and the entire solution turned red. The mixture was 
cooled to room temperature and quenched with aqueous NH4Cl solution and then 
extracted with CH2Cl2 or CHCl3 (three times) and the combined organic layers were 
washed with water, brine and dried over anhydrous Na2SO4, The solvent was removed 
and the product was purified by silica gel column chromatography (eluting with 
CH2Cl2/hexane) to give the product. 
1H NMR (400 MHz; CDCl3): 7.39-7.19 (m, 15H), 
6.18 (s, 2H), 2.88 (s, 6H), 2.62(s, 6H).  
General procedure for Stille coupling reactions  
8-Chloro-BODIPY 74 (56.4 mg, 0.2 mmol), Pd(PPh3)4 (10.0 mg, 5% mmol) and 
organotin reagent (2.4-3.0 mmol) were added to a round bottom flask. The flask was 
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flushed with argon and then anhydrous toluene was added, followed by injection of the 
Stille reagents. The mixture was refluxed for 5 h after which the reaction was completed; 
the toluene was then removed and the residue was taken up in CH2Cl2 and washed with 
water, brine and then dried over anhydrous Na2SO4. The crude product was purified by 
column chromatography on silica gel (eluting with CH2Cl2/hexane). 
BODIPY 88: Yield: 50.7 mg, 97%; Mp 245-247 °C; 1H NMR (400 MHz; CDCl3): δ =  6.05 
(s, 2H), 2.56 (s, 6H), 2.51 (s, 6H), 2.40 (s, 3H); 13C NMR (100 MHz; CDCl3): δ = 153.59, 
141.43, 141.01, 132.06, 121.25, 17.31, 16.37, 14.43; HRMS (ESI): m/z Calcd for 
C14H18BF2N2: 262.1562; found: 262.1556; UV/vis (CH2Cl2) λmax (ε) 487 nm (66000). 
BODIPY 89: Yield: 50.7 mg, 97%; Mp 245-247 °C; 1H NMR (400 MHz; CDCl3): δ =  6.05 
(s, 2H), 2.56 (s, 6H), 2.51 (s, 6H), 2.40 (s, 3H); 13C NMR (100 MHz; CDCl3): δ = 153.59, 
141.43, 141.01, 132.06, 121.25, 17.31, 16.37, 14.43; HRMS (ESI): m/z Calcd for 
C14H18BF2N2: 262.1562; found: 262.1556; UV/vis (CH2Cl2) λmax (ε) 487 nm (66000). 
BODIPY 90: Yield: 59.1 mg, 93%; Mp. 105-107 °C; 1H NMR (400 MHz; CDCl3): δ = 6.03 
(s, 2H), 4.46 (d, J = 2.9 Hz, 1H), 4.37 (d, J = 2.8 Hz, 1H), 3.89 (q, J = 7.0 Hz, 2H), 2.52 
(s, 6H), 2.23 (s, 6H), 1.39 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz; CDCl3): δ = 155.97, 
153.56, 142.50, 134.98, 131.29, 88.11, 63.67, 14.65, 14.34; HRMS (ESI): m/z Calcd for 
C17H22BF2N2O: 318.1824; found: 318.1817; UV/vis (CH2Cl2) λmax (ε) 513 nm (40700). 
BODIPY 91: Yield: 16.8 mg, 31%; Mp. > 260 °C; 1H NMR (400 MHz; CDCl3): δ = 6.07 (s, 
2H), 3.92 (s, 1H), 2.53 (s, 6H), 2.45 (s, 6H); 13C NMR (100 MHz; CDCl3): δ = 155.07, 
142.61, 133.28, 121.06, 118.92, 94.42, 79.19, 15.47, 14.63; HRMS (ESI): m/z Calcd for 
C15H16BF2N2: 272.1405; found: 272.1380; UV/vis (CH2Cl2) λmax (ε) 544 nm (37200). 
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BODIPY 92: Yield: 62.1 mg, 95%; Mp 179-181 °C; 1H NMR (400 MHz; CDCl3): δ = 6.77 
(dd, J =  2.7, 1.7 Hz, 1H), 6.21 (dd, J = 3.6, 2.7 Hz, 1H), 6.07 (dd, J = 3.6, 1.7 Hz,1H), 
6.01 (s, 2H), 3.40 (s, 3H), 2.55 (s, 6H), 1.50 (s, 6H); 13C NMR (100 MHz; CDCl3): δ 
156.14, 143.34, 133.13, 131.73, 124.64, 122.47, 121.01, 109.34, 108.84, 33.84, 14.67, 
12.68; HRMS (ESI):  m/z calcd for C18H21BF2N2: 327.1827; UV/vis (CH2Cl2) λmax (ε) 513 
nm (53700). 
BODIPY 93: Yield: 69.8 mg, 99%; Mp 197-199 °C; 1H NMR (400 MHz; CDCl3): δ = 7.50 
(dd, J = 5.0, 1.3 Hz, 1H), 7.13 (dd, J =5.1, 3.5 Hz, 1H), 6.99 (dd, J = 3.5, 1.3 Hz, 1H), 
6.00 (s, 2H), 2.55 (s, 6H), 1.58 (s, 6H); 13C NMR (100 MHz; CDCl3): δ = 156.07, 143.50, 
134.64, 133.99, 132.41, 127.81, 127.61, 127.41, 121.50, 14.64, 13.55; HRMS (ESI): m/z 
Calcd for C17H17BF2N2NaS (M
++Na): 352.1102; found: 352.1094; UV/vis (CH2Cl2) λmax (ε) 
514 nm (74100). 
 
 
 
 
 
 
 
 
 
 
 
 
  
193 
 
4.5 Supporting Information 
 
 
1H-NMR spectra of pyrroles 44 and 54 in CDCl3 at 400 MHz 
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1H-NMR spectra of pyrroles 41 and 43 in CDCl3 at 400 MHz 
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1H- and 13C-NMR spectra of dipyrrothione 55 in CDCl3  
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1H- and 13C-NMR spectra of dipyrroketone 59 in CDCl3  
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1H- and 13C-NMR spectra of dipyrrothione 58 in CDCl3  
 
  
198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H- and 13C-NMR spectra of dipyrroketone 60 in CDCl3  
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1H- and 13C-NMR spectra of meso-chloro-dipyrrin 65 in CDCl3  
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1H- and 13C NMR spectra of dipyrrothione 66 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 74 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 75 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 63 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 64 in CDCl3  
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1H- and 13C-NMR spectra of unexpected pyrrole 72 in CDCl3  
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1H- and 13C-NMR spectra of unexpected pyrrole 73 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 69 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 76 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 77 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 78 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 80 in CDCl3  
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1H- and 13C-NMR spectra of BODIPY 79 in CDCl3  
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11B-NMR spectra of BODIPYs 78 and 79 in CDCl3  
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1H- and 13C-NMR of BODIPY 81 in CDCl3  
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1H- and 13C-NMR of BODIPY 82 in CDCl3  
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1H- and 13C-NMR of BODIPY 83 in CDCl3  
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1H- and 13C-NMR of BODIPY 86 in CDCl3  
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1H- and 13C-NMR of BODIPY 85 in CDCl3  
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1H- and 13C-NMR of BODIPY 88 in CDCl3  
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1H- and 13C-NMR of BODIPY 89 in CDCl3  
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1H- and 13C-NMR of BODIPY 90 in CDCl3  
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1H- and 13C-NMR of BODIPY 91 in CDCl3  
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1H- and 13C-NMR of BODIPY 92 in CDCl3  
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1H- and 13C-NMR of BODIPY 93 in CDCl3  
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1H- and 13C-NMR of meso-unsubstituted BODIPY in CDCl3  
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 1H-NMR spectra of dipyrrothione 56 and BODIPY 84 in CDCl3 at 400 MHz 
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1H-NMR spectrum of BODIPY 87 in CDCl3 at 400 MHz 
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Chapter 5: Syntheses of Symmetrical and Asymmetrical BODIPYs Through 
Functionalization of Halogenated BODIPYs 
5.1 Introduction 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) is a class of very versatile 
fluorophore recognized in the last several decades and that are used widely as labeling 
reagents, sensors, and photoelectronic devices.1-3 Compared with other fluorophores, 
BODIPY has a lot of advantages, such as strong absorption and fluorescent bands in the 
visible region, relatively high thermal and photochemical stability, and easy 
functionalization, thus enabling variations in properties such as absorption wavelength 
and amphiphilicity.4 Due to their relatively low molecular weight, BODIPY conjugates 
with biomolecules tend to have good permeability to living cells. Another advantage of 
BODIPY dyes is their low tendency for self–association, which means they have 
negligible aggregation because of the lack of intermolecular interactions.  
Various methods have been developed to functionalize BODIPYs to change their long 
wavelength absorption or hydrophobicity and hydrophilicity. These methods include 
coupling reactions, replacement reactions and Knoevenagel reactions.5-9 Coupling 
reactions and Knovenagel reactions are usually used to increase the absorption 
wavelength by introducing extended conjugation into the BODIPYs, while replacement 
reactions are used to modify the amphiphilicity by introducing heteroatom-based groups. 
Halogenated BODIPYs are very versatile substrates for functionalization purposes and 
applicable halogens include iodide, bromide and chloride which have already been 
introduced into all the positions of BODIPYs11-17 (Figure 5.1). Coupling and replacement 
reactions were explored on these BODIPYs since different positions of the BODIPY core 
have different reactivity toward coupling reagents and nucleophiles. The coupling 
reactions explored on BODIPYs5 include palladium-catalyzed Suzuki, Stille, Sonogashira 
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and Heck coupling reactions, all of which worked at the 3,5-positions of the BODIPY; 
Heck coupling reactions have not yet worked on the 8-position. For the 2,6-positions, 
Suzuki and Stille coupling reactions have been reported.16 These coupling reactions 
significantly facilitated the functionalization of BODIPYs and a number of compounds 
were synthesized using these methods.  
 
Figure 5.1: The halogenated BODIPYs. 
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5.2. Syntheses of Halogenated BODIPYs 
In Chapter 4, we initially used pyrroketones 10 and 11 as starting material to synthesize 
BODIPYs; however, the reactions such as chlorination using various chlorinating 
reagents did not work on these two pyrroketones due to the presence of the two 
electron-withdrawing ester groups on the α-positions. To avoid this problem, we 
switched from these two pyrroketone to alkylated pyrroketones possessing no electron 
withdrawing groups and as a result the halogenation reactions worked very well. When 
we came back to reinvestigate at the reactions of these two pyrroketones 10 and 11, we 
devised another strategy to make them useful by elimination of the two ester groups and 
subsequent introduction of some other functional groups such as halogens. It was 
surmised that if the chlorination reaction works on pyrroketone 12, we can introduce 
halogens to the 3, 5, and 8-positions of BODIPYs at the same time, or maybe even 
sequentially(Scheme 5.1).  
Based on this idea, the pyrroketone 10 was subjected to hydrogenation using Pd/C as 
catalyst in THF, and the dipyrroketone dicarboxylic acid was obtained in 90% yield. Then 
an electrophilic iodination reaction15 under basic conditions using iodine gave 
diiodopyrroketone 12 in 75% yield. Diiodopyrroketone 12 was treated with phosgene18 in 
chloroform and the reaction was monitored by UV/visible absorption spectroscopy. A 
peak around 480 nm indicated the fully conjugated dipyrromethene was obtained. 
Complexation with BF3.OEt2 using DIEA as base gave a reddish solution, which had an  
absorption maximum at 538 nm. This absorption wavelength is a little lower than 
expected for 3,5-diiodo-BODIPYs.15 Chromatographic separation showed the product to 
a mixture of di-and tri-chloro-BODIPYs 15 and 16, and this conclusion was confirmed by 
an X-ray crystal structure (Scheme 5.2).  
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Scheme 5.1: The strategy to access halogenated BODIPYs. 
10 R = PMe, 11 R = Me 
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Scheme 5.2: Synthesis of halogenated BODIPYs 15 and 16, and X-ray crystal structure 
of 15. 
5.3. Global and Selective Stille Coupling Reactions 
According to the resonance structure of BODIPY, the meso-position is more electrophilic 
than the other positions such as the 3,5 or 2,6-postions; a computational study of the 
BODIPY by Mulliken charge distribution, and reactivity studies also reached same 
conclusion.19 Therefore, the 8-chloro-position is more reactive than the 3,5-positions of 
BODIPY 15 and selective coupling reactions on 8-position over 3,5-position are possible 
in this case. Since we found that the Stille coupling reaction is very efficient on meso-
chloro-BODIPYs (Chapter 4), we hoped that selective and global coupling reactions 
could both work if stoichiometric amounts of excess coupling reagents are used.  
The global coupling reaction was tried first with excess organotin reagents including 2-
(tributylstannyl)thiophene, tributylphenylstanne and trimethyl[(tributylstannyl)ethynyl]-
silane (Scheme 5.3). A typical reaction procedure followed the Stille coupling reaction 
conditions we used in Chapter 4. In all cases, when the solutions were heated to 110 oC, 
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the reaction solution started to change color and became deeper in color with time. The 
reactions were monitored with UV/visible spectrophotometry and TLC; when the starting 
material was all used according TLC and the UV/visible spectrum showed a strong peak 
around 600 nm, the reactions were stopped. The global coupling reactions were usually 
left stirring overnight. The tri-thiophene-BODIPY prepared in this way with 2-
(tributystannyl)thiophene has an absorption at 592 nm and tri-TMS-ethynyl-BODIPY has 
a very red shifted absorption at 648 nm while the corresponding tri-phenyl-BODIPY has 
a slight red shift at 546 nm. The 2-(tributystannyl)thiophene is the most reactive among 
the three reagents investigated, and gave the highest yield (83%), followed by TMS-
ethynyltin, which gave a 79% yield. the phenyltin r,eagent was the least reactive one, 
giving a 60% yield. 1H NMR spectra of these compounds showed different chemical 
shifts for the same group on the meso-position and 3,5-positions. For example, tri-TMS-
ethynyl-BODIPY has different chemical shifts for the TMS groups at 0.30 and 0.28 ppm, 
although the tri-thiophene and triphenyl BODIPYs showed multiple aromatic peaks 
beween 7.56-7.09 ppm and 7.53-7.38 ppm, respectively. Structures of all these new 
BODIPYs were confirmed by mass spectrumometry with m/z at 639.1429 (MW+H), and 
681 2970 (MW+H) for BODIPYs 17 and 19, respectively. 1-Methyl-2-
(tributylstannyl)pyrrole was also tried on the tri-chloro-BODIPY 15; the product showed a 
peak in its UV/visible spectrum at 582 nm, but it was not possible to successfully 
separate the tin reagent from the product.  
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Scheme 5.3: The global Stille coupling reactions of tri-chloro-BODIPY 15, and the X-ray 
structure of BODIPY 17 and 19. 
 
Regioselective coupling reactions were tried with the three organotin reagents above, 
using a reagent ratio of 1:1 (Scheme 5.4). The solutions were refluxed for five hours 
instead of overnight and the slight color change, compared with the tri-chloro-BODIPY, 
indicated that only the meso-chloro group was selectively coupled. For 2-
(tributylstannyl)thiophene, the BODIPY 20 has absorption at 545 nm, a slightly red 
shifted compared with starting material at 538 nm. The meso-phenyl-BODIPY 21 is 
slightly hypsochromically shifted with an absorption at 533 nm, there is a 5 nm difference 
from the starting tri-chloro-BODIPY. The TMS-ethynyl-BODIPY 22 has a significant 
bathochromic shift at 584 nm, which is due to the conjugation of the triple bond of TMS-
ethynyl group with the BODIPY core. 1H NMR spectroscopy showed resonances at 7.11-
7.58 ppm for the meso-thiophene group, 7.38-7.50 ppm for meso-phenyl group, and 
0.30 ppm for the TMS-ethynyl. The structures of the three new BODIPYs were also 
confirmed by mass spectrometry, which showed peaks at m/z 523.0836 (MW+H) for the 
meso-thiophene-BODIPY 20 and 517.1238 (MW+H) for the meso-phenyl-BODIPY 21  
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Scheme 5.4: The selective Stille coupling reactions on meso-position of BODIPY 15, and 
X-ray scrystal strucyures of BODIPYs 20 and 21. 
 
For the three new meso-substituted BODIPYs, different functional groups were 
introduced at the 3,5-positions using 2.4 equivalents of organotin reagents (Scheme 5.5). 
For meso-thiophene-BODIPY 20, pheny and TMS-ethynyl groups were introduced to 
yield the  symmetrical BODIPYs 23 and 24, which have UV/visible absorption maxima at 
562 and 608 nm. 1H NMR spectroscopy showed that these two compounds have 
chemical shift at 7.10-7.59 ppm for BODIPY 23, which overlapped with meso-thiophene 
group, and 0.33 ppm for TMS group of BODIPY 24. The identities of these two product 
were also confirmed with their mass spectra, with m/z at 607.2238 (MW-F) and 
667.2473 (MW+H), respectively.  
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Scheme 5.5: Cross-coupling reaction on 3,5-positions of BODIPYs 23 and 24. 
 
Similarly, using the meso-TMS-ethynyl-BODIPY 22, phenyl and thiophene groups were 
introduced at the 3,5-positions to given the BODIPYs 25 and 26. These two BODIPYs 
have UV/visible absorption maxima at 601 and 631 nm, respectively. 1H NMR 
spectroscopy showed the aromatic areas at 7.36-7.45 ppm and 7.11-7.54 ppm for 
BODIPYs 25 and 26, and these two products were structurally confirmed by mass 
spectrometry, with m/z at 651.1888 (MW+H) and 663.2634 (MW+Na). For the meso-
phenyl-3,5-dichloro-BODIPY 21, the thiophene group and TMS-ethynyl group have not 
been efficiently introduced due to the low yields observed in the reaction. We are 
optimizing the conditions to achieve better yield for the selective coupling reaction of 
meso-chloro-BODIPY 21.  
Syntheses of unsymmetric BODIPYs through Stille coupling reactions were also 
attempted (Scheme 5.6). When two equivalents of organotin reagents were used, the 
meso-position and one of α-positions (3 or 5-positions) could react with the organotin 
reagent but leave the other α-position untouched and available for introduction of a third 
(different) group using a different organotin reagent. However, the generated di-
substituted product could continue to react with organotin reagent to give a tri-
substituted product as a side product, which should be a minor one due to the electronic 
and steric effect compared with meso-substituted BODIPY intermediate. Therefore, we 
tried TMS-ethynyltin first, and the di-substituted product 27 was the major product, a 
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small fraction was separated and was proven to be tri-substituted product. The BODIPY 
27 has an absorption at 615 nm in its UV-visible spectrum. 1H NMR spectroscopy 
showed two different chemical shifts for the two TMS groups at 0.27 and 0.30 ppm. The 
identity of the product was also confirmed with its mass spectrum, with m/z at 619.2185 
(MW+H).  
 
 
Scheme 5.6: Synthesis of asymmetric BODIPYs through Stille coupling reactions of 
BODIPY 15.  
 
5.4. Conclusion  
Tri-chloro-BODIPY 15 was synthesized by phosgenation of di-iodopyrroketone 12, and 
with this cmpound global and regioselective Stille coupling reactions were explored. 
Coupling reactions can take place selectively on meso-position (over the 3,5-positions) 
of BODIPYs. Therefore, the same group can be introduced to the 8, 3, and 5-positions of 
a BODIPY once, or one group can be selectively introduced to the meso-position, 
followed by the different groups on the 3 and 5-postions. We also explored the synthesis 
of asymmetric BODIPYs through Stille coupling reactions by introducing the same group 
to the meso and one of α-positions simultaneously, followed by introduction of a different 
group on the one remaining α-position. Some new products were synthesized and 
characterized by 1H NMR, 13C NMR and mass spectrometry. The results above indicate 
that it should be possible to introduce one Stille substituent to the meso-position, 
followed by another to an α–position, and yet a third to the second (remaining) α –
position (see below). 
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5.5 Near Future and Future Work 
1. Syntheses of asymmetric BODIPYs by Stille coupling reactions.  
We already tried the synthesis of asymmetric BODIPYs by changing the ratio between 
tri-chloro-BODIPYs and organotin reagents (1:2). Another way to synthesize asymmetric 
BODIPY is to introduce three different groups to 8, 3, and 5-positions one by one 
accordingly. For example, the meso-position could be substituted by introduction of a 
pheny group first, followed by introducing a thiophene group to the 3-position, and then 
the 5-position could be substituted with a TMS-ethynyl group. All these three steps 
should use one equivalent of organotin reagents. Another route to synthesize  
Method I 
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asymmetric BODIPY is by using dichloro-BODIPY 16; two groups can be introduced to 
the BODIPY, followed by halogenation (such as bromination) on the 5-position; then 
another Stille coupling reaction can be performed on the molecule. 
Method II 
 
 
 
2.  Replacement reactions 
Selective or global replacement reactions by using various nucleophiles could be 
explored on tri-chloro-BODIPYs to see if there is selectivity between the meso-position 
and the 3 and 5-positions of BODIPYs.  
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3. Introducing carboranes to BODIPYs.  
We already synthesized several BODIPYs which contained TMS-ethynyl group at 
different postions; the TMS-protective groups can be cleaved and then reacted with 
decarborane to introduce carboranes to BODIPYs. In this way, one, two or three 
carboranes could be introduced onto the BODIPY core, and their potential as BNCT 
reagents can be investigated. The In addition, an ester group can be functionalized to 
introduce biomolecules such as lysine, etc, polyamines and PEFs to improve their 
biological properities.  
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5.6 Experimental Part 
Dimethyl3,3'-(2,2'-carbonylbis(5-iodo-4-methyl-1H-
pyrrole3,2diyl))dipropanoateCompound 12: Dipyrromethane 17 (6.14 g, 0.01 mol) 
was dissolved in 300 ml THF, and then 5% Pd/C (350 mg) catalyst was added. The 
suspension was stirred under a H2 atmosphere overnight. After TLC showed that 
reaction was complete, it was stopped and the reaction solution was passed through a 
Celite cake to remove the catalyst. The sticky solid on the top of Celite cake was 
redissolved and neutralized in water with aqueous ammonia and the solution was 
passed through the Celite cake again. The filtrate was acidified with acetic acid and a 
precipitate appreared from the aqueous solution. The solid was collected by filtration. 
The THF part was evaporated and combined with the solid to give total (4.0 g, 92%) of 
debenzylated product. Then the dicarboxylic acid was suspended in a solution of H2O 
(250 ml)/MeOH (100 ml) and NaHCO3 (4.48 g, 51.2 mmol) was added to the solution, 
which was sonicated to form a slurry, and then a clear solution. Then a solution of I2 
(3.84 g, 14.72 mmol) in methanol (60 ml) was added to the mixture dropwise at room 
temperature with vigorous stirring and some brown solid was formed during the addition. 
When the addition of iodine was finished, the stirring was continued for another 2 h and 
the precipitate was filtered and washed with water, saturated aqueous NaHCO3 and 
water, followed by hexane to remove excess I2 to obtain a yellowish solid. The product 
was left to air dry or dissolved in CH2Cl2 and dried over anhydrous Na2SO4 before 
removal of the solvent to give di-iodopyrroketone 10 (4.2 g, 75%). 1H NMR (400 MHz; 
CDCl3): 9.47 (s, 2H), 3.65 (s, 6H), 2.70 (t, 4H), 2.61 (t, 4H), 2.04 (s, 6H); 
13C NMR (100 
MHz; CDCl3): 173.81, 173.48, 132.72, 128.49, 126.44, 51.78, 33.91, 20.89, 12.19; 
HRMS (ESI): m/z Calcd for C19H23I2N2O5 (MW+H
+): 612.9691; found: 612.9697 
BODIPYs 15 and 16:  
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Diiodopyrroketone 12 (1.0 g, 1.63 mmol) was dissolved in CHCl3 (150 ml) and excess 
phosgene in toluene solution was added to the reaction solution, which turned deep red 
with time; the reaction was monitored by UV/visible spectrophotometry and the reaction 
was stopped when a sharp peak appeared at about 480 nm. Then nitrogen gas was 
passed through solution to purge it of excess phosgene into an aqueous NaHCO3 
solution trap. Solvent was removed in vacuo to give a reddish solid, which was dissolved 
in 150 ml of CHCl3, followed by addition of DIEA (2 ml, 7.0 equiv). The solution was 
stirred for 30 min, then BF3.OEt2 (2.1 ml, 10 equiv) was added and the solution turned 
bright red with a yellow fluorescent under UV long wavelength light. The reaction was 
monitored by UV/visible spectroscopy which showed a sharp peak at 538 nm. The 
mixture was left stirring for 24 h before being washed with water, saturated NaHCO3 and 
brine, and then dried over anhydrous Na2SO4 to give a red solid. The product was 
purified by silica gel column chromatography, eluting with ethyl acetate/hexane (1:4) to 
give the product 15 as the major fraction and 16 as a minor product. BODIPY 15: 1H 
NMR (400 MHz; CDCl3): 3.72 (s, 6H), 3.20 (t, 4H), 2.57 (t, 4H), 2.05 (s, 6H); 
13C NMR 
(100 MHz; CDCl3): 172.50, 143.99, 142.31, 134.94, 128.45, 127.33 51.97, 33.80, 22.78, 
8.87; HRMS (ESI): m/z Calcd for C19H19 BCl3F2N2O4 (MW-H
+): 493.0581; found: 
493.0574; BODIPY 16: 1H NMR (400 MHz; CDCl3): 7.57 (s, 1H), 3.71 (s, 3H), 3.71 (s, 
3H), 3.20 (m, 4H), 2.58 (m, 4H), 2.07 (s, 3H), 2.04 (s, 3H); 13C NMR (100 MHz; CDCl3): 
172.50, 172.54, 143.54, 142.59, 142.39, 136.82, 130.12, 129.12, 128.67, 127.33, 126.83, 
51.95, 51.89, 33.94, 33.87, 22.78, 22.19, 9.86, 8.87; HRMS (ESI): m/z Calcd for 
C19H121BCl3FN2O4 (MW-F): 441.0955; found: 441.0935.  
 
General Procedure for Stille Coupling Reactions: 
Global coupling reactions: BODIPY 15 (15 mg, 0.03 mmol) and Pd(PPh3)4 (3.0-5.0 mg, 
8%) and were added to a round bottomed flask. The flask was flushed with argon and 
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then anhydrous toluene (15 ml) was injected, followed by injection of the organotin 
reagent (0.045 mmol). The solution was refluxed for 12 h until the starting material 
disappeared from TLC and the UV/visible spectrum gave a sharp peak around 600 nm. 
Then toluene was removed and the residue was taken up in CH2Cl2 and washed with 
water, brine and then dried over anhydrous Na2SO4. The crude product was purified by 
chromatography to give the fully (tri-) substituted products.  
BODIPY 17: 1H NMR (400 MHz; CDCl3): 7.56-7.49 (m, 5H), 7.20-7.09 (m, 4H), 3.63 (s, 
6H), 2.33-2.22 (m, 6H), 2.00 (s, 6H), 1.94-1.86 (m, 2H); 13C NMR (100 MHz; CDCl3): 
172.53, 149.74, 142.43, 134.43, 133.20, 132.97, 131.69, 129.72, 128.78, 128.02, 127.35, 
127.23, 51.63, 35.08, 21.41, 10.62. HRMS (ESI): m/z Calcd for C31H30BF2N2O4S3 
(MW+H+): 638.146; found: 638.143. 
BODIPY 18: 1H NMR (400 MHz; CDCl3): 
1H NMR (400 MHz; CDCl3): 7.53-7.38 (m, 15H), 
3.60 (s, 6H), 2.12 (t, 4H), 2.00 (m, 4H), 1.80 (s, 6H). 
BODIPY 19: 1H NMR (400 MHz; CDCl3): 3.69 (s, 6H), 3.25 (t, 4H), 2.25 (t, 4H), 2.08 (s, 
6H). 0.32 (s, 9H), 0.28 (s, 9H); 13C NMR (100 MHz; CDCl3): 172.84, 140.51, 135.96, 
134.72, 132.80, 118.30, 113.96, 113.33, 99.15, 96.43, 51.67, 34.20, 21.39, 14.11, 9.52; 
HRMS (ESI): m/z Calcd for C34H48BF2N2O4Si3 (MW+H
+): 680.3014; found: 680.680.3001.  
 
Selective Stille Coupling Reactions:  
The selective coupling reactions followed the procedure of general coupling reactions. 
The only difference was that 1.0 equiv of organotin reagent was used instead of excess 
organotin reagents.  
BODIPY 20: 1H NMR (400 MHz; CDCl3): 7.56 (dd, 1H), 7.15 (dd, 1H), 7.09 (dd, 1H), 
3.62 (s, 6H), 2.28-2.02 (m, 6H), 1.96 (s, 6H), 1.89-1.83 (m, 2H); 13C NMR (100 MHz; 
CDCl3): 172.14, 145.04, 143.34, 133.48, 132.80, 130.97, 129.12, 128.48, 127.41, 126.92, 
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51.72, 34.84, 21.45, 8.83; HRMS (ESI): m/z Calcd for C23H23BCl2FN2O4S (MW-F): 
523.0833; found: 523.0836 
BODIPY 21: 1H NMR (400 MHz; CDCl3): 7.56-7.38 (m, 5H), 3.58 (s, 6H), 2.04 (t, 4H), 
1.95 (m, 10H); 13C NMR (100 MHz; CDCl3): 171.93, 144.35, 143.17, 141.09, 133.25, 
130.07, 129.90, 129.03, 128.11, 126.49, 51.59, 34.29, 21.35, 8.74; HRMS (ESI): m/z 
Calcd for C25H25BCl2F2N2O4 : 517.1268; found: 517.1278. 
BODIPY 22: 1H NMR (400 MHz; CDCl3): 3.71 (s, 6H), 3.30 (t, 4H), 2.59 (t, 4H), 2.04 (s, 
6H), 0.30 (s, 9H); 13C NMR (100 MHz; CDCl3): 172.58, 143.02, 142.12, 131.69, 126.43, 
119.32, 114.82, 98.36, 51.76, 34.15, 21.65, 8.78. 
 
Cross Stille Coupling Reactions: 
 BODIPY 23 (10 mg, 0.018 mmol) and Pd(PPh3)4 (2.0 mg, 10%) were added to a round 
bottomed flask and flushed with argon several times. Anhydrous toluene (10 ml) was 
added, followed by injection of tributylphenyltin (17 µl, 3.0 equiv); the solution was 
refluxed for 12 h until a sharp peak appeared in the UV/visible spectrum at 562 nm in 
CH2Cl2. The reaction was stopped and the toluene was removed; the residue was taken 
up in CH2Cl2 and washed with water, brine and the dried over anhydrous Na2SO4. The 
crude product was purified by silica gel column chromatography, eluting with ethyl 
acetate/hexane (1:4) to give the product as a purple-red solid. All the other cross Stille 
coupling reaction followed this procedure.  
BODIPY 23: 1H NMR (400 MHz; CDCl3): 7.59-7.14 (m, 13H), 3.65 (s, 6H), 2.29-2.27 (m, 
6H), 2.07-1.96 (m, 2H), 1.86 (s, 6H); 13C NMR (100 MHz; CDCl3): 172.61, 157.21, 
142.46, 134.46, 132.27, 131.85, 129.63, 128.85, 128.67, 128.33, 127.89, 127.78, 127.19, 
51.61, 35.08, 21.48, 9.81; HRMS (ESI): m/z Calcd for C35H33BFN2O4S (MW-
F) :607.2238 ; found: 607.2234.  
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BODIPY 24: 1H NMR (400 MHz; CDCl3): 7.54 (dd, 1H), 7.14 (dd, 1H), 7.08 (dd, 1H), 
3.63 (s, 6H), 2.19 (m, 6H), 2.02 (s, 6H), 1.90 (m, 2H), 0.33 (s, 18H); 13C NMR (100 MHz; 
CDCl3): 172.39, 141.68, 137.79, 133.96, 133.58, 133.24, 129.01, 128.07, 127.21, 113.65, 
96.17, 51.58, 34.87, 21.19, 9.54, 0.25; HRMS (ESI): m/z Calcd for 
C33H42BF2N2O4SSi2 :667.2465 ; found: 667.2473. 
BODIPY 25: 1H NMR (400 MHz; CDCl3): 7.54 (dd, 1H), 7.50 (dd, 1H), 7.11(dd, 1H), 3.72 
(s, 6H), 3.39 (t, 4H), 2.64 (t, 4H), 2.09 (s, 6H), 0.32 (s, 18H); ); 13C NMR (100 MHz; 
CDCl3): 172.98, 147.91, 141.22, 133.78, 131.87, 131.72, 129.13, 128.72, 127.30, 119.21, 
113.57, 99.39, 51.66, 34.38, 31.59, 21.61, 10.58, 1.10; HRMS (ESI): m/z Calcd for 
C32H35BFN2O4S2Si (MW-F) :633.1885 ; found: 633.1883.  
BODIPY 26: 1H NMR (400 MHz; CDCl3): 7.45-7.36 (m, 10H), 3.72 (s, 6H), 3.39 (t, 4H), 
2.67 (t, 4H), 1.89 (s, 6H), 0.33 (s, 9H); 13C NMR (100 MHz; CDCl3): 173.04, 155.46, 
141.29, 133.06, 131.91, 129.68, 128.78, 128.09, 127.72, 113.28, 99.30, 51.62, 34.42, 
21.70, 9.74, 1.09; HRMS (ESI): m/z Calcd for C36H39BFN2O4Si (MW-F) :621.2756 ; found: 
621.2757. 
Synthesis of asymmetric BODIPY 27: BODIPY 15 (15 mg, 0.03 mmol) and Pd(PPh3)4 
(3.0-5.0 mmg, 8%) and were added to a round bottomed flask. The flask was flushed 
with argon and then anhydrous toluene (15 ml) was injected, followed by injection of the 
organotin reagent trimethyl[(tributylstannyl)ethynyl]silane (22.3 µl, 0.06 mmol). The 
mixture was refluxed until the starting material disappeared as observed by TLC and the 
UV/visible spectrum showed a sharp peak around 615 nm. Then the toluene was 
removed and the residue was taken up in CH2Cl2 and washed with water, brine and then 
dried over anhydrous Na2SO4. The crude product was purified by silica gel column 
chromatography to give the fully substituted products. 1H NMR (400 MHz; CDCl3): 3.68 
(s, 3H), 3.68 (s, 3H), 3.25 (m, 4H), 2.56 (m, 4H), 2.07 (s, 3H), 2.02(s, 3H), 0.30 (s, 9H), 
0.27 (s, 9H); 13C NMR (100 MHz; CDCl3): 172.79, 172.67, 143.97, 142.12, 140.47, 
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135.15, 133.30, 132.94, 126.60, 118.91, 114.44, 113.05, 98.73, 96.03, 51.76, 51.72, 
34.24, 34.11, 21.67, 21.40, 9.53, 8.82, 0.32, 1.17; m/z Calcd for C29H39BClF2N2O4Si2 
(MW+H) :619.2198; found: 619.2185.   
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5.7. Supporting Information 
 
 
 
 
 
 
 
 
 
 
 
 
1H and 13C NMR spectra of dibenzyl 5,5'-carbonylbis(4-(3-methoxy-3-oxopropyl)-3-
methyl-1H-pyrrole-2-carboxylate) in CDCl3. 
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1H and 13C NMR spectra of dimethyl 3,3'-(2,2'-carbonylbis(5-iodo-4-methyl-1H-pyrrole-
3,2-diyl))dipropanoate 12 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 15 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 16 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 17 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 19 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 20 in CDCl3. 
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1H  and 13C NMR spectra of BODIPY 21 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 22 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 23 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 24 in CDCl3. 
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1H and 13C NMR spectra of BODIPY 25 in CDCl3. 
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1H and 13C NMR of BODIPY 26 in CDCl3. 
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1H and 13C NMR of BODIPY 27 in CDCl3. 
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1H NMR spectrum of BODIPY 18 in CDCl3 at 400 MHz. 
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